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 Abstract 
Background: Interleukin (IL)-37 is a newly identified member of IL-1 cytokine 
family, and has five isoforms (IL-37a-e). While the function of IL-37b has been 
well studied as an important immunosuppressive cytokine that plays an anti-
inflammatory role in several diseases, the functions of other IL-37 isoforms are 
largely unknown. The five IL-37 isoforms are varying in protein sequences, 
induction and tissue distribution, suggesting that the isoforms may differ in 
function. This study was focusedon the IL-37a isoform, with IL-37b as a control. 
This was because our preliminary results showed that IL-37a expression is highly 
inducible in human macrophages by inflammatory stimuli compared to other IL-
37 isoforms, suggesting that IL-37a may play an important role in inflammatory 
response.  Furthermore, IL-37a protein is different from other IL-37 isoforms, in 
particular the N- terminal which contains a nuclear localisation sequence (NLS) 
and an elastase cleave site, suggesting that IL-37a may have unique biochemical 
features and functions.   
 
Hypothesis: Based on the differences at the N-terminal, IL-37a and IL-37b 
isoforms may differ in cellular location and function. Based on protein sequence 
similarities with IL-37b at the C-terminal, which contains the IL-1 domain for 
receptor binding and signalling. IL-37a may be also bioactive by signalling via the 
same receptor as IL-37b.  
  
Aim: To address the hypothesis, I set out the following aims: 1) to produce 
recombinant IL-37a and IL-37b proteins and compare their differences in protein 
levels (Chapter 3). 2) To investigate whether IL-37a is bioactive and what is the 
difference between IL-37a and b in the regulation of Toll-like receptor (TLR)-
induced inflammatory response in immune cells (Chapter 4). 3) To explore the 
molecular mechanism by which IL-37a and b differently regulate inflammatory gene 
profiles and signalling pathways by transcriptomics.  
 
Methods: To investigate their effect and difference in bioactivity, I produced 
recombinant IL-37a and b in Escherichia coli (E.coli) system and purified by affinity 
chromatography and gel filtration (Chapter 3). The effect of IL-37a and IL-37b on 
the regulation of TLR-induced inflammatory cell function been determined and 
ii 
 
compared in macrophages and in B cells in vitro (Chapter 4). The B cells from IL-
37a transgenic (IL-37a-tg) mice and wild type (wt) control mice were used for 
studying the effect of IL-37a on B cell functions (Chapter 4). The microarray and 
bioinformatics analysis was used to unravel the differences between IL-37a and b in 
term of genes regulation and signalling pathways in lipopolysaccharide (LPS)-
stimulated spleenocytes from IL37a and b transgenic and wt control mice (Chapter 
5). 
 
Results: 
i) Recombinant IL-37a and b proteins were successfully expressed in E.coli and 
purified by Nickel affinity chromatography, gel filtration and LPS removal. The 
proteins were used for crystallisation and biological study. The difference 
between IL-37a and b in protein and biochemical features was compared 
(Chapter 3). 
ii) IL-37 isoforms expressions are differently regulated in immune cells, 
depending on the activation conditions, dose, and time of the stimuli. The IL-37a 
is one of the highly induced isoforms. By using several biological approaches, 
including IL-37a recombinant protein, ribonucleic acid (RNA) knockdown, and 
transgenic cells, my results demonstrated that IL-37a is bioactive. It is generally 
immunosuppressive and can regulate the expression of several TLR-induced 
inflammatory cytokines in macrophage and monocytes. IL-37a and IL-37b share 
functional similarity in the tested experimental conditions, suppress the same 
cytokine expressions, and full length IL-37a (FL-IL-37a) is more effective than 
the full length IL-37b (FL-IL-37b) in the suppression of LPS-induced IL-6 
production in macrophages. Unexpectedly, both isoforms can increase B-cell 
antibody production and proliferation. The effect of IL-37a is more pronounced 
in mice than human B cells. This may be due to the difference between mice 
and human in the regulation of IL-37 and receptor expressions. Thus, IL-37a is a 
novel immunoregulatory cytokine of IL-37 family (Chapter 4). 
 
iii) My transcriptomic analysis results revealed that IL-37a has a broad regulatory 
effect on global gene expression, by enhancing the expression of 2881 genes and 
down regulating the expression of 2905 genes. IL-37a differs from IL-37b in gene 
regulation; IL-37a specifically inhibited 1182 and enhanced 1525 genes; in 
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addition, common regulated genes between the two IL-37 isoforms were also 
identified, explaining the functional similarity between the two isoforms.   
 
IL-37a and IL-37b control LPS/TLR4 signalling transduction through inhibiting of 
the co-receptor cluster of differentiation-14 (CD-14) and myeloid differentiation 
primary response gene-88 (MYD88) and toll/interleukin-1 receptor adaptor 
protein (TIRAP). The IL-37a also induces the expression of LPS-binding 
proteinphospholipid transfer protein (PLTP) to block LPS function. Both isoforms 
suppress the downstream TLR signalling, including Mitogen-activated protein 
kinase (MAPKs), phosphatidylinositol 3-kinase (PI3K), mammalian target of 
rapamycin (mTOR), nuclear factor kappa-light-chain (NF-κB) and Janus kinase- 
signal transducer and activator of transcription (JAK-STAT) pathways. However, 
both isoforms can also act independently in gene modulation and control TLR 
signalling, IL-37a supresses the expression of interferon response factors (IRF7) 
and interferon-beta-1 (IFN-β1) in the TIR-domain-containing adapter-inducing 
interferon-β (TRIF)-dependent pathway, on the other hand, IL-37b inhibited 
IRF3, together, this may lead to the down regulation of type I IFN production. 
 
My results showed that IL-37a increased the expression of several anti-
inflammatory immunoregulators, including peroxisome proliferator-activated 
receptors (PPARγ) which inhibits TLR4-mediated inflammations and type II 
cytokine IL-13; and both IL-37 isoforms enhanced IL-4 receptor as well. 
Altogether, these effects may impair the LPS-induced production of 
inflammatory cytokines, chemokines and mediators and also ameliorate inflamed 
leucocyte migration, cell metabolic and immune reactions, and thereafter 
decrease inflammatory response. 
 
The results also showed that both IL-37a and b significantly suppressed the 
expression of tyrosine-protein phosphatase non-receptor type-6 (PTPN6) or SHP-
1, and IL-37b suppressed Phosphatidylinositol-3, 4, 5-trisphosphate 5-
phosphatase-1 (Inpp5d) encoding SHIP in LPS-stimulated spleenocytes. Thus, 
down regulation of SHP-1 and/or SHIP may contribute to IL-37-enhanced 
antibody production and proliferation in B cells while previously in Chapter 4 
were mentioned that IL-37 signals increased IgG production and cellular 
proliferation in LPS-stimulated murine CD19+B cells. 
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Conclusion and prospects: 
My results demonstrated for the first time that both the endogenous and 
exogenous IL-37a is bioactive with immune regulatory property. IL-37a is highly 
inducible by inflammatory signals. Intriguingly, while IL-37a and b inhibit 
inflammatory response in macrophages, both the cytokines increase antibody 
production in murine and human CD19+ B cells. This strongly suggests that IL-37 
may not only suppress but also enhance immune response depending on cell 
types. The success in the production of recombinant IL-37a and b allows further 
study, and to compare their function in many immunological and biochemical 
conditions in vitro and in vivo. I found that, while IL-37a and b share the 
functional similarity, they are different in transcriptomics and some functions; 
this may be due to their difference in protein sequence, in particularly the NLS 
in the N-terminal. More works is needed to answer the question. Altogether, IL-
37a is a previously unrecognised immunoregulatory cytokine and may play an 
important part in immune tolerance and the regulation of inflammatory 
disorders.  
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1 Introduction 
1.1 The Immune System 
The human immune system is composed of immune organs, immune cells and 
effector immune molecules; that work together in a complementary way to 
protect against infection. The immune response is a process of recognition and 
elimination of foreign antigens and is divided into innate and adaptive immune 
response (Abbas et al, 2012). The immune system functions to defend against 
invading pathogens including viruses, bacteria, parasites and fungi. Moreover, 
the immune system can also detect and eliminate necrotic, apoptotic and 
transformed cells such as tumour cells caused by gene mutagenesis (Delves and 
Roitt, 2011). Although the immune system protects the body against pathogens, 
dysfunction of immune balance can cause certain diseases (Murray et al, 2012). 
1.1.1 Innate immunity 
The innate immunity is the first line of defence against pathogens via tissue 
barrier and innate immune cells. It is unspecific, rapid, without immunological 
memory and controls the infection quickly within the first few days using several 
strategies, including pro-inflammatory signalling cascades activation, 
opsonisation, phagocytosis and activation of complements (Abbas et al, 2012).  
The innate immunity detects and recognizes microbial invaders through innate 
immune cells via their pattern recognition receptors (PRRs), including Toll-like 
receptors (TLRs), that recognize pathogen-associated molecular patterns 
(PAMPs) and damage associated molecular patterns (DAMPs) to trigger immune 
response (Armant and Fenton, 2002; Abbas et al, 2012). Following pathogen 
recognition, multiple immune defence mechanisms and pathways are activated 
including phagocytosis and killing by phagocytic cells; complement pathway 
activation; acute inflammatory responses activation by cytokines and 
chemokines; transcription of several anti-viral proteins by type I IFN that leads 
to viral infection clearance. Therefore, pathogens recognition via PRRs/TLRs 
activates several acute immune responses that are necessary to limit the early 
spread of infection, while a sophisticated tool of specificity and memory to re-
infections countering is provided by activation of adaptive immune responses 
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(Pasare and Medzhitov, 2001). The innate immune system can also activate and 
shape the adaptive immune response through cytokines, antigen presentation 
and co-stimulatory molecules (Pasare and Medzhitov, 2005).  
1.1.1.1 Tissue barrier 
Tissue barriers are the first line of defence to prevent infection; these include: 
1. Mechanical barriers that restricts pathogen entrance such as skin 
epithelial cells that arejoined by tight junctions in the skin, gut, eyes, 
lungs and nose. 
2. Chemical barriers involving secreted chemical molecules that can destroy 
pathogens in different ways such as stomach pepsin enzyme and low pH in 
the gut, lactic acid from sweat glands, lysozyme in the saliva.  
3. Microbiological barrier including normal flora and microbiotas (Janeway et 
al, 2007). 
1.1.1.2 Innate immune cells 
Innate immune cells are developed from myeloid progenitors in the bone 
marrow, the key innate immune cells including macrophages, neutrophils, and 
dendritic cells. With one exception, innate lymphoid cells (ILCs) that are 
developed from lymphoid progenitors are the same as T and B cells but without 
antigen receptors (Abbas et al, 2012). 
1.1.1.2.1 Macrophages 
 
Macrophages are generated from monocytes and can differentiate into tissue 
specific macrophages such as Kupffer cells, alveolar macrophages, and microglia 
in different organs. The main function of macrophages is their critical role as 
phagocytic immune cells in the host defence against infectious antigens, 
cleaning the cell debris and apoptotic cells (Aderem and Underhill, 1999; Alber 
et al, 2012). Macrophages are also involved in wound healing and immune 
regulation. Macrophages are one of the professional antigen presenting cells 
(APCs) and can initiate T cell-mediated adaptive immune response; thus 
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macrophage can be a key linker between the innate and adaptive immunity 
(Yurasov et al, 2005). 
According to their function, macrophages can be differentiated into two 
activated subtypes: classically activated macrophages (M1) and alternative 
macrophages (M2) in response to different activation conditions. M1 is polarised 
in response to (LPS), IFNϒ and IL-12. M1 macrophages express pro-inflammatory 
cytokines and inducible nitric oxide synthetase (iNOS), an enzyme for the 
production of nitric oxide (NO) which has a major role in killing microbes 
through a respiratory burst mechanism (Babior et al, 1984). These classic 
macrophages resist microbial infection through NO and IFNγ that mediate the 
antimicrobial and tumoricidal properties of M1 macrophage. The dysregulation of 
M1 may also lead to inflammatory diseases (Parisi et al, 2018). M2 Macrophages 
or alternativly activated M2-macrophages are generated in the presence of IL-13 
and IL-4, which release IL-13 and transforming growth factor beta (TGF-β), and 
express prototypical marker arginase (Hesse et al, 2001). The M2 macrophages 
contribute to wound healing and tissue repair (Levings and Schrader, 1999) and 
protection against parasite infection. However, over-activation of M2 cells may 
cause tissue remodelling, fibrosis and allergic conditions. 
1.1.1.2.2 Neutrophils  
 
Neutrophils are classified as granulocytes due to the abundance of granules in 
their cytoplasm. They are the most abundant leucocytes, comprising 60-70% of 
white blood cells (Abbas et al, 2012). Neutrophils are the first cells recruited to 
the site of infection, and are essential for immune defence against bacteria and 
fungi. Neutrophils are phagocytic cells and can kill pathogens by the toxic 
chemicals and enzymes in their granules, including defensins, eosinophil cationic 
protein, lysozyme and superoxide (Segal, 2005). However, neutrophils are short 
lived, with survival about 4-5 days in the peripheral blood. Thus, they are mainly 
involved in the early immune activation against infection and inflammation.  
1.1.1.2.1 Dendritic cells  
Dendritic cells (DCs) are also generated from monocytes. DCs localise in the 
tissues and there are three types of DCs that have been identified: conventional 
dendritic cells, plasma cystoid DCs and the myeloid dendritic cells, which are 
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derived from blood monocytes (Plantinga et al, 2010; Spears et al, 2011). While 
DCs are located in the tissues, their distinct morphology enables them to move 
to lymph organs all over the body. The main function of DC is to act as 
professional APC. DCs can process antigen, upload it onto their surface major 
histocompatibility complex (MHC-I) and (MHC-II) molecules and present the 
peptide antigen to T cells. As a professional APCs, DCs can not only provide the 
antigen signal to naive T cells, but also the co-stimulatory signals via CD80/86 
and CD40L as well as cytokine signals (Abbas et al, 2012). The three signals lead 
to the activation and proliferation of T cells and the differentiation of naive T 
cells into effector T cells (Ni and O'Neill, 1997). Thus, DCs are considered to be 
the key bridging cells between innate and adaptive immunity, in addition, they 
also generate reactive oxygen species (ROS), NO, and anti-microbial proteins 
that kill intracellular pathogens. 
1.1.1.2.2 Natural killer (NK) cells 
NK cells are lymphocytes derived from common lymphoid progenitor, the same 
as B cells and T cells are derived. However, NKs do not express antigen-binding 
receptors as B and T cell. They are cytotoxic cells and kill tumour and virus- 
infected cells. NK cells kill other cells via secretion of cytotoxic molecules, such 
as perforin and granzyme proteases that induce apoptosis in the target cells. NK 
cells can also kill the target cells via other pathways, including antibody-
dependent cell-mediated cytotoxicity (ADCC) and cytokine-induced NK and 
cytotoxic T lymphocyte (CTL) activation (Abbas et al, 2012). 
1.1.1.2.3 Innate lymphoid cells (ILCs) 
ILCs are innate immune cells, which are derived from common lymphoid, but not 
myeloid progenitors. They are lymphocytes, but different from T and B cells 
they do not express antigen receptors. They are mainly located in the tissues 
and are innate immune cell lineages (Buonocore et al, 2010; Moro et al, 2010). 
Functionally, they are associated with the innate immune response. However, 
ILC1 and ILC3 can also express MHC II and can serve as APC. Based on cytokine 
production and transcription factors, ILCs can be classified into three subsets 
(Spits et al, 2013; Walker et al, 2013): 
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 ILC1 cells express transcription factor T-bet and produce IFN-γ upon 
stimulation by IL-12 and IL-18. ILC1 cells shares functional similarity with 
Th1 cells and plays important role in protection against intracellular 
infection. The over-activation of ILC1 may lead to inflammatory disorders 
(Gordon et al, 2012). 
 ILC2 cells express GATA3 and produce IL-5, IL-9 and IL-13 cytokines in 
response to IL-25 and IL33. Therefore, ILC2 cells are closely associated 
with Th2 cells and play critical role against parasite infection. 
Dysregulation of ILC2 cells can cause allergy and asthma by 
overproduction of type II cytokines (Hoyler et al, 2012). 
 ILC3 cells express RORγt and produce Th17 cytokines IL-17a and IL-22 in 
response to IL-23 and IL-1β. ILC3 cells are important in defence against 
extracellular pathogens. However, abnormality of ILC3 may lead to 
autoimmune disorders, the same as Th17 cells (Spits et al, 2013). 
1.1.2 Adaptive immunity 
The adaptive immune system consists of T and B-lymphocytes cells. These cells 
express surface antigen receptors. The adaptive immune response includes 
humoral response induced by B cell and cell mediated response by T cell 
(Murphy, 2011). The adaptive immune response appears later than innate 
immune response and is characterised by antigen specificity and memory 
development (Sattler et al, 2013). 
Immunological memory is crucial for the strong and specific response in the host 
defence against reinfections (Kindt et al, 2007; Abbas et al, 2012). The adaptive 
immune response develops through four phases: 
1. Initiation: it is called the priming phase in that the T and B cells recognise 
antigen through their antigen receptors; T cells via their T-cell receptor (TCR) 
and B cells via B-cell receptor (BCR). 
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2. Activation and differentiation phase: lymphocytes that recognise antigens and 
receive co-stimulation and cytokine signals from APCs start the proliferation and 
differentiation into effector cells. 
3. Effector-stage: T and B effector cells eliminate pathogens via their related 
effector molecules. 
4. Recovery phase: some effector cells develop into memory cells against 
reinfection and most of them are eliminated by apoptosis (Murphy, 2011). 
1.1.2.1  T Cell-mediated immunity 
T cells (CD4+ and CD8+ T cells) originate from bone marrow common lymphoid 
progenitors and develop into mature T lymphocytes in the thymus. The mature 
antigen-naive T cells will differentiate into effector cells in the peripheral lymph 
organs when they sense antigen from APCs. 
Effector T cells lead the cellular immune response against microbial infection. 
The defence mechanism that both CD4+ and CD8+ T cells provide is via their cell 
surface receptors and secreted molecules, mainly the cytokines and chemokines 
(Delves et al, 2011). 
The cellular immune response is initiated by antigen-presenting cells (APC), 
which could be macrophages, B cells or the DCs. DCs are the most efficient 
antigen-presenting cell type. To induce optimal activation and differentiation of 
naive into effector T cells, APCs need to provide three signals to naive T cells 
(Garcia and Adams, 2005): signal 1 is initiated when T cells through their T cell 
receptor (TCR) recognise the processed peptide antigen presented by APC via 
the MHC molecule. The second signal is induced by the interaction of 
ligand/receptor pairs of co-stimulatory molecules on both APCs and T cells, 
including CD80 on APC and CD28 on T cells. While the two signals can result in 
the activation and proliferation of T cells, these are not enough to induce the 
differentiation of naive T cells into effective T cells if the cytokine signals are 
not provided. Once the three signals are received, naive CD8+ T cells 
differentiate into cytotoxic T cells which will kill infected cells and tumours 
(O'Shea and Paul, 2010), while naive CD4+ T cells differentiate into several 
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subsets including T helper (Th) 1, Th2, Th9, Th17 and T-regulatory cells (T-reg) 
(O'Shea and Paul, 2010). This differentiation depends on the milieu of 
polarisation cytokines, for example, IL-12 is required for Th1 polarisation and IL-
4 for Th2 development (Fig 1.1). Th1 cells play an important role in the 
protection against intracellular pathogen infection and in inflammatory diseases 
if over-activated; Th2 cell differentiation is associated with anti-parasite 
infection. However, dysregulation of Th2 responses may also cause allergy and 
asthma. Th17 cells are closely associated with anti-fungal and extracellular 
bacterial infection. Abnormality of Th17 response may lead to inflammatory and 
autoimmune diseases (Weaver et al, 2013). The T-reg cells are the suppressive T 
cells in immunity and disease and play an important role in immune balance and 
tolerance. Effector T cells have short life spans, however some of them can 
differentiate into memory T cells which are long-lived and expand quickly upon 
cognate antigen re-exposure. Memory cells are important in protection against 
reinfection (Sprent and Surh, 2002; Garcia and Adams, 2005; O'Shea and Paul, 
2010).  
8 
 
 
 
 
Figure 1.1 CD4+ T cell subsets. 
Upon encourting with foreign antigensand costimulatory molecules presented by DCs, naive CD4+ 
T cells differentiate into TfH, TH1, TH2, TH17 andTreg cells. These differentiations are shaped 
by cytokines, and are characterized by the expression of lineage-specific transcription factors 
and the production of signature cytokines. In response to IL-6, naive CD4+ T cells differentiate in 
to TfH cells which is important for germinal center B cell; IL-4 is important for the 
differentiation of TH2 cells that play a crucial role in antiparasite; and humural immunity. IL-12 
is required for the differentiation of TH1 cells. IL-6 together with TGF-drive naive T cells to 
develop into TH17, while TGF- alone promotes naive T cells to differentiate into Foxp3-
expressing Treg cells. TCR (T cell receptor); CD40 L (CD40 ligand); Gata-3 (Gata-binding factor); 
B-cell lymphoma 6 protein; T-bet (T-box transcription factor); RORγt (RAR-related orphan 
receptor gamma t) FOXP3 (forkhead box P3). 
 
(Modified from O'Shea, J. J. & Paul, W. E. (2010). Mechanisms underlying lineage 
commitment and plasticity of helper CD4+ T cells. Science, 327, 1098-1102.) 
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1.1.2.2  B cell-mediated humoral immunity 
B cells and the antibodies they produce drive the humoral immune response; 
these antibodies protect the body against extracellular pathogens. B cells 
activation and differentiation into plasma cells that produce antibodies depend 
on antigen and Th cells. T-cell independent (ID) antigens do not require T cell 
help, but T-cell dependent (TD) antigens require Th cells. The B cells in the 
periphery are present as B1 and B-2 cells subset, and they can be distinguished 
by their surface markers, origin, location, and distinct antibody production 
profile (Fig 1.2) (Fagarasan, 2000; Martin and Kearney, 2001). 
B cells bind to antigens through somatically mutated specific receptor called B 
cell receptor (BCR), which triggers the first signal for B cell activation. B cells 
can be activated by other stimuli, such as the CD40 ligand on T cells interact 
with CD40 on B cells, and IL-4, IL-5 and IL-13 cytokines secreted by T cells. 
Furthermore, B cells express TLRs that in response to their ligand provide an 
additional signal for B cell activation (O'Rourke et al, 1997). Upon activation, 
mature B cells proliferate and differentiate into antibody-producing plasma cells 
and memory B cells which do not produce antibody, but they can be activated 
quickly in a recall to the cognate antigen or TLR agonists and rapidly produce a 
large amount of antibody (Liu et al, 1991; Hardy and Hayakawa, 2001). 
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Figure 1.2 B cells subsets 
(Modified from Abbas, A, Lichtman, A and Pillai, S. (2012). Cellular and 
molecular immunology. Philadelphia: Elsevier). 
  
11 
 
1.2 B cell 
1.2.1 B cell development 
The same as T cells, B cells are developed from the common lymphoid 
progenitors (CLP). In human, B cells develop in the yolk sac fetal liver before 
birth; however, after birth the development is restricted to the bone marrow. 
While the detailed mechanism is still missing, B cells develop into mature B cells 
in bone marrow via pro, pre and immature B cell stages (Namen et al, 1988; 
Svensson et al, 1998). At pro-B cell stage, the rearrangement of the Ig heavy-
chain D-J and V-DJ genes occurs. This leads to the surface expression of Igα and 
Igβ heterodimers and the developing into pre-B cells (Abbas et al, 2012). Pre-B 
cells express the pre-BCR consisting of the µ heavy-chain paired with germline 
encoded λ5 and Vpre-B chains; this is called the surrogate light chain that is 
associated with Igα/Igβ heterodimers to form the functional pre-B cell receptor 
that has ability to transduce signal (Schlissel and Baltimore, 1989; Meffre 
andWardemann, 2008). Pre-B cell receptor signalling is essential for pre-B cell 
progression long its developmental pathway. 
The pre-BCR generation enables the pre-B cells to further develop into immature 
B cells followed by the rearrangement of the Ig light-chain locus that results in 
antigen specificity and increases the B cell repertoire diversity (Schlissel and 
Baltimore, 1989; Nishimoto et al, 1991; Lassoued, 1993). The successful 
recombination and BCR expression on the surface of immature B cells allow the 
cells to recognise specific antigen and the further development by negative 
selection. During the BCR development, some auto-reactive B cells can be 
generated due to the BCRs being generated randomly and these cells may cause 
autoimmune disease if not depleted. To do so, the immature B cells in the bone 
marrow undergo negative selection, in which they are exposed to self-antigen 
and the autoreactive cells will be depleted by either receptor editing or clonal 
deletion. The B cells that are not for self-antigen will escape the selection, 
become mature B cells and migrate into the periphery tissues. In the periphery, 
the newly generated B cells or antigen naive B cells are non-dividing cells, with 
a very short life span, and the majority of them die by apoptosis in the absence 
of antigen within a few weeks. However, upon antigen recognition, these B cells 
enter the secondary lymphoid organs such as the spleen in which they survive 
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and differentiate into effector, plasma and memory B cells (Lam and Rajewsky, 
1997; Harless et al, 2001).  
1.2.2 B cell subsets 
B cell subsets develop from different progenitors. There are two subsets of B 
cells: B-1 B cells and B-2 B cells. B-1 B cells (CD5+) comprise a minor population 
about 5% of B-cells (Nishimura et al, 1992). B -1 B-cells are part of innate 
immunity as their response to pathogen is rapid. B-1 B cells develop from fetal 
liver haematopoietic stem cells during haematopoiesis, and mainly locate to 
peritoneal and mucosal cavities (Kantor, 1993). B-1 B cells express surface 
markers, CD19 and CD54, although CD45R is expressed at low levels in 
comparison to other B cell lineage; B-1 cells also express CD11, IgM (high), IgD 
(low) (Rothstein and Kolber, 1998; Abbas et al, 2012). 
B-1 cells provide protection in innate immune manner through secretion of 
natural IgM, for instance in streptococcus infection (Baumgarth et al, 2005). B-
1cells promote long-lasting protective immunity to T-cells ID antigens by 
secreting IgM against pathogenic antigens (Alugupalli et al, 2004). B-1 B cells 
express low level of BCR, therefore they do not respond properly to activation 
through BCR (Morris, 1993; Bikah et al, 1996; Rothstein and Kolber, 1998). 
B-2 (CD5-) B cells comprise the major population among the other B cell types 
and are crucial for humoral response to infection. These cells produce high 
affinity antibodies (IgG, IgE) and can undergo somatic hyper-mutation (SHM), 
and class switch recombination (CSR). B-2 B cells, in addition, reside in the 
follicles and can migrate from one to another of the lymph nodes (Abbas et al, 
2012). 
1.2.3 B cell function 
Current evidence suggests that B cell functions are not restricted to antibody 
production in immune response (O'Neill et al, 2005; Cariappa et al, 2007). 
Effector B cells have three main functions: cytokines secretion, serving as APC, 
producing antibody: 
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1.2.3.1  Cytokines secretion 
B Cells contribute to and modulate immune response through secretion of a wide 
range of cytokines that influence the outcome of the immune response. B cells 
secret different types of cytokines, including inflammatory and regulatory 
cytokines, thus B cells can regulate all types of immune response; for instance, B 
cells secrete Th1 and Th2 cytokine IFNγ and IL-4 and can affect Th1 cells and 
Th2 cell development and functions, respectively (Harris et al, 2005a; 2005b). 
Effector B cells also produce IL-6 and other pro-inflammatory cytokines such as 
IL-12, TNFα, and lympho-toxins, which are important in shaping secondary 
lymphoid organs (Lund, 2008). In addition, these pro-inflammatory cytokines 
produced by B cells can contribute the severity of autoimmune disease. In 
Experimental autoimmune encephalomyelitis (EAE), specific B cells producing IL-
6 are associated with the EAE disease the severity (Barr et al, 2012). However, in 
another study, B cell deficient mice in EAE models revealed an increase in the 
disease severity; suggesting that these cells are necessary to regulate the 
disease progression (Wolf et al, 1996). B cells modulate immune response 
through producing IL-10, which inhibits inflammatory cytokine secretion from 
monocytes and macrophages (Fiorentino et al, 1991). Furthermore, B cells can 
also regulate immune responses by the induction of regulatory T cells via their 
secretion of IL-10 and TGF-(Akdis and Blaser, 2001; Fillatreau et al, 2002; 
Matsushita et al, 2010). 
1.2.3.2  Antigen presenting cells (APC) 
B cells are efficient antigen presenting cells, due to their ability to endocytosis 
antigen via BCR and present it via surface MHC-II and I molecules. BCR is able to 
concentrate small amount of antigens and present it efficiently to Th cells, 
which are resident in the secondary lymphoid organs together with B cells 
(Lanzavecchia, 1985; Vanderveen et al, 1992). In addition, B cells can also 
provide costimulation and cytokine signals. B cell APC are important in the 
development of autoimmune diseases. 
1.2.3.3  Antibody production 
B cell defence against pathogens is mainly carried out through their specific 
antibody production.It has been shown that antibody deficiency results in 
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susceptibility to infection (Duraisingham et al, 2014). Although antibodies do not 
directly remove pathogens, they can do so indirectly, via binding to antigens and 
a broad mediating range of effector responses (Lanzavecchia, 1985; Vanderveen 
et al, 1992). 
1.2.4 Antibodies 
Antibodies are immunoglobulins which are a heterodimeric protein composed of 
two heavy (H) and two light (L) chains. Functionally, an antibody has a variable 
domain (V) in Fab part, which binds to antigens and an FC part in constant H 
chain domains (C). The variable domains are subjected to SHM after exposure to 
antigen, which increases the antibody specificity to antigens (Arnold et al, 
2007). The FC part has specific effector functions involved in complement 
activation (IgG and IgM) and Fc receptor binding. 
1.2.4.1  Antibody types 
Based on the difference in heavy chain sequence, the antibodies have five 
classes: IgM, IgG, IgA, IgD, and IgE isotypes. 
1.2.4.1.1 IgM 
 
IgM is the biggest immunoglobulin with five protein units. IgM is expressed on 
naive B cells surface and associated with both CD79a and CD79b. IgM is the first 
immunoglobulin expressed during B cell development, and is a pentameric 
immunoglobulin with high avidity and low affinity towards antigens. IgM has 
short lifespan ofabout 3 days and is associated with both innate and adaptive 
immune response, in which it has ability to activate complement through 
opsonizing or coating the target antigen (Boes, 2000).  
1.2.4.1.2 IgD 
 
The IgD immunoglobulin has very low levels in the serum, and it is a monomer 
immunoglobulin with a short life span of two days. The IgD expressed on mature 
B cell surface as bounded immunoglobulin associated with Igα and Igβ for 
signalling (Geisberger et al, 2006; Riesbeck and Nordstrom, 2006). 
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1.2.4.1.3 IgG 
 
The IgG is a monomer with four subclasses, IgG1; IgG2; IgG3; and IgG4 
(Schroeder and Cavacini, 2010).  IgG is the predominant immunoglobulin isotype 
among other immunoglobulin isotypes in the body with the longest life span of 
21-28 days. IgG mediates the clearance of pathogens through opsonisation and 
complement cascade activation, and all the subclasses can trigger complement 
fixation with exception of IgG4 that fails to fix complement. IgG subclasses 
affinityfor the first component of the complement (C1q) differs with 
(IgG3>IgG1>IgG2). In addition, IgG1 and IgG3 bind to all three FcγR classes (FcγR 
I, II and III), while IgG4 only binds to FcγRII and III (Parlowsky et al, 2003; 
Kawasaki et al, 2006). 
1.2.4.1.4 IgA 
 
The IgA has predominant levels in secretions including saliva and breast milk, 
and at the mucosal surfaces (Woof and Mestecky, 2005; Schroeder and Cavacini, 
2010). IgA is a monomer in the serum with level lower than IgG. Secretory IgA 
(sIgA) is a dimer and sometimes trimer or tetramer that is associated with a J-
chain and has a critical role to protect mucosal surfaces from virus, toxins, and 
bacteria. Neutrophils express IgA receptor that is important for local clearance 
of pathogens through antibody dependent cell cytotoxicity (ADCC) (Stubbe et al, 
2000). 
1.2.4.1.5 IgE 
 
The IgE has the lowest serum concentration with the shortest life span.  While 
IgE is closely associated with hypersensitivity and allergic reactions, its main 
functions protective against parasites and worm infections. The IgE has high 
affinity to the FcεRI receptor, whichis expressed on basophils, eosinophils, mast 
cells and Langerhans cells (Chang et al, 2007). 
1.2.4.2  Antibody function 
1.2.4.2.1 Phagocytosis 
 
Antibody is one of the phagocytosis receptors on the surface of phagocytes and 
can trigger phagocytosis process. Antibody can fix pathogens on the surface of 
phagocytes, including monocyte, macrophage and neutrophils. When an antibody 
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binds to a pathogen with its Fab fragment, its Fc fragment will bind to the Fc 
receptor on the surface of the phagocytic cells. Following successful 
engagement, the phagocytes will engulf the targeted pathogen or cells and 
destroy it (Nimmerjahn and Ravetch, 2007; 2008). 
1.2.4.2.2 Neutralization 
 
Some antibodies can bind to antigen and block the function or bioactivity of the 
antigen. For instance, anti-IL-1 neutralising antibody can bind to and block IL-1’s 
ability of binding to its receptor (Botsios, 2005); also, some antibodies against 
pathogen surface proteins can prevent the pathogen to infect host cells via the 
antigen’s receptor on host cells (Hessell et al, 2007; Forthal, 2014).  
Neutralization is a key function of antibody that depends on antibodies’ 
capability without the help of effector cells or other molecules.  
1.2.4.2.3 Complement activation 
 
IgM and IgG can kill pathogen, tumour or pathogenic cells via antibody-
mediated, complement-dependent cytotoxicity (AMCDC). This is an immune 
killing mechanism via the classic complement activation pathway. When the 
antibodies bind to their surface antigen on pathogen or pathogenic cells via their 
Fab fraction to form an immune complex, this will trigger the recruitment and 
activation of complement protein (C1) which binds with its C1q subunits through 
binding to the Fc portion of IgM or IgG. The activation of C1 will activate 
downstream complement activation cascades to form the membrane attach 
complex on the surface of pathogen and kill the pathogen by osmotic lysis of the 
cells. (Roitt et al, 2001; Abbas and Lichtman, 2012). 
1.2.4.2.4 Antibody dependent cell cytotoxicity (ADCC) 
 
ADCC is an independent mechanism from the complement system. It is part of 
the adaptive immune response since the antibody has major role in this 
biological process. The IgG coats the antigen on target cells via Fab domain, its 
Fc part can also bind to NK cell FC receptors FcγRIII (CD16) receptor on their 
surface. This cross-linking will lead to the activation and degranulation of NK 
cells to release the toxic cytoplasmic granules containing perforin, granzymes, 
and cell death by apoptosis (Wallace et al, 1994; Horner et al, 2007; Chen and 
Freedman, 2008; Tudor and Bomsel, 2011). 
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1.2.5 B cell function in immunity and disease  
1.2.5.1 B cell response to T- independent and T-dependent antigens 
Based on the requirement for T cell help in B cell activation, B cell responses to 
antigens can be classified into TD antigen response (TD-antigen) and T-cells ID 
antigen response (TI-antigen). TD-response is induced by TD antigen and mainly 
mediated by B-2 cellswith immune memory, while TI-response is induced by TI 
antigen and mainly associated with B1 cells IgM production and without immune 
memory. 
Majority antigens are the TD antigens, including pathogen and foreign proteins 
that activate B cells via BCR with the requirement of direct help with T-cells. 
The process occurs in the secondary lymphoid follicles. In order to obtain T cell 
help, B cells present the antigen on the MHC II molecule to Th cells. After 
antigen recognition, T cell provide helpto B cells through CD40L on that 
interaction with CD40 R on B cells. This interaction initiates B cell activation and 
drives B cells into the cell cycle. Together also with the cytokine milieu secreted 
by T cell at the time of activation, all these supporting signals lead B cell clonal 
expansion and become effector cells and plasma cells that are able to produce 
antibodies and cytokines. The plasma cells that undergo further SHM for their 
BCR affinity maturation and antibody class switch resulting in various antibody 
isotypes that are more functionally versatile and enhance the humoral response 
(Parker, 1993; Haas et al, 2011). 
In contrast, B cell T-cells ID antigen response does not require T cells help.  
While follicular B-2cells can mediate TD-antigen response, TI-antigens; are 
mainly mediated by marginal zoneand B1cells, and results mainly in IgM 
secretion (Abbas et al, 2012).  
TI-antigens fall into two types with different acting mechanisms: TI- type I 
antigens are mitogenic stimuli or polyclonal B cell stimulants with intrinsic B cell 
activating activity that directly drive the B lymphocyte proliferation and 
differentiation. This activation can be mediated with or without BCR 
stimulation, for example, LPS and CPG activate B-cells via Toll-like receptors. 
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This type of B cell immune response is rapidly activated, and does not require T 
cell help; thus, it is important in protection against extracellular pathogens at 
early stages of infection (Haniuda et al, 2011; Grant et al, 2012). 
TI- type II antigens are mainly the polysaccharide antigens, for instance, the 
highly repetitive surface epitopes of encapsulated bacteria can activate mature 
B-lymphocytes. TI-type II antigen activate B cells through cross-linking of BCR 
with the antigens. Cross activation of these receptors results in proliferation, 
differentiation, and antibodies production in B-cells (Obukhanych et al, 2006).   
A subset of B cells that contributes to immunological tolerance are called 
regulatory B cells (B-Reg). This type of B cells is immune suppressive by releasing 
anti-inflammatory cytokines including TGF-, IL-10, and IL-35. Expression of IL-
10 is a critical feature of B Reg cells in both human and mice; and B Reg cells 
inhibit effector lymphocytes such as T-cells and B cells as well (Rudensky, 2011). 
While the transcription factor and detailed development pathways are still 
unclear, B-reg appear to have multiple subsets and can arise from B cell subset 
in response to inflammation, including PAMPs, but are not found in normal 
tissues (Rosser and Mauri,2015).  
1.2.5.2  B cell function in autoimmune disease 
B cells have a vital role in pathogen clearance through humoral response; 
however, balance disruption of B cell function and self-tolerance break down 
can cause autoimmunity (Samuels et al, 2005; Yurasov et al, 2005). B cells play a 
central role in autoimmune disease by autoantibodies, pro-inflammatory 
cytokine production and autoantigens presentation to T cells.  
Most of the autoantibodies in autoimmune disorders are IgG isotype that have 
undergone SHM with T cell help. In autoimmune disease, autoantibodies are 
considered the preferred marker for the diagnosis and prediction in some 
autoimmune disorders. These autoantibodies are associated with pathogenic 
effects by different mechanisms. The autoantibodies may bind to free self-
antigen to form immune complexes (ICs), the ICs can circulate in the peripheral 
tissues and the deposition of these ICs in tissues may trigger complement-
mediated cytotoxicity and tissue damage (Rojko et al, 2014). Autoantibodies 
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acting against endocrine glands may affect organ function through stimulation or 
inhibition of organ bioactivity (Howard et al, 1987; Michalek et al, 2009; Susuki 
et al, 2012). For example, in medical conditions such as Gravis disease 
(hyperthyroidism), autoantibody acting against thyroid can stimulate thyroid 
growth and produce more thyroid hormone.  
Dysregulated profiles of cytokine production by B cells are often seen from 
patients with autoimmunity, with enhanced production of pro-inflammatory 
cytokines and diminished anti-inflammatory cytokine secretion (Takai, 2002; 
2005). B cells secrete pro-inflammatory cytokines such as IL-6, TNF-α, IFNγ, IL-4, 
which in turn activate macrophages, modulate DCs migration; regulate T cell 
functions; and provide stimulatory feedback signal for B cell activation 
(Lanzavecchia, 1985; Amigorena and Bonnerot, 1999). In autoimmune disease, B 
cells develop ectopic germinal centres as consequence of chronic inflammation 
associated with autoimmune disease. Due to the lymph-toxins secreted by T and 
B cells and infiltrate to the site of chronic inflammation, LTα1 and β2 promote 
the resident stromal cells to differentiate into dendritic cells, thus promoting 
disease progression (Schalke et al, 1985; Nielsen, et al, 2001). 
Auto-reactive B cells process and present self-antigens to T cells in autoimmune 
conditions. B cells’ function as APC is clearly seen in autoimmune disease; B 
cells can potentiate disease by promoting pro-inflammatory T cell responses to 
the self- antigen (Lehmann-Horn et al, 2013). For example, B cell deficient mice 
impaired T cell priming and proliferation in a model of autoimmune disorder, 
suggesting that T cell activation requires B cell antigen presentation (Svensson 
et al, 1998; Lin et al, 2015).  
1.2.6 B cell signalling 
The B cells responed to antigens through signalling transduction via BCR 
complex. BCR complex is consists of BCR and two heterodimer subunits of Igα 
(CD79a) and Igβ (CD79b). BCR on B cell surface is for antigens binding (Fig 1.3). 
BCR intracellular signalling is carried out by the two-heterodimer tyrosine 
residues CD79a and CD79b that contain immune receptor tyrosine-based 
activation motifs (ITAMs) (Cambier, 1995). ITAMs are responsible for the 
initiation and propagation of BCR signalling. Signalling through BCR is triggered 
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once an antigen binds to BCR, leading to BCR aggregation, followed by activation 
of the intracellular protein kinases, such as Lyn, a protein tyrosine kinase (PTKs) 
that is already associated with BCR in an inactive form. Lyn activation triggers 
ITAM phosphorylation, which in turn enables ITAM to bind more protein kinases 
blnk, Grb2, SYK, BTK, PLCϒ, and Vav.  
The BCR signal can be further amplified by CD19, a B cell co-receptor that is 
cluster with aggregated BCR. CD19 can also be phosphorylated by Lyn and 
become activated. This leads to direct activation of phosphatidylinositol-3 
kinase (PI-3K) and AKT. The PI3K- AKT pathway will lead to the activation of 
transcription factor NF-Кβ. BTK activation via PI3K-PIP3 will activate MAPK and 
nuclear factor of activated T cells (NFAT) pathways (Tsubata, 1999; Dalporto, 
2004).  
These activated transcription factors, including NF-κB, NFAT, MYC, ATF2 and 
JUNin B cells; will subsequently translocate into cell nucleus, bind to the 
specific binding site on many genes and results in the expression of related 
genes (DeFranco et al, 1995; Campbell, 1999). Together, a successful BCR 
signalling in responding to an antigen will lead to B cell survival, proliferation, 
migration, and antibody production (Burger, 2011; Choi and Kipps, 2012; Burger 
and Chiorazzi, 2013). 
Antigen-independent pathways can also activate B cells, for instance TLR 
signalling (Abbas et al, 2012). This will be described in related sections in the 
introduction. 
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Figure 1.3 B-cell receptor signalling pathway 
 
BCR signaling is comprosed of a surface Ig molecule associated non-covalently with CD79a and b. 
Aggregation of the BCR quickly activateLyn, which activates Syk, and this latter serves as a 
nucleation site for Blnk, Btk, and Vav. These molecules trigger a series of downstream signalling 
events leading to coordinated gene expression, cell survival, proliferation, andmigration. Lyn 
(Src-family kinase), Syk (spleen associated tyrosine kinase), Blnk (B cell linker), Btk (Bruton 
tyrosine kinase), Vav (guanine nucleotide exchange factor). 
 
(Modified from Choi, M. and Kipps, T. (2012). Inhibitors of B-Cell Receptor 
Signalling for Patients with B-Cell Malignancies. The Cancer Journal, 18(5), 
pp.404-410). 
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1.3 Toll-like receptors 
Sensing pathogens and tissue damage by innate immune cells is the first step in 
immune activation against infection. This is attributed to the evolutionary 
developed the PRRs on/in immune cells. PRRs sense PAMPs and host damage-
associated molecular patterns (DAMPs), which play initial role in immune 
activation. Four groups of PRRs have been identified: TLRs, Retinoid acid-
inducible gene (RIG)-like receptors or (RLRs), Nucleotide-binding oligo-
merization domain (NOD)-like receptors (NLRs), and C-type lectin receptors 
(CLRs) (Abbass et al, 2012). These PRRs form a network for the detection of all 
pathogens in or out of cells. The TLRs are the most important group of pattern 
recognition receptors. 
The TLRs are transmembrane or cytoplasmic signalling receptor proteins and 
belong to the IL-1R/TLR superfamily. Human TLR10 and murine TLR13 have been 
identified and can discriminate diverse classes of microbial products (Armant 
and Fenton, 2002; Kaisho and Akira, 2006). TLRs 1-10 are found in human and 
mice; while TLRs 11-13 are only found in mice not in humans (Takeda, 2004; 
Kaisho and Akira, 2006). TLRs are widely expressed on immune cells, including 
macrophages, dendritic cells, mast cells, eosinophils, neutrophils, B and T 
lymphocytes and tissue cells such as epithelial cells, endothelial cells 
cardiomyocytes and adipocytes. 
1.3.1 TLR cellular location and the recognition of PAMPs 
The TLRs are transmembrane proteins characterised by containing three 
domains; the extracellular domain composed of leucine rich repeat (LRR) motifs 
for pathogen recognition, the cytoplasmic part containing the TLR/IL-1 receptor 
(TIR) domain for signalling; and the transmembrane domain for fixing the 
receptor on the cell membrane (Armant and Fenton, 2002). 
TLRs are different in their cellular locations. TLRs 1, 2, 4, 5, and 6 are on the 
cell surface as transmembrane receptors. These cell surface TLRs are 
responsible for sensing extracellular pathogens. TLR2 can form heterodimers 
with TLR1 or TLR6 and allow recognising peptidoglycan and lipopeptides from all 
bacteria and parasites, while TLR4 recognises LPS from gram-negative bacterial 
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and TLR5 is for bacterial flagellin (Table 1.1). In contrast, TLRs3, 7, 8 and 9 are 
located intracellularly on the endosomal membrane and recognise intracellular 
PAMPs of virus and bacterial (Table 1.1). TLR3 is specifically for sensing double-
strain RNA viruses, TLR7 and 8 are for single- strain RNA viruses, and TLR9 for 
pathogen DNA cytosine-phosphate-guanine motifs (CpG) (Kindt et al, 2007). 
Together, TLR family members recognise a wide-range of PAMPs or DAMPs intra 
and extracellularly. 
Table 1.1 Toll-like receptors classes 
Receptor type Microbial ligands 
TLR2/ TLR1a Triacyllipopeptides 
TLR2 
Lipoproteins, glycolipids and peptidoglycans of 
Gram-positive organisms 
TLR3 Double-stranded viral RNA 
TLR4 LPSb of Gram-negative organisms 
TLR5 Bacterial flagellin 
TLR2/ TLR6 Diacyllipopeptides 
TLR7 Guanosine or uridine-rich single-stranded viral RNA 
TLR8 Guanosine or uridine-rich single-stranded viral RNA 
TLR9 Unmethylated bacterial CpG motifs 
TLR10 Possibly similar to TLR1 and TLR6 
TLR11 Non-functioning in humans 
 
a: Toll like receptor, b:  Lipopolysaccharide. 
 
(Modified from Armant, A., Fenton, J. (2002). Toll-like receptors: a family of 
pattern-recognition receptors in mammals. Genome Biology, 3(8), pp. 3011: 1-6. 
 
1.3.2 TLR signalling pathways 
TLRs signal in 5 steps: 1) Microbial PAMPs interact with the LRR motifs of TLRs to 
form a complex and induce dimerization of TLRs. 2) Intracellular signalling 
adaptor molecules (MYD88, MAL, TRIF, TIRAP, and/or TRAM) are recruited to TLR 
via their TIR domains. 3) Several protein kinases. 4) Transcription factors are 
recruited, and activated via phosphorylation and dephosphyoration by the 
protein kinases. 5) The activated transcription factors translocated into the 
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nucleus bind to the target genes and induce the expression of various genes 
including pro-inflammatory cytokines, chemokines, and surface molecules (Fig 
1.4) (Medzhitov,2001). 
Based on the usage of adaptor molecule MYD88, TLRs can signal through two 
different signalling pathways; the MYD88-dependent and MYD88-independent 
pathways (Akira and Takeda, 2004). MYD88 signalling pathway plays a crucial 
role in all IL-1R and TLR signal transductions except TLR3 (Medzhitov, 2001). The 
MYD88-dependent pathway begins with the recruitment of the adaptor protein 
MYD88 after engagement of TLRs with the specific ligand. MYD88 molecule 
stimulation is followed by interaction of the TIR domains of both MYD88 and IL-
1R-associated kinase (IRAK-4) to form a complexes called the Myddosome (Lin et 
al, 2010). IRAK-4 phosphorylates IRAK-1, which associates with the RING-domain 
of E3 ubiquitin ligase TNF receptor-associated factor 6 (TRAF-6), activating 
either TAB or TGF- activated kinase (TAK-1) complex (Akira et al, 2006). TAK-
1/TAB complex activation enhances the IκB kinase (IKK) complex activity, which 
induces degradation of IκBα leading to nuclear translocation of the transcription 
factor NF-κB. The translocated NF-кB induces the transcription of inflammatory 
cytokines IL-6, IL-8, TNF-α, IL-1β, and IL-12 and mediators (Wang et al, 2001). 
The MYD88-independent pathway is also known as the TIR domain containing 
adaptor inducing IFNβ (TRIF)-dependent pathway (Kawai and Akira, 2006; Jiang 
and Chen, 2012). Only internalised TLR4 and TLR3 signal through this pathway. 
Activation of this pathway begins when these TLRs are stimulated by their 
ligands, leading to recruitment of TRIF molecule, followed by the activation of 
transcription factor IRF-3. The IRF-3 then translocates into the nucleus and 
delayed phase NF-кB activation (Kawai and Akira, 2006). The MYD88-
independent pathway mainly leads to the production of type I IFNs that in turn 
activate STAT1 and induce IFN-inducible genes (Toshchakov et al, 2002). Thus, 
the MYD88-independent pathway plays an important role in the anti-virus and 
intracellular infection by inducing type I IFNs.  
1.3.3 Function in immune response 
TLR signals play a central role in the initiation and activation of innate and 
adaptive immune responses (Akira et al, 2000). This is because TLRs are widely 
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expressed by all innate and adaptive immune cells and TLR signals are powerful 
in immune cell activation.  
TLRs orchestrate innate immune defence mechanisms against invading 
pathogens, in particular the intracellular pathogen elimination in macrophages 
(Lang, 2005). In macrophages, TLR signals enhance the phagocytosis of 
pathogens and the formation of phagolysosomes (Doyle et al, 2003). TLR signals 
also induce the production of antimicrobial mediators including reactive 
oxygenspecies (ROS) and reactive nitrogen species (RNS); together these will kill 
the intracellular pathogen. However, microglial activation through TLRs releases 
chemokines that attract peripheral immune cells into the site of infection in the 
brain, such as macrophage inflammatory protein-2 (MIP-2) and monocyte 
chemoattractant protein-1 (MCP-1) (Patel et al, 2012). Macrophage activation by 
TLR4 may also result in proinflammatory cytokines IL-6, IL-12, IL-8, TNF-α, and 
IL-1β and chemokine production and plays a pathogenic role in proinflammatory 
and autoimmune disorders (Chang et al, 2007). 
TLR also promote the activation of neutrophils, for instance, enhancing 
neutrophil phagocytosis, the production of reactive oxygen and nitrogen species 
as well as the antimicrobial peptides. TLR signals enhance cytotoxicity of NK 
cells and the production of IFN to kill infected cells and tumour cells (Guo and 
Zhang, 2012). DCs are the professional APCs in tissue and can initiate T cell 
activation. TLRs can promote maturation of immature DC to become mature DC, 
which can provide antigen, costimulatory, and cytokine signals to induce naive T 
cell priming (Casals et al, 2007). 
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Figure 1.4 Mammalian TLRs signalling 
Cell surface TLRs including TLR5, TLR11, TLR4, and the heterodimers of TLR2–TLR1 or TLR2–TLR6 
bind to their respective extracellular ligands, whereas TLR3, TLR7–TLR8, TLR9 and TLR13 
localizedat the endosomes, and these intracellular ones sense microbial nucleic acids.  All TLRs 
signal via the adaptor MyD88, except TLR3 that can function only via TRIF. TLR signalling is 
initiated by ligand-induced dimerization of receptors, followed by the activation of the TIR 
domainand adaptor protein MYD88 or TRIF; MyD88 leads to the activation of kinases such as IL-1 
receptor-associated kinases (IRAKs). The resulting phosphorylation cascade activates members of 
TNF receptor associated factor 6 (TRAF6), and ultimately transcription factors NF-κB, JNK and 
p38 (as well as IRF7 for TLR7 and TLR9). The TRIF pathway stimulates TRAF6, and the 
transcription factors IRF3, IRF7, NF-κB. Membrane signalling triggers an inflammatory response 
whereas intracellular TLR signalling leads to antiviral response.  
 
(Adapted from O’Neill, L., Golenbock, D. and Bowie, A. (2013). The history of 
Toll-like receptors — redefining innate immunity. Nature Reviews Immunology, 
13(6), pp.453-460). 
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During the virus infection, the intracellular virus can be recognised by TLR3, 7/8 
and 9 in tissue or macrophages. The activation and signalling of intracellular 
TLRs will lead to the production of type I IFNs to kill the infected virus 
subsequently (Uematsu and Akira, 2007).  
 
To prevent host tissue destruction from excess production of pro-inflammatory 
cytokines produced in TLR activated immune cells, type I IFNs are released 
which in turn upregulate IL-10 production; the autocrine action of IL-10 induces 
the expression of signal-transducer and activator of transcription (STAT3) which 
promotes the production of anti-inflammatory mediators (Chang et al, 2007). A 
range of cytokines, including IL-10, IL-6 and IL-27, are activated by STAT3 
signalling (Lang, 2005). Therefore, the release of IL-10 and sustained activation 
of STAT3 are critical anti-inflammatory feedback mechanisms in macrophages 
(Kühn et al, 1993; Berg et al, 1995; Takeda et al, 1999; Lang, 2005; Murray, 
2005). 
1.3.4 TLRs function in adaptive immune cells 
Current evidence suggests that both B and T cells express different TLRs. While 
the function of TLRs on T cells is less understood, their roles in B cell activation 
and function are well studied. TLR expression in human naive B cells is low to 
undetectable in general, but the expression can be upregulated with BCR 
stimulation. In contrast, human memory B cells constantly express TLR9. Mouse 
B cells express TLR9, and TLR4 is the predominant TLR in naive and memory B 
cells (Bernasconi et al, 2003; Bourke et al, 2003; Lanzavecchia and Sallusto, 
2007). 
Mouse B cells stimulated with LPS induces polyclonal expansion, isotype 
switching and differentiation to plasma cells (PCs) in switched memory B cells in 
the absence of T-helper cells. However, primary humoral responses can also be 
induced in response to LPS in naive and un-switched memory B cells (Bourke, 
2003; Lanzavecchia and Sallusto, 2007). In humans, CpG stimulation induces 
naive B cell proliferation, and expression of CD40, CD80, and MHC-II on the cell 
surface (Jiang and Lederman et al, 2007). In addition, CpG is an excellent agent 
for inducing cell proliferation in B cells activated by BCR and T- helper cells in 
vitro, and rescues B cells from abortive proliferation (Krieg, 2000; Rupercht and 
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Lanzavecchia, 2006). The CpG alone cannot mediate naive, memory and class 
switch B cell differentiation into plasma cells, but it can do so in combination 
with additional signals provided through CD40 or BCR. CpG in combination with 
IL-4 rescues naive B cells from apoptosis in vitro (Jiang and Lederman et al, 
2007). 
Research from this lab demonstrated that TLRs can be induced in naive T cells 
by TCR stimulation and activation (Komai-Koma et al, 2004). TLR signals can 
replace the costimulatory signals in T cell activation, and enhance T cell 
proliferation, cytokine production and survival. Intriguingly, TLR signals mainly 
induce IFNγ and IL-2 production, suggesting that TLRs may predominantly 
polarise Th1 cells (Komai-Koma et al, 2004). 
1.4 Cytokines 
Cytokines are small peptides (8-40) kDa, secreted by all nucleated cells, 
especially immune cells (Thomson and Lotze, 2003). Cells expressing intact 
cytokine receptors are responsive to cytokine signalling, which is considered the 
major communication mechanisim between cells of the immune system 
(Marshall, 1992). More than 200 cytokine-like molecules have been identified 
which work synergistically or antagonistically, that may regulate other cytokine 
production positively and negatively (Dinarello, 2007). Cytokines are pleotropic 
in immune response, and they act in autocrine action, paracrine action, and 
endocrine manner (Tayal and Kalra, 2008). 
1.4.1 Cytokine classification 
1. Cytokines are classified according to their source, functions and structure. 
Based on cellular sources, cytokines can be classified into three types: 
 Monokines, which are cytokines produced by monocytes and macrophages 
 Lymphokines,which are cytokines produced by lymphocytes 
 Interleukins, which are cytokines mainly produced by leukocytes  
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2. According to their function, cytokines can be divided into 4 classes: 
 Pro-inflammatory cytokines: produced during inflammation and 
responsible for inflammatory response 
 Anti-inflammatory cytokines: inhibiting inflammation and promoting 
healing 
 Growth factors: necessary for cell growth and survival 
 Chemokines: chemoattractant cytokines for attracting cells to the site of 
inflammation  
(Thomson and Lotze, 2003; Dinarello, 2007) 
3. Based on structural homology, cytokines can be divided into 9 cytokines 
families: 
a) The hematopoietic family (IL-2, IL-4, IL-5, IL-13, IL-15, IL-21)  
b) The interferon family (IFNα, IFNβ, IFNγ) 
c)  The tumour necrosis factor (TNF) family (TNFα, LTα, LTβ, RANKL, APRIL) 
d) The IL-1 family (IL-1α, IL-1β, IL-1Ra, IL-18, IL-33, IL-36α, IL-36β, IL-36γ, IL-
36Ra, IL-37, IL-38)  
e)  The IL-17 family (IL-17, IL-25)  
f)  The IL-10 family (IL-10, IL-22)  
g)  The IL-12 family (IL-12, IL-23, IL-35, IL-27) 
h) The TGF family (TGF-α and )  
i)  The chemokine family (CCL1 to 28, CXCL1 to 17, XCL1,2, CX3CL1) 
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Table 1.2 Functional classification of cytokines and receptors 
Functional class Primary property Other effects Examples 
Lymphocyte growth 
factors 
clonal expansion Th1/Th2/Th17 
polarization 
IL-2, IL-4, IL-7, IL-17,IL-
15 
Th1 cytokines ↑ Th1 responses clonal expansion of CTL IFN-γ, IL-2, IL-12, IL-18 
Th2 cytokines 
Th17 cytokines 
Pro-inflammatory 
cytokines 
↑Th2 responses 
↑Th17 responses, IFNγ 
↑inflammatory 
mediators 
↑ antibody production 
autoimmune responses 
↑ innate immune 
responses 
IL-4, IL-5, IL-18, IL-25, IL-
33 
IL-17, IL-23, IFN-γ 
IL-1α, IL-1β, TNF-α, IL-
12, IL-18, IL-23, MIF, IL-
32, IL33, CD40L 
Anti-inflammatory 
cytokines 
↓ inflammatory genes 
 
↓ cytokine-mediated 
lethality,↓ autoimmune 
disease 
IL-10, IL-13, TGF-, IL-
22, IL-1Ra, IFNα/ 
Adipokines 
 
pro-inflammatory pro-atherogenic, anti-
inflammatory 
IL-1α, TNF-α, IL-6, leptin, 
adiponectin, resistin 
gp130 signalling 
cytokines 
growth factors B cell activation, acute 
phase 
IL-6, CNTFc), IL-11, LIFc), 
CT-1c) 
Nerve growth factors ↑ nerve/Schwann cells B cell activation BNDFc), NGFc) 
Osteoclast activating 
cytokines 
bone resorption immune stimulation RANKLc) 
Colony-stimulating 
factors 
haematopoiesis pro- and anti-
inflammatory 
IL-3, IL-7, G-CSF, 
GM-CSF, M-CSF 
Angiogenic cytokines neovascularization pro-metastatic VEGFc), IL-1, IL-6, IL-8 
Mesenchymal growth 
factors 
fibrosis pro-metastatic FGF, HGF, TGF-, BMPc) 
Type II IFN macrophage 
activation 
↑ MHC class II IFNγ 
Type I IFN anti-viral 
↑ MHC class I 
anti-inflammatory, 
anti-angiogenic 
 
IFNα, IFNβ 
Chemokinesb) 
 
↑ cellular emigration ↑ cell activation IL-8, MCP-1, MIP-1α, 
others 
 
a) Does not include soluble cytokine receptors such as sTNFRp55, sTNFRp75, sIL-1R type II, IL-18 
binding protein, osteoprotegerin. b) The chemokine family includes CC and CXC chemokine with 
over 30 members. c) BMP, bone morphogenic protein; BNDF, brain-derived neurotrophic factor; 
CNTF, ciliary neurotrophic factor; CT-1, cardiotrophin-1; LIF, leukemia inhibitory factor; NGF, 
nerve growth factor; RANKL, receptor activator of NF-κB ligand; VEGF, vascular endothelial 
growth factor. 
 
(Adapted from Dinarello, C. A. (2007). Historical insights into cytokines. Eur J 
Immunol, 37 Suppl 1, S34-45). 
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1.4.2 The IL-1 family cytokines 
Since the cytokines in IL-1 family are closely involved in the study I should like to 
introduce the family in detail. 
The IL-1 family is composed of about 15 members and includes 12 cytokines with 
agonist activity (IL-1α and β, IL-18, IL-33, IL-36α, β, γ, IL-37a, b, c, d, e) and 
three receptor antagonists (IL-1Ra, IL-36Ra, IL-38) (Vande veerdonk et al, 2015). 
This family of cytokines is characterized by the β-trefoil domain structure (IL-
1like domain) for receptor binding and bioactivity (Dinarello, 2009; Dinarello et 
al, 2013; Garlanda et al, 2013).  
There are several distinct features of the IL-1 family cytokines:   
 All the family members have the IL-1-like domain (Garlanda et al, 2013).   
 IL-1 family cytokines secreted through unconventional protein secretory 
pathways, via secretory lysosomes, exosomes or exocytosis vesicles, due 
to the lack of a signal peptide (Carruth et al, 1991). 
 All members signal via a heterodimer receptor complex composed of a 
receptor and a co-receptor (Lingel et al, 2009). 
 IL-1 cytokine functions are self-regulated, either by soluble receptors or 
antagonising proteins (Garlanda et al, 2013).  
 Some of the IL-1 family members function as cytokines when released or 
as a nuclear factor in the nucleus, for instance IL-33, IL-1α, and IL-37 
(Carriere et al, 2006; Boraschi et al, 2011). 
1.4.2.1  IL-1 family cytokines function 
The IL-1 family plays a central role in the initiation and development of innate 
and adaptive immunity and diseases with both proand anti-inflammatory 
properties. Intriguingly, the function of the IL-1 family is self-regulated by the 
antagonist, soluble receptor and binding proteins. As illustrated in table 1.2, IL-
1α and IL-1β are important in the initiation of inflammatory responses and the 
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polarisation of Th17 cells (Volchenkov et al, 2017). IL-1 receptor antagonist (IL-
1Ra) regulates IL-1 function (Arend et al, 1998). IL-18 promotes Th1 responses 
and Th1 cell development by facilitating IL-12’s effect, however, this effect can 
be inhibited by IL-18 binding protein (IL-18BP). IL-18 is able to stimulate Th2 
responses in the absence of IL-12 and IL-15 (Sedimbi et al, 2013 ; Dinarello et al, 
2013). IL-33 signals via co-receptor ST2 and IL-1RAcP. It mainly induces type II 
cytokines, IL-5, and IL-13 in many innate immune cells. IL-33 can also promote 
Th2 cell function and plays an important role in protection against parasite 
infection and also allergy and asthma and this induction can be regulated by 
soluble ST2 (sST2) receptor (Schmitz et al, 2005).  
IL-36 is composed of three isoforms, IL-36α, IL-36β, and IL-36γ that share the 
common receptor complex (IL-36 receptor). IL-36 plays a pathogenic role in lung 
inflammation and dermatitis (Vigne et al, 2012; Keermann et al, 2015).  Both IL-
36 receptor antagonist (IL-36Ra) and the IL-36 binding protein IL-38 control IL-36 
functions (van de Veerdonk et al, 2015). The latest member of the IL-1 family 
cytokines is IL-37 with five isoforms IL-37(a-e), it is an important immune-
regulator that suppresses inflammatory responses in immunity and in disease 
(Nold et al, 2010).  
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Table 1.3 IL-1 Family members 
 
 
(Adapted Carta, S., Lavieri, R. and Rubartelli, A. (2013). Different Members of 
the IL-1 Family Come Out in Different Ways: DAMPs vs. Cytokines?. Frontiers in 
Immunology, 4.) 
 
 
 
 
 
Family name Name Receptor/ 
coreceptor 
 
Property Synthesized 
as precursor 
Processing 
required for 
activity 
IL-1F1 IL-1α IL-1RI  
 
IL-1RAcP 
Pro-
inflammatory 
Yes No 
IL-1F2 IL-1β IL-1RI  
 
IL-1RAcP 
Pro-
inflammatory 
Yes Yes 
IL-1F3 IL-1Ra IL-1RI 
 
 
Antagonist for 
IL1α,β 
No No 
IL-1F4 IL-18 IL-18Rα  
 
IL-18Rβ 
Pro-
inflammatory 
Yes Yes 
IL-1F5 IL-36Ra IL-1Rrp2 
 
 
Antagonist for 
IL36 
Yes Yes 
IL-1F6 IL-36α IL-1Rrp2 
 
 IL-1RAcP 
Pro-
inflammatory 
Yes Yes 
IL-1F7 IL-37 IL-18Rα  
 
 IL-18BP 
Anti- 
inflammatory  
 
Yes Yes 
IL-1F8 IL-36β IL-1Rrp2  
 
IL-1RAcP 
Pro-
inflammatory 
Yes Yes 
IL1-F9 IL-36γ IL-1Rrp2 
 
 IL-1RAcP 
Pro-
inflammatory 
Yes Yes 
IL-1F10 IL-38 
 
 
IL-1Rrp2 
 
? Antagonist Yes ? No 
IL-1F11 IL-33 ST2  
 
IL-1RAcP 
 
Pro-
inflammatory 
Yes No 
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1.4.3 IL-37  
IL-37 was discovered in silico research in 2000 (Moretti et al, 2014). IL-37 gene 
was also called IL-1H4, IL-1RP, or IL-1F7. 
1.4.3.1  IL-37 isoforms 
The human IL-37 gene is located on chromosome 2 between the IL-1β and IL1F9 
genes (Fig 1.5). IL-37 gene in mice is missing, thus mice do not express IL-37 
(Boraschi et al, 2011). The IL-37 gene consists of 6 exons and can encode five 
isoforms (a, b, c, d, and e) by mRNA alternative splicing.  Exons 1-3 encode the 
N-terminal domain of IL-37 isoforms. Exons 4-6 encode the C-terminal domain of 
IL-37 isoforms containing 12 putative β-strands to form the β-trefoil protein 
structure, which is the characteristic of the IL-1 family (IL-1 like domain) and 
can bind to IL-1Rs for signalling (Fig 1.8) 
IL-37b is the longest among the IL-37 isoforms encoded by exons 1, 2, 4, 5, and 
6. A caspase-1 cleavage siteis detected in its N-terminal domain between the 
amino acids asparagine (D20) and glutamine (E21), and this cleavage site exists in 
all IL-37 (b-e) isoforms except IL-37a. This may give a mature IL-37b starting at E 
21. In contrast, IL-37a is encoded by exons 3, 4, 5, 6; and it is the only isoform 
using exon 3 to encode protein (Fig 1.6) (Taylor et al, 2002). IL-37a lacks the 
caspase-1 cleavage site. Instead, it has a putative elastase cleavage site at the 
N-terminus upstream of the β-trefoil structure between leucine (L21) and 
arginine (R22) (Fig 1.7) (Dinarello et al, 2016). In addition, Il-37a has a putative 
NLS for protein translocation into the nucleus, suggesting that IL-37a may be a 
nuclear protein (Taylor et al, 2002; Boraschi et al, 2011). IL-37d is encoded by 
exons 1 and 4 to 6. IL-37c is encoded by exons 1, 2, 5 and 6 and IL-37e is 
encoded by exons 1, 5 and 6 (Boraschi et al, 2011). The same as IL-37b, all the 3 
isoforms can be processed by caspase-1. 
Based on whether or not carrying the IL-1-like domain, the isoforms can be 
divided into two functional groups; the isoforms IL-37a, b, and d (i.e. those 
encoded by the complete exon 4-6) will therefore be expected to bind to the 
same receptor and trigger the same range of biological effects. In contrast, IL-
37c and e lack the key exon 4 and are expected to give rise to a partial IL-1-like 
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β-trefoil structure and their functions are unknown (Taylor et al, 2002; Boraschi 
et al, 2011).This protein/structural evidence suggests that the isoforms may vary 
in function. 
Another important domain in the IL-37 gene is the instability element within 
exon 5 represented by a conserved ten-nucleotide homology box thatis found in 
the open reading frame of IL-37 gene (Bufler et al, 2004; Quirk and Agrawal, 
2014). The sequence can control IL-37 RNA stability and can be inactivated by 
inflammatory signals. In resting cells, IL-37 mRNA will be rapidly degraded, and 
can be induced by inflammatory signals, for instance LPS stimulation. Thus, this 
instability element limits IL-37 mRNA and protein levels and ensure that it is 
induced only during inflammatory but not in resting conditions (Bufler et al, 
2004). 
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Figure 1.5  Genomic location of IL1F7 gene in human and mouse. 
Panel A shows the genes of IL-1 family locus on human chromosome. 2) Panel B illustrates the 
genes of IL-1 family locus on mouse chromosome 2. The IL1F7 (IL-37) gene is between IL1B and 
IL1F9 in human. In mouse it is absent, instead IL-1F8 is localised at the expected IL-1f7 position. 
(Adapted from Boraschi, D., Lucchesi, D., Hainzl, S., Leitner, M., Maier, E., 
Mangelberger, D., Oostingh, G., Pfaller, T., Pixner, C., Posselt, G., Italiani, P., 
Nold, M., Nold-Petry, C., Bufler, P., Dinarello, C. (2011). IL-37: a new anti-
inflammatory cytokine of the IL-1 family. Eur Cytokine Netw, 22(3), pp. 127-47). 
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Figure 1.6 Structure of the IL-37 gene 
IL-37 gene is composed of 6 exons (1-6) as shown. A) Illustrates IL-37 gene and related 5 
isoforms; B) illustrates the protein domains of IL-37a and IL-37b isoforms, IL-37a possesses NLS 
and elastase putative site in exon 3, while exons 4-6 encode the receptor binding sequence. IL-
37b has exon 1, which contains a caspase-1 cleavage site, while IL-37b shares exons 4-6 with IL-
37a and express the receptor-binding site. Size of the exons indicated as numbers down each 
exon.  More info    
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Figure 1.7 Cleavage sites in predicted amino acids sequences of exon 1, 2, 
and 3 
The figure illustrates the enzyme cleavage sites of IL- 37a and b. A)  Exon 3 expressed 
exclusively by IL-37a isoform contains a unique elastase cleavage site encoded by exon 3, 
between leucine (L21) and arginine (R22) (the black arrow). The location of NLS highlighted by 
yellow colour. (B) Illustrates the two caspase-1 cleavage sites of IL-37b, encoded by exon1 and 
exon 2, respectively (indicated by arrows). The first is between asparagine (D20) and glutamine 
(E21) and the second is between phenyl- alanine (F45) and valine (V46).  
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Figure 1.8 The predicted amino acids encoded by exons 4, 5, and 6 
Both IL37a and IL37b isoforms share exons 4-6 that encode the trefoil domain.The lines 
underneath each group of amino acids represent β strand. There are 12β strands. Together these 
form the β trefoil structure of IL-37 
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1.4.3.2  IL-37 Maturation 
IL-37 is translated as a full length immature or pro-IL-37 protein. The  immature 
IL-37 isoforms except IL-37a and contain a caspase-1 cleavage site and can be  
processed efficiently by caspase-1 into mature IL-37. Mature IL-37b beginning 
with (EPQC) amino acids sequence at the N-terminal suggests that the predicted 
cleavage site of caspase-1occurs between  aspartic acid(D20), and glutamic acid 
(E21) (Fig 1.8) (Kumar et al, 2002). Although IL-37 may also contain a second 
caspase-1 cleavage site  encoded by exon 2, the main  caspase-1 cleavage site 
may be located around D20, because mutation of aspartic acid at position (D20) 
markedly reduced caspase-1-mediated maturation processing of pro-IL-37 (Bulau 
et al, 2014). However, the caspase-1-mediated processing in other IL-37 isoforms 
carrying the caspase-1 cleavage site is largely unknown, but is expected to have 
the same effect because of their similarity in protein sequences. IL-37a is a 
unique isoform that carries a putative elastase but not caspase-1 cleavage site at 
its N-terminal. This suggests that IL-37a differs from other isoforms in 
maturation. This is under investigation in our lab. Interestingly, different from 
IL-1β and IL-18, maturation seems not important in the function of IL-37, 
because both mature and immature IL-37 can bind to and signal via the IL-37 
receptor complex composed of IL-18Rα and IL-1R8 (Nold et al, 2010). The 
physiological and pathological impact of maturation on IL-37 function is still 
unclear.   
1.4.3.3 Secretion and nuclear location 
The same as other members in the IL-1 family, IL-37 isoforms do not have a 
signal sequence that facilitates the protein secretion out of the cells.  Both pro 
and mature IL-37 can be secreted outside the cell by unknown mechanism, 
independent of the conventional endoplasmic reticulum and Golgi apparatus 
(Dinarelloet al, 2016). This suggests that different from IL-1 and IL-18, 
maturation is not required for their secretion (Nold-Petry et al, 2015). 
It has been demonstrated that both IL-37b and IL-37d can also translocate into 
the nucleus (Luo et al, 2017; Zhao et al, 2018), While the detailed mechanism is 
still unknown. It has been shown that only the mature but not the immature 
form of IL-37b can do so by binding to and co-translocating into nucleus with 
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Smad3 (Nold et al, 2010; Dinarello et al, 2013). It has been evidenced that 
caspase-1 is necessary for IL-37b maturation and translocation to the nucleus, as 
a caspase-1 inhibitor abolished completely IL-37 maturation and nuclear 
translocation (Fig 1.9) (Kumar et al, 2002). 
Different from other IL-37 isoforms, the putative nuclear localizing sequence 
(NLS) sequence in pro-IL-37a predicts that immature IL-37a may be able to 
translocate to the nucleus (Nold et al, 2010). The research result from this lab 
confirmed that the NLS has a function, which enables immature IL-37a to 
translocate to the nucleus without maturation (Dr. Xu unpublished result). Thus, 
IL-37 isoforms may be also dual functional, able to serve as both a nuclear factor 
and a cytokine by different mechanisms. 
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Figure 1.9 IL-37 maturation 
The figure illustrates the induction and maturation of pro-IL-37. (1) IL-1B and LPS activate 
immune cellswhich express IL-37. (2) Upon stimulation, IL-37 expression increases and is released 
into the cytoplasm as pro-IL-37. (3) Caspase-1 enzyme catalyses pro-IL-37 into mature IL-37. (4) 
Mature and pro-IL-37 are able to release into the extracellular space. (5) pro-IL-37 can be 
catalysed by extracellular protease into mature IL-37. (6) Mature and pro-IL-37 can both bind to 
the IL-37 receptor complex and trigger signalling. 
(Modified from Dinarello, A., Nold-Petry, C., Nold, M., Fujita, M., Li, S., Kim, S., 
Bufler, P. (2016). Suppression of innate inflammation and immunity by 
interleukin-37. Eur J Immunol, 46(5), pp.1067-81) 
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1.4.3.4  Dimerization  
The study of crystal structure of IL-37b indicates that IL-37 can form a head-to-
head homodimer, suggesting a configuration that is unique in IL-1 superfamily 
cytokines. Both pro (IL-37(1-218)) and mature (IL-37(21-218) or IL-37(46-218)) protein 
can form homodimers. The key amino acids that are involved in the dimer 
formation have also new identified. IL-37b monomers form dimers through the 
formation of hydrogen bonds between Tyr85 and Arg87, and this interaction is 
protected by an ionic gate provided by another two amino acids Lys83 and Asp73 
(Ellisdon et al, 2017). More over, Tyr85, amino acid is highly conserved, 
suggesting a key role in stabilizing the dimer.  Isoforms IL-37c and IL-37e lack 
the dimer interface amino acids. Due to the absence of strands β1 to β3, 
suggesting that these isoforms do not dimerize (Ellisdon et al, 2017).  
Furthermore, the homodimer formation mainly occurs when the protein 
concentration is higher than 1.35 uM (Ellisdon et al, 2017). Importantly, the 
homodimer formation reduced or even abolished IL-37-mediated suppressive 
function in vitro and in vivo (Kumar et al, 2002; Ellisdon et al, 2017). Whereas 
the detailed mechanism is still not fully understood, this may represent a novel 
way for the self-regulation of IL-37 function. Together with the RNA instability 
element in IL-37 gene, these suggest that IL-37 expression and function are 
highly self-regulated. 
1.4.3.5  Regulatory effect of IL-37 on immune cell function  
Growing evidence has demonstrated that IL-37 is an immune regulatory cytokine 
and suppresses innate and adaptive immune cell function via receptor-
dependent and independent pathways (Nold-Petry et al, 2015). This is attributed 
to its dual functions, as a nuclear factor and a cytokine.  
1.4.3.5.1 IL-37 receptor-dependent pathway 
 
As a cytokine, IL-37 signals via the receptor complex consisting of IL-18R and IL-
1R8. IL-37 binds to IL-18Rα first at the extracellular space, and then recruits IL-
1R8 receptor to form a ligand/receptor complex for intracellular signal 
transduction (Nold-Petry et al, 2015). 
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The interaction between IL-37 and IL-18Rα is due to IL-37 sharing similarity in 
amino acids with the IL-18, in particular the two amino acids Glu and Lys that 
are conserved in IL-18 and IL-37 for the IL-18Rα binding (Bufler et al, 2002; 
Sharma et al, 2008; Bulau et al, 2014). However, the initial interaction between 
IL-37/IL-18Ra is not sufficient to trigger the intracellular signal transduction, 
therefore the IL-1R8 is recruited to the IL-37-IL-18Rα complex to form the 
tripartite complex on the cell surface and to elicit downstream signal 
transduction (Fig 1.10) (Bufler et al, 2002; Garlanda et al, 2009; Quirk et al, 
2014; Nold-Petry et al, 2015). IL-1R8 is an orphan receptor of IL-1R family 
(Garlanda et al, 2009). Many reports demonstrated even before the finding of IL-
37 that IL-1R8 (sigirr) is a negative immune regulator in immunity and disease (Li 
et al, 2015). While the detailed mechanism by which IL-1R8 regulates immune 
response is still lacking, it may do so via its mutation in the TIR domain (Riva et 
al, 2012). TIR domain, in particularly the conserved amino acids (Ser447 and 
Tyr536), are essential for signal transduction in all the IL-1R family (Garlanda et 
al, 2013). It has been revealed that IL-1R8 carries mutations in the TIR domain in 
which the conserved amino acids Ser447 and Tyr536 are replaced by the Cys222 and 
Leu305 (Riva et al, 2012). These mutations in IL-1R8 tail can still recruit adaptor 
MYD88 but it prevent the recruitment and activation of downstream protein 
kinases (Polentarutti et al, 2003; Lech et al, 2007). 
Thus, the IL-18Rα is important for the initiation of IL-37/receptor complex 
formation and IL-1R8 for triggering IL-37 signalling. The importance for both the 
receptors in IL-37 function and signalling has been evaluated by using 
neutralising antibody siRNA knock down and gene deficient mice of IL-18Rα or IL-
1R8 and showed that the anti-inflammatory signal transmission of IL-37 requires 
both receptors (Nold-Petry et al, 2015). 
Because of the regulatory effect of IL-1R8 on MYD88 function, it was thought 
originally that IL-37 may only regulate IL-1 and TLR signalling (the first IL37 
paper). Indeed, it has been shown that IL-37b is critical in the inhibition of IL-1 
and TLR by affecting the MYD88-dependent pathway and the production of 
inflammatory cytokine/mediators, including TNF-α, IL-1 and IL-6 (Ye et al, 
2014). This plays a central role against extracellular infections and 
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inflammation. However, its role in the regulation of the TRIF-dependent 
pathway is less studied.  
Interestingly, growing evidence suggests that the IL-37-mediatedreceptor-
dependent immunosuppressive capability may extend beyond the IL-1/TLR 
signalling and can also suppress inflammatory response induced by many other 
cytokines, for example TNFα, IL-6 and IL-17 (Nold-Petry et al, 2015). IL-37 may 
do so by inhibiting many protein kinases, includingFyn, TAK1, MAPK, and the 
transcription factor NF-кB, STAT3 and cell metabolic molecule mTOR, depending 
on the stimuli (Petry and Rudloff et al, 2015). Thus, via the receptor-dependent 
pathway, IL-37 has a wide range of effects in the regulation of major 
inflammatory pathways in immunity. 
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Figure 1.10 IL-37 receptor-dependent signalling pathway 
The figure illustrates IL-37 receptor dependent signal. A) The classical pathway of IL-18 
receptor. IL-18 binding to IL-18Rα, followed by IL-18RB chain activation and signal transduction 
results in pro-inflammatory mediator release.  B) IL-37 receptor dependent-pathway. 
Extracellular IL-37 binds to IL-18Rα first, followed by the tripartite complex formation (IL-37-IL-
18Rα-IL-1R8) and triggers anti-inflammatory signalling that inhibits downstream pro-
inflammatory response.  
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1.4.3.5.2  IL-37 receptor-independent signalling. 
 
Another important feature of IL-37 isoforms is their receptor-independent 
regulatory capability in inflammatory gene expression. It has been shown that 
both IL-37b and IL-37d are able to suppress inflammatory cytokine production in 
cells without the IL-37 receptor (Luo et al, 2017; Zhao et al, 2018). While the 
precise mechanism is still unclear, in particular for IL-37d, this is mainly due to 
their capacity for nuclear translocation by different mechanisms. It has been 
reported that IL-37b nuclear translocation requires active caspase-1, Smad3, and 
mature IL-37b but not pro-IL-37b is able to translocate into cell nucleus (Fig 
1.11) (Zhao et al, 2018). This was evidenced by: 1) Caspase-1 inhibition prevents 
IL-37 maturation, nuclear translocation and immune suppressre function. 2) 
Mutation in the caspase-1 cleavage site (D20) prevents IL-37b translocation to the 
nucleus (Bulau et al, 2014).3) Smad3-inhibitor prevents IL-37 nucleas 
translocation and ability to suppress inflammation in vitro and in vivo (Grimsby 
et al, 2004; Bulau et al, 2014; Dinarello et al, 2016).  
Thus, it is possible that stimulation with IL-1 or TLR signals increases IL-37 
precursor synthesis in the cytoplasm. In addition, LPS or IL-1 also induces 
caspase-1 expression. Caspase-1 then catalyses pro-IL-37 into mature IL-37 which 
binds to phosphorylated-Smad3 to form a IL-37- Smad3 complex which 
translocates to the nucleus. However, how the Smad3-IL-37 complex regulates 
gene expression in the nucleus is largely unknown. As Smad3 is also required for 
TGF--mediated immunosuppression, it is possible that IL-37 may also employ 
the TGF-Smad3 signalling pathway to control downstream gene expression 
(Grimsby et al, 2004).  
In contrast, we found that pro-IL-37a is able to translocate into cell nucleus via 
its NLS (unpublished result). However, the effect of nuclear pro-IL-37a on 
inflammatory gene expression is largely unknown and currently under 
investigation. 
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Figure 1.11 IL-37 receptor independent signalling pathway. 
Pro IL-37b expression is induced in the response to pro-inﬂammatory stimuli (TLR agonists, IL-1β; 
TNF). The precursor is processed by caspase-1; both the precursor and the mature forms of IL-
37b can be released from the cells via non-classic secretory pathways. The mature IL-37b binds 
to phosphorylated Smad3 and translocates to the nucleus, where it inhibits transcription of Pro-
inﬂammatory mediators.  
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1.4.3.6  IL-37 expression and function in human diseases 
The isoforms of IL-37 are widely expressed in different immune cells and 
different tissues (Wang et al, 2018). The expressions of IL-37 isoforms are 
induced by inflammatory signals, including TLR and inflammatory cytokines 
(Nold-Petry et al, 2015). IL-37a, IL-37b, and IL-37c expressed in stimulated B 
cells monocytes, skin keratinocytes, epithelial cells, natural killer (NK) cells. 
Interestingly, IL-37 isoform expression differs in different tissues; IL-37a is the 
only isoform that expressed in the brain, while only IL-37b expresses in kidney, 
IL-37c specifically in the heart; and IL-37d only expressed in the bone marrow 
and testis (Wang et al, 2018).  
IL-37 expression is low in normal cells and tissues, but the expression levels can 
bechanged in disease conditions. More importantly, the cytokine exerts 
regulatory effect in many diseases including endotoxemia, autoimmune, 
inflammatory diseases and cancers (Wang et al, 2018). The function of IL-37 in 
immunity and disease will been discussed in more details in Chapter 6. 
1.4.3.7  The effect of IL-37 on LPS-induced endotoxemia. 
Endotoxemia is a critical condition caused by LPS from gram-negative bacteria 
infection. Severe endotoxemia may lead to endotoxic shock and death due to 
multiple organ failure (Li et al, 2017). This is due to the over-activation of TLR4 
by high doses of LPS inducing inflammatory mediator production, including IL-6, 
IL-8, IL-1, TNF-α, histamine, and oxygen free radicals which in turn lead to 
septic shock (Wang et al, 2018). Endotoxemia is the best studied IL-37-regulated 
disease (Li et al, 2015). Current evidence shows that both IL-37b and IL-37d are 
able to control LPS-induced endotoxemia in mice (Li et al, 2017). 
IL-37b transgenic mice had reduced sub-lethal dose of LPS-induced tissue 
inflammation and hypothermia compared to the wild-type mice (Bulau et al, 
2014). Pro-inflammatory cytokine production is also reduced. Thus, IL-37b is a 
potent repressor of inflammation and protects against endotoxemia through 
inhibiting the expression of pro-inflammatory cytokines (Li et al, 2015; 2017). 
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Recent evidence suggests that IL-37d can also protect against endotoxemia in 
mice (Zhao et al, 2018). In vitro, bone marrow-derived macrophages from IL-37d 
transgenic mice express less pro-inflammatory cytokines, IL-1, IL-6 and TNF-α, 
after LPS stimulation, compared to wild type (wt) cells. In vivo, compared to wt 
mice, IL-37d transgene protects the mice against a lethal dose of LPS challenge 
(30 mg/kg), reduced mortality and hypothermia (Nold-Petry et al, 2015). The 
expressions levels of IL-6, TNF-α, IL-1β, IFN-γ, IL-17a, and chemokine MCP-1 in 
IL-37d-transgenic (IL-37d-tg) mice were markedly reduced compared with wt 
mice. However, the underlying mechanism by which IL-37 isoforms suppress LPS 
shock may be different.  
It has been shown that IL-37b can regulate the LPS response via IL-37 receptor-
dependent and independent pathways in vitro using cells expressing or not IL-
37b and receptor IL-1R8 in a RNA-sequencing assay (Nold-Petry et al, 2015). IL-
37 signalling in IL-1R8-dependent pathway activates anti-inflammatory and 
metabolic mediators including Mer, PTEN, PG2 (dok), GSK-3B, STAT3, FOXO-1, 
HD1-5. In addition, the IL-1R8 dependent pathway also inhibits the metabolic 
check-point mTOR and other inflammatory mediators such as Fyn, PBP, TAK1, 
TBK1, c-jun, Iкβ proteins. NF-кB pathway is also downregulated by IL-37 using 
receptor dependent pathway (Nold-Petry et al, 2015).  
IL-37b can also regulate important LPS-induced kinases and transcription factors 
activity independently from the receptors in vitro using RNA-sequencing assay 
(Nold-Petry et al, 2015). In this pathway, IL-37 significantly down regulates the 
expression of many inflammatory genes CADTK, Raf-1, KSR, MKK1, MKK6, MKK4, 
MKK7, ERK1, ERK3, ATF-2, SYK, FADK, STAT5α, STAT5β, SHP-2, PAK1, Vav1, S6k-
B, IR and IGF-1 receptor. This suggests that IL-37b can regulate inflammatory 
pathways without the receptor. While this may contribute to IL-37b-mediated 
regulatory effect, it is unknown how IL-37 does that. Although IL-37 can regulate 
LPS responses independently from IL-1R8, it has been demonstrated that the 
receptor-dependent pathway is required for the IL-37-mediated anti-
inflammatory effect in endotoxemia since transgenic IL-37 transgenic mice 
without IL-1R8 completely failed to protect against LPS challenge (Nold-Petry et 
al, 2015). This result is important to show the relative importance of the two 
pathways in IL-37-mediated effects. How IL-37d regulates LPS response is less 
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clear, it has been suggested that IL-37d mediated protective effect is largely 
receptor-independent in vitro. IL-37d may do this by interacting with Smad3 and 
promoting nuclear translocation of Smad3 (Zhao et al, 2018). However, whether 
this is also the case in vivo is unknown. IL-37b is also able to regulate 
inflammatory bowel disease (IBD). The expression level of IL-37b is markedly 
high in the epithelial cells of the inflamed mucosa of both Crohn's disease (CD), 
and ulcerative colitis (UC) patients, while it is not detected in normal colonic 
mucosa (Imaeda et al, 2013). Using an experimental colitis model, IL-37-tg mice 
exhibit improved tissue inflammation and clinical scores compared to wt mice 
(Bello et al, 2018). The reduced inflammatory response may be due to IL-37 
targeting the key inflammatory NF-κβ pathway in the inflamed bowel mucosa. 
IL-37 is also highly expressed in patients with rheumatoid arthritis (RA) 
compared with healthy controls. Local intra-articular injection of rIL-37 results 
in delayed disease onset and ameliorates the clinical symptoms of arthritis, 
mainly through the inhibition of Th17 cell proliferation and the production of 
inflammatory cytokines, particularly IL-1β and IL-6 (Ye et al, 2014). IL-37 also 
suppresses allergic inflammation by abrogating the Th2 response in asthma. 
Local administration of IL-37 significantly reduces the inflammatory cell 
infiltration in lung tissue in a murine model of asthma as well as decreasing Th2 
cytokine production in lung (Zhang et al, 2017). Intriguingly, IL-37 plays a 
prominent therapeutic role in several types of cancers. IL-37 suppresses cervical 
cancer (CC) cell proliferation and invasion in vitro. In CC IL-37, down regulates 
of key tumorigenic factor STAT3 expression and phosphorylation. Consequently, 
IL-37 may be a new anticancer cytokine that offers a potential treatment for CC 
through down regulation of STAT3 expression and phosphorylation (Wang et al, 
2015). Colon cancer tissues express IL-37 barely, but IL-37 overexpression in 
colon cancerous tissues suppresses cancer cell proliferation, migration, invasion, 
and colony formation by suppressing the expression of β-catenin.  In mice colon 
cancer model, transgenic expression of IL-37 increases cancer cell sensitivity to 
chemotherapy drugs, suggesting that IL-37 might be a novel therapeutic 
regulator in colon cancer (Yan et al, 2017). IL-37 also reduces myocardial injury 
in ischemia reperfusion through suppressing the pro-inflammatory cytokines and 
chemokines production and reducing infiltration of neutrophils (Wu et al, 2014). 
All these result in decreased cardiomyocyte apoptosis and ROS generation. 
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1.5 Recombinant protein production and application 
Recombinant proteins have a wide range of applications in clinical treatment 
and in research. Successful recombinant protein production depends on several 
factors (Rosano and Ceccarelli, 2014). 
1.5.1 Recombinant protein expression systems 
1.5.1.1  Host cells 
The cellular host for recombinant protein production can be mammalian, insect 
cells or microorganism systems including bacteria, yeast, filamentous fungi and 
unicellular algae. The host selection depends on the nature and quality of the 
recombinant protein. For instance, eukaryotic cells can be used for protein 
expression if post-translational modifications (such as protein glycosylation) are 
necessary. Otherwise, a prokaryotic system is preferred (Demain and Vaishnav, 
2009; Rosano and Ceccarelli, 2014). Other factors including post-translational 
modifications of the functional recombinant product, cost, protein yield, toxicity 
of the protein and secretion of the protein are all critical for the host cell 
selection since each host system has advantages and disadvantages (Demain and 
Vaishnav, 2009; Adrio and Demain, 2010). 
1.5.1.2  Expression vector 
Recombinant protein gene canbe expressed from a plasmid vector, which 
expresses the protein in the host cells. An expression vector contains the 
interested protein gene (cDNA) which is substituted by the upstream promotor, 
ribosome-binding site, and downstream stop sequences in the expression vector. 
Vector specificity is governed by the host system and choosing an appropriate 
promotor controls the expression of the protein, for instance inducible 
promotors are needed to avoid the toxicity of recombinant protein to the host; 
in contrast, constitutive promotors do not need inducer agent (Overton, 2014). 
The addition of tags to the expressed protein gene is important for recombinant 
protein detection and purification; and most of these tags not only do not affect 
the protein folding or secretion but also improve the expressed protein solubility 
and stability. In addition, tags provide strong affinity for the chromatography 
medium such as polyhistidine tags that consists of four to 10 histidine residues; 
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other tags include glutathione S-transferase (GST), maltose-binding protein 
(MBP) and streptavidin tag strep-tag II (Oliveira and Domingues, 2017). 
1.5.1.3  Recombinant protein purification 
The purification of tagged recombinant proteins iscarried out through 
immobilised metal affinity chromatography (IMAC) technique with almost a 
successful single step and different metal affinity chromatography used for 
different tagged proteins. IMAC can be used as manual or automated system for 
small and large-scale purification of tagged proteins respectively. Since manual 
purification is time-consuming, the automated purification system, such as the 
ÄKTA chromatography systems, is used for large-scale protein preparations with   
reproducible results. IMAC is based on the interaction between specific amino 
acid side chains in the tagged recombinant protein and a transition metal ion 
immobilized on a matrix. This transitional ion could be di-valent ions including 
CO+2, Ni+2, Cu+2, or Zn+2 or trivalent cations such as Al+3, Ga+3, and Fe+3, or 
tetravalent such as Zr+4 depending on the application. Di-valent ions are used for 
His-tagged proteins, while tri and tetravalent ions are used for phosphoproteins 
and phosphor peptides (Waugh, 2005; Carson et al, 2007). Soluble recombinant 
proteins produced in E-coli can be purified by IMAC directly.  However, the 
insoluble protein products in the inclusion bodies can also be efficiently purified 
as denatured soluble protein using denaturing purification conditions such as 
high concentrations of urea or guanidinium hydrochloride. The purified 
denatured proteins can then be renatured by replacing the denaturing reagents 
with balanced buffers via dialysis (Structural Genomics Consortium, 2008).  
1.5.2 The applications of recombinant protein 
Recombinant proteins are widely used clinically and in research in different 
fields. 
1.5.2.1  Medicine  
Several recombinant proteins are used clinically as effective therapeutics for 
several fatal metabolic disorders or endocrine dysfunctions, suchas insulin for 
the treatment of type I diabetes and clotting factor VIII for haemophilia, 
respectively (Hermeling et al, 2004; Akash et al., 2013a, 2013d). Bioactive 
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recombinant proteins may serve as therapeutic drugs to induce beneficial 
immune responses; for instance recombinant IFNα for hepatitis C treatment, and 
recombinant erythropoietin to treat chronic anaemia (Corwin et al, 2002; van 
Zonneveld et al, 2004; Akash et al, 2015). Recombinant therapeutic proteins 
with specific targeting activity such as Ibritumomab tiuxetan (anti-CD20 
recombinant antibody) and anakinra (IL-1 antagonist) are used to treat 
transformed non-Hodgkin’s lymphoma and rheumatoid arthritis respectively 
through different mechanisms, including interfering with a molecule’s function 
or lysis of pathogenic cells or pathogens. Recombinant vaccines are another 
application of recombinant proteins that trigger  the body’s natural defence 
immune response to protect against infectious diseases. For example, the 
recombinant hepatitis virus surface antigen (HBsAg) vaccine can be used to 
immunise and protect against HBV infection (Akash et al, 2015).  
1.5.2.2  Applications in Research 
Recombinant proteins are important in the study of many subjects including cell 
and molecular biology, structural and biophysical studies, immunology and 
biochemistry. Recombinant bioactive proteins are used to study the function of 
the protein in different cellular activities, such as metabolism, growth, cell 
signalling and disease progression, transcription, translation, protein 
modification, depending on the bioactivity of the proteins (Andersen and 
Krummen, 2002).  
Recombinant proteins and antibodies are useful tools in the understanding of 
protein-protein interactions. They have been applied in several laboratory 
techniques, such as ELISA, western blot, and immunohistochemistry (IHC) 
(Andersen and Krummen, 2002). 
1.5.2.3  Protein quality control 
Protein quality depends on the evaluation of three important aspects; purity, 
homogeneity and structural conformity. Purity is the most important aspect, 
since recombinant proteins are usually contaminated with proteins and other 
molecules from the host cells, such as nucleic acids, endotoxins and other 
proteins, or by the extraction and purification procedures (Glasel, 1995); and 
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these contaminants are serious, especially for therapeutic applications (Dullah 
and Ongkudon, 2016). Heterogeneity is also important for recombinant protein 
quality, since low or high molecular weight soluble protein aggregates form by 
the association of two or more polypeptide chains through non-covalent bonds to 
form dimers and tetramers. These dimers and tetramers affect the protein 
activity, immune response and structural assays such as crystallization (Murphy 
and Roberts, 2013).  A valuable complementary feature in protein quality control 
is the validation of the protein folding. Protein conformational changes circular 
dichroism (CD) is preferred for determination of the folding properties, 
secondary structures, mutations, and fusion tags effects on the protein stability 
(Healey et al, 2017; Zvonova et al, 2017). 
Hypotheses:  
1- Based on the current studies and evidence described above, I 
hypothesised that IL-37a was expressed and induced in immune cells 
including B cells. 
2- Based on comparison at the C-terminal with IL-37b, IL-37a should be 
bioactive with anti-inflammatory effects. 
3- IL-37b function in innate immune cells as an inflammatory suppressive 
cytokine, however IL-37a and b isoforms function on B cells is unknown. 
4- Based on the differences   at the N-terminal, IL-37a and b regulate 
different genes and pathways. 
Aims: 
1. To produce recombinant IL-37a and b (Chapter 3). 
2. To find out the function of IL-37a in B cells (Chapter 4). 
4. To explore the differences between IL-37a and b (Chapter 5).   
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Chapter 2 
Materials and Methods 
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2 Materials and Methods 
2.1 Mice model 
Transgenic IL-37a C57BL/6 mice and wt mice were housed in the Biological 
Services facility, University of Glasgow, according to United Kingdom Home 
Office regulation. The mice were used typically starting at 4-6 weeks old. IL-37a 
and wt mice were kindly supplied by Dr. Xu (Institute of Infection, Immunity and 
Inflammation. University of Glasgow/ Glasgow, UK). 
2.2 Cell stimulators 
Cell stimulators are illustrated in table 2.1 with the appropriate concentrations 
that used.  
Table 2.1 Stimulators used in cell activation 
 
cell stimuli 
 
Supplier 
 
working 
concentrations 
 
  Human CD40 
 
Enzo Life 
Sciences 2ug/ml 
Human anti-IgM 
 
 Jackson 
ImmunoResearch 10 ug/ml 
Human IL-2 
 eBioscience 10 ng/ml 
Human IL-21 
 eBioscience 50 ng/ml 
Lipofectamine™ RNAiMAX 
 
Thermo Fisher 
 
25 ul/well (96 well plate) 
 
 CpG  
 
 InvivoGen 
 
3 ug/ml 
 
LPS 
 
Thermo Fisher 
 
100 ng/ml, 10ug/ml 
 
rhIL-37a 
 House made 50 ng/ml 
rhIL-37a 
 House made 50 pg/ml 
rhIL-37b 
 House made 50 ng/ml 
rhIL-37b 
 House made 50 pg/ml 
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2.3 Antibodies 
Antibodies used for ELISA and western blotting are listed in Table 2.2 
Table 2.2 Antibodies used in ELISA and western blotting 
 
Antibody 
 
 
Produced in 
 
 
Stock 
concentration 
 
Dilution 
 
 
Company: 
Cataluge number 
 
Anti-6 His-tag 
 
Mouse    
0.1 mg/ml 1 :1000 Abcam: ab18184  
horseradish 
peroxidase (HRP) 
 
Rabbit 
1.0 mg/ml 1:2000 Abcam: ab97046 
Biotinylated 
anti-human IgG 
 
Mouse 1 mg/ml 1:1000 Invitrogen: 05–4220 
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2.4 Chemicals and reagents 
Chemicals and buffers used throughout the project are listed in Tables 2.3 and 
2.4. 
Table 2.3 Chemicals 
 
Chemicals 
 
Supplier 
 
Usage 
 
1M /1N hydrochloric acid 
 Sigma-Aldrich, USA ELISA 
Tween® 20 
 Sigma-Aldrich, USA ELISA 
3, 3', 5, 5'-Tetramethylbenzidine (TMB) 
 eBioscience, USA ELISA 
Imidazole 
 Sigma-Aldrich, USA 
Protein 
purification 
EDTA-free complete protease inhibitor 
cocktail 
 Sigma-Aldrich, USA 
Protein 
purification 
DNAseI 
 Sigma-Aldrich, USA 
Protein 
purification 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) 
 Sigma-Aldrich, USA 
Protein 
purification 
30% (v/v) Acrylamide 
 Sigma-Aldrich, USA 
Protein 
purification 
10% (w/v) SDS 
 Sigma-Aldrich, USA 
Protein 
purification 
10% (w/v) Ammonium persulfate (APS) 
 Sigma-Aldrich, USA 
Protein 
purification 
N, N, N′, N′-tetramethylethylene-diamine  
(TEMED) Sigma-Aldrich, USA 
Protein 
purification 
Lysozyme 
 Sigma-Aldrich, USA 
Protein 
purification 
Ampicillin 
 Sigma-Aldrich, USA 
Protein 
purification 
Kanamycin 
 Sigma-Aldrich, USA 
Protein 
purification 
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Table 2.4 Buffers 
 
 
Buffer 
 
Composition 
 
Phosphate buffered saline 
(PBS) 
 
 
NaCl (0.137 M), Na2HPO4 (0.01 M), KCl (0.0027 M), 
KH2PO4 (0.0018 M), pH7.4 
 
 
ELISA coating buffer 
 
 
100 mM NaHCO3 pH 8.4, unless specified otherwise 
 
 
ELISA wash buffer 
 
 
0.05% (v/v) Tween-20 in PBS pH 7.4, unless specified 
otherwise 
 
ELISA assay buffer 
 
 
10% (v/v) FBS in PBS, unless specified otherwise 
 
 
Nickel binding buffer   
 
 
10 mM Imidazole, 20 mM Tris-Base,500 mM NaCl 
 
 
Nickel gradient buffer 
(Elution buffer) 
 
500 mM Imidazole, 20 mM Tris-Base, 500 mM NaCl     
 
 
10X SDS running buffer 
 
 
248 mM TriS base, 1.92 M glycine, 1% (w/v) SDS , in 2 
litter, pH 8.3 
 
Coomassie stain buffer 
 
 
0.1% (w/v)  Coomassie Brillant Blue R-250, 50% (v/v) 
methanol and 10% (v/v)  glacial acetic acid 
 
De-staining solution  
 
 
30% (v/v) methanol, 10% (v/v) glacial acetic acid 
 
 
Lura bertani  
 
 
1% (w/v) NaCl, 1% Trypton (w/v), 0.5% (w/v)  yeast , pH 
7.5 
 
 
Tris buffer 
 
 
250 mM NaCl, 50 mM Tris PH=7.5. 
 
 
5X SDS-PAGE sample loading 
buffer 
0.25 M Tris-HCl pH 6.8, 0.5 M DTT, 10 % (w/v) SDS, 50 % 
(v/v) Glycerol, 0.5 % (v/v) bromphenol blue. 
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2.5 Preparation and transformation of chemically competent E. 
coli cells 
In order to purify IL-37a and b, plasmids for each isoform were transformed into 
competent E. coli DH5α cells. To prepare chemically competent E.coli, bacterial 
cells were cultured overnight in Lura Bertani (LB) medium at 37°C and 120 rpm. 
100 ml of fresh LB was inoculated with 1 ml of the overnight culture. The culture 
was incubated at 37°C and 120 rpm for approximately 1.5-2 hours until OD 600  
reached 0.350. The flask was immediately transferred in to on ice for 10 minutes 
to stop bacterial growth. The culture was split between two 50 ml conical tubes, 
and both were pelleted at 4°C at 400 xg for 10 minutes. The supernatant was 
removed and cell pellets re-suspended in 15 ml ice-cold, sterile 0.1 mM CaCl2 
solution before being re-pelleted at 400 Xg, 4°C for 15 minutes. After that, the 
pellets were re-suspended in 2 ml of 0.1 mM CaCl2 solution and 200 μl frozen at -
80 °C with 20% (v/v) sterile glycerol. The bacterial cells should be kept on ice at 
all times. For transformation, aliquots of competent cells were thawed on ice 
before adding 10 μl of the ligation mix. The reaction mixture was incubated on 
ice for 15 minutes before being heat-shocked in a 42°C hot plate for 90 seconds, 
and then immediately placed on ice. After 2 minutes, 600 μl of LB liquid medium 
was added and incubated for (1-2) hours at 37°C on an orbital shaker set at 120 
rpm. The transformation mixture was centrifuged at 400 xg for 1 minute. The 
supernatant was decanted and the pellet re-suspended in the residual mediaby 
vortexing. Subsequently, transformation mixture was spread on to LB plates 
supplemented with 100 μg/ml ampicillin or kanamycin. All plates were incubated 
at 37°C for 24 hours. 
2.5.1 Plasmid DNA extraction 
Plasmid DNA was extracted from DH5α strains of E. coli using the QIAprep®Spin 
Miniprep Kit (Qiagen) according to the manufacturer’s instructions.  
2.5.2 Storage and bacterial growth conditions 
All bacteria strains were stored for long term as glycerol stocks held at -80ºC. 
Single colony was grown in the appropriate selection media supplemented with 
the correct antibiotic and stored in 1ml aliquots with 10% (v/v) glycerol. DH5α E. 
coli strain was routinely grown at 37°C in typical LB agar or broth. Media were 
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supplemented with (50 µl/ml or 100 µl/ml) of Ampicillin or Kanamycin 
antibiotics respectivly according to the transfected plasmid. 
2.6 Recombinant IL-37 production 
The His-tagged recombinant IL-37 proteins were produced in E.coli and affinity 
purified using Nickel-nitrilo triacetic acid-agarose (Ni-NTA) in Dr. Xu’s lab. 
2.6.1 Recombinant human IL-37a and IL-37b purification 
The His-tagged human IL-37 plasmids (pET-28a- IL-37b and pET21 a- IL-37a) for 
IL-37b and IL-37a respectively were prepared by Dr. Xu’s lab, and used for 
recombinant IL-37 b and IL-37a protein production in E. coli using immobilized 
metal affinity chromatography (IMAC) followed by size exclusion chromatography 
(SEC). 
2.6.2 Recombinant IL-37 test expression 
Initially the levels of expression of both recombinant IL-37 proteins were 
assessed in E. coli host strains BL21 (DE3) PlysS competent cells using different 
time points. Single colony containing recombinant IL-37 vector DNA (pET-28a/IL-
37b or pET21 a/IL-37a) was used to inoculate 10 ml of LB broth supplement with 
50 ug/ml of kanamycin or 100 ug mlampicillin for IL-37b and IL-37a respectively; 
and grown overnight at 37 ˚C with shaking. The following day, 100 µl of 
overnight culture were added to 5 ml of LB broth with antibiotic and incubated 
with shaking until an optimum density of 600 (OD 600) reached (0.4-0.6). The 
protein expression was induced by the addition of 1 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG; Sigma-Aldrich, Poole, Dorset, UK) directly to the 
cell suspension. Expression was induced for (1-7) hours at 37 °C with shaking at 
180 rpm. Following incubation, 200 µl of broth were collected and centrifuged at 
400 xg at 4°C for 10 minutes. Supernatants were decanted and bacterial pellets 
were weighed and then stored frozen at -80°C until protein expression tested on 
sodium dodecyl sulphate polyacrylamide SDS-PAGE. 
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2.6.3 Large scale expression of rIL-37 in E. coli 
For large-scale expression in E. coli, a single colony of bacteria containing 
recombinant vector DNA (pET-28a/IL-37b or pET21 a/IL-37a) was used to 
inoculate a 60 ml overnight culture as described in the previous section. The 
following day, the overnight culture was diluted 1/100 in fresh 625 ml of LB 
broth (6.25 ml for a 625 ml culture) and incubated at 37°C with shaking at 180 
rpm until an OD 600  of reached (0.4-0.6). Recombinant IL-37 protein expression 
was induced with 1 mM of IPTG for (4.5-5.0) hours and the cells were harvested 
by centrifugation at 400 xg at 4°C for 10 minutes; using the Avanti J-26PI 
centrifuge (Beckman Coulter, Inc). Supernatants were decanted and the 
bacterial pellet collected and stored at -80 °C until protein purification. 5 litres 
of LB broth were used in each experiment. 
2.6.4 Purification of recombinant IL-37 from E. coli using immobilized 
metal affinity chromatography (IMAC) 
Following recombinant IL-37 expression containing the N-terminal 6X His-tag as 
described in the previous section, the cell pellet was thawed on ice and re-
suspended in 35 ml of lysis buffer (35 ml of binding buffer, 1mg/ml lysozyme, 1M 
MgCl2, pH7.9, one tablet of EDTA-free complete protease inhibitor cocktail and 
5 μg/ml DNase I). The pellet was mixed into a homogeneous suspension in lysis 
buffer, and then sonicated 10 cycles with 15 seconds on, and 45 seconds off, 
keeping on ice throughout. The total cell lysate was centrifuged for 30 minutes 
at 5000 xg at 4°C in 50 ml conical centrifuge tubes (ThermoFisher Scientific, 
Loughborough, UK). After centrifugation, the target protein was purified with 
the Nickel nitrilo triacetic acid (Ni-NTA) column (His-TrapTM HP column, GE 
Health care), according to the manufacturer’s instructions, using the Akta 
Purifier chromatography system (UPC 10, GE Healthcare). Purification of the 
target proteins was confirmed by SDS-PAGE, and Coomassie blue staining. The 
purified protein dialysed in 200 mM NaCl, 50 mM Tris, pH 7.5 overnight at 4 ºC, 
using standard diyalysis membrane 5 kDa (Fisher Scientific), and the next day 
purified by gel filtration.     
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2.6.5 Purification of rIL-37 using size exclusion chromatography (SEC) 
Size exclusion chromatography (SEC) (also known as gel filtration column 
chromatography), is a method used to separate proteins, primarily based on 
molecular size. A sample volume of up to 5ml was loaded onto a Sephadex S-75 
column (GE Healthcare) according to the manufacturer’s protocol. The column was 
run using the Prime purifier chromatography system (GE Healthcare), and the elute 
was collected into 1.5 ml/fraction. Samples from the observed peaks were collected 
and analysed by SDS-PAGE. 
2.6.6 Sodium dodecyl Sulphate-Polyacrylamide gel electrophoresis (SDS-
PAGE) 
SDS-PAGE was performed to check IL-37 expression and purity, following the 
steps below:  
SDS-PAGE preparation: To prepare 15% SDS-PAGE the following chemicals were 
mixed: H2O 1.1 ml, 30% Acrylamide 2.5 ml, 1.5 M Tris–HCl (pH 8.8) 1.3 ml, 10% 
SDS 50 µl, 10 % (w/v) ammonium persulfate (APS) 50 µl and N, N, N′, N′-
tetramethylethylene-diamine (TEMED) 2 µl. The gel poured to the cast and left 
approximately 2 cm below the bottom of the comb for the stacking gel. The top 
of the gel was layered with isopropanol to remove any bubbles and to keep the 
gel from drying out. After the gel completely polymerized, the isopropanol was 
removed, and the gel washed with distilled water (dH2O). The stacking gel was 
then prepared by mixing H2O 1.4 ml, 30% Acrylamide 0.33 ml, 1 M Tris–HCl (pH 
6.8 0.25 ml, 10% (w/v) SDS 20 µl, 10% (w/v) APS 20 µl and TEMED 2 µl); the 
stalking gel was poured on the top of the separation gel; the comb was added to 
make the wells. 
Sample running: The purified recombinant IL-37 was diluted 1:1 with 2X SDS 
loading buffer composed of (125 mM Tris-HCl, 3% SDS, 40% glycerol and 5% β-
mercaptoethanol, pH 6.8), and incubated at 95 °C for 10 minutes before being 
loaded on to 15% SDS gel. Samples were separated at a constant voltage of 160 V 
for 1 hour in a 1X running buffer. 5 μl of SeeBlue Plus 2 pre-staining molecular 
weight standards (Invitrogen, Life Technologies, Paisley, UK) were used for 
molecular size estimation. Once electrophorised, the gel was stained with 
Coomassie blue (the next section). 
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2.6.6.1 Coomassie blue staining of proteins 
Within this study Coomassie blue dye was used to visualise proteins separated by 
SDS-PAGE. Following electrophoresis, the gel was incubated at room 
temperature with constant shaking in a solution of Coomassie brilliant blue stain 
(0.1% (w/v) Coomassie Brilliant Blue R-250, 50% (v/v) methanol and 10% (v/v) 
glacial acetic acid) for 30 minutes. The gel was then washed with a de-staining 
solution (10% methanol, 10% glacial acetic acid) at room temperature with 
constant shaking for 10 minutes. This washing step was repeated several times 
to enable the visualisation of individual protein bands. 
2.7 Western blotting 
Different fractions of the purified proteins (rIL-37a and rIL-37b) after Ni-NTA 
purification were electrophoretically separated for 1 hour (150 V). The 
separated proteins were transferred on to a nitrocellulose membrane for 1 hour 
(30 V) in an X Cell II blot module (Invitrogen, UK) containing transfer buffer. The 
membrane was then washed in PBS, and blocked with 10 % (w/v) non-fat milk 
powder in PBS for 1 hour at room temperature. After 3 × 5 minutes washes in 
PBS, the membrane was probed with primary antibody mouse anti-6His-tag 
(1:1000 dilution) in 5% (w/v) non-fat milk powder in PBS-tween for 2 hours at 
room temperature. The membrane was washed in 3×5 minutes washes in PBS-
tween; and probed with horseradish peroxidase-conjugated anti mouse 
secondary antibody (1:2000) in PBS-Tween for 1 hour at room temperature. After 
the 3×5 minutes washes in PBS, the membrane was incubated in 
chemiluminescent substrate (Amersham ECL, Amersham Bioscience) for 30 
seconds. The membrane was then drained from the excess substrate, and 
imaged with the fluorescence scanner. 
2.8 Protein concentration measurement 
Recombinant human IL-37 protein concentrations were determined using 
Coomassie Protein Assay Kit (Bradford). First, 2-fold serial dilutions of the 
standard protein (Bovine serum albumin standards, Thermo Scientific, USA) were 
performed. 480 μl of Coomassie Reagent were added to 20 μl of the serial 
diluted standards, samples and PBS as blank, mixed well and incubated 10 
minutes at room temperature. 150 μl of the samples were transferred to a 96-
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well flat-bottom plate; the OD values were measured using an ELISA reader using 
600-nm absorbance. The protein concentrations in the samples were determined 
by interpolating the readings to the OD values of the standards. 
2.9 Endotoxin removal 
Endotoxin in the purified recombinant human IL-37a and b (rIL-37a, rIL-37b) 
proteins was removed by purification with polymyxin B columns following the 
manufacturer’s instruction. A new column (EndoTrap) was placed in a holder and 
the top cap removed first then the bottom cap, allowing the storage solution to 
drain from the column (approximately 8 minutes), making sure that the 
EndoTrap resin does not run dry. The column was activated as follows: the 
column was filled with regeneration buffer (approximately 3 ml) and allowed to 
drain out, repeated once; the column was filled with equilibration buffer 
(approximately 3 ml) and drained out, repeated once. Then the column was 
filled with sample (purified rhIL-37 proteins) in PBS and the flow through liquid 
collected immediately; the column could be repeatedly filled with up to 50 ml of 
samples. The column was filled with 1 ml of PBS and drained out to elute 
samples completely. 
2.9.1 Endotoxin detection 
Endotoxin levels in the rhIL-37 preparations were measured using 
Limulusamebocyte lysate (LAL) QCL-1000 pyrogen test following the 
manufacturer’s manual. The microplate was preheated to 37˚C in a heating 
block adapter (Thermo Fisher Scientific, USA). While  leaving the plate on the 
heating block, 50 μl of standards and samples were added to the wells, for the 
blank control; 50 μl of LAL reagent water was used. 50 μl of LAL were then 
added into each well using amulti-channel pipette in the order of the reagent 
addition. The plate was tapped for mixing and incubated for 10 minutes followed 
by adding 100 μl ofpreheated substrate solution into each well. 16 minutes later, 
the reaction was stopped by adding 100 μl of stop reagent in the same sequence 
as the previous steps. The plate was removed from the heat block and read with 
an ELISA reader (Dynex Technologies, USA) using absorbance at 410 nm, 
theopticaldensity (OD) recorded and the samples’ concentration calculated 
based on the linear standard curve obtained by the standards on the same plate. 
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2.10 Bioactivity test of recombinant IL-37a and b in RAW 264.7 
cell line. 
To determine the bioactivity of the in-house prepared rIL-37a and b, murine 
RAW 264.7 cells (106/ml per well) were cultured in 24 well plate using DMEM 
medium, stimulated with LPS (100 ng/ml) and treated with different doses of 
rIL-37a and rIL-37b purified by different columns previously. Cells were 
harvested after 24 hours of culturing for gene expression estimation; the culture 
supernatant was tested for IL-6 ELISA using murine IL-6 cytokine ELISA kit from 
R&D system, and the cells pellet were  harvested for gene expression by qPCR.  
RAW 264.7 cells were cultured in a 75 cm2 flask with total volume of 10 ml DMEM 
medium. Cells splitting was carried out carried out after confluence, which was 
estimated to be around 60-70%. The growth of RAW cells was monitored; once a 
monolayer of cells had partially covered the flask (approximately 70% 
confluence), cells were removed by lifting, and passaged as follows. RAW 264.7 
cells are quite adherent to tissue culture flask; thus, trypsin does not lift the 
cells; therefore, cells were washed twice with 3 ml of PBS, gently lifted and 
scraped off the flask with a scraper and warm media. The cell suspension was 
collected from the flask; spun for 8 minutes at 300 xg; re-suspended into fresh 
media; seeded in to a new flask with 1:3, 1:4 or 1:5 dilutions; and placed back 
into  humidified incubator (5% CO2 at 37°C).  
2.11 Protein Crystallization 
Purified IL-37b was dialysed overnight against PBS pH 7.5, then concentrated 
into 14 mg/ml using Sartorius viva spin (50 ml tube from thermos Fisher 
Company) and kept on ice.  Several commercial High throughput screens were 
used including: JCSG- plus-HT-96, MIDAS-96, Morpheus-HT-96, and PACT 
premier-HT-96 using drop vapour diffusion. All crystal trays were set up using a 
Cartesian Honeybee robot (Hamilton, UK). Crystal drop was set up 1:1 protein: 
buffer ratio, with a final volume of 1 ul. The trays were kept at 17 ºC in the 
incubator. 
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2.12 Mass Spectroscopy (MS) 
IL-37a band on the SDS-PAGE was cut, and put in an epindroph, sent to Wolfson 
Wohl Cancer Research Centre/ University of Glasgow, for confirming IL-37a 
identity.    
2.13 Circular Dichroism (CD) 
IL-37b diyalised in PBS, and CD performed at final concentration of 120 ug/ml, 
at Institute of Molecular Cell & Systems Biology/ Glasgow University  
2.14 Tissue culture 
Cells were cultured in complete medium (Roswell Park Memorial Institute (RPMI) 
1640 for suspension cells or Dulbecco's modification of Eagle medium (DMEM) for 
adherent cells, supplemented with 10% heat inactivated FBS, 100 U/ml 
Penicillin, 100 μg/ml Streptomycin, 2 mM L-glutamine (Invitrogen Ltd., UK, 
unless otherwise specified). Cultures were incubated at 37.0°C in a humidified 
incubator (Heraeus Instruments, Germany) supplemented with 5% CO2. Viable 
cells were counted with a Neubauer haemocytometer (Weber Scientific 
International Ltd, UK) on a Nikon Labphot microscope, staining with 0.1% (w/v) 
Trypan Blue (Sigma-Aldrich, USA). 
2.14.1 THP-1 cells line 
Human monocytic THP-1 cells were used to identify IL-37 isoform expression. 
THP-1 cells were cultured in 24 well plate (106/ml) using RPMI medium, cells 
were stimulated with different doses of LPS (100 and 200 ng/ml), and IL-37 
isoforms expression estimated by qPCR. After determination of the suitable dose 
of LPS for IL-37 isoforms expression, different time points (3, 16, and 24 hours) 
were used to determine the best time of IL-37 expression.  
2.14.1.1 IL-37 knocks down in THP-1 cells  
On the day of transfection, cells were harvested and seeded to 24 well plate at 
the density of 1.5 x 105 cells/ ml/ well in a culture medium without antibiotics 
and left for an hour in the incubator. 100 nM siRNA (Thermo Fisher Scientific) 
and Lipofectamine RNAiMax reagent (Thermo Fisher Scientific) were diluted as 
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described in the protocol and incubated for 5 minutes at room temperature. A 
mixture of primers was used to silence the isoforms, and the sequences of the 
primers used can be found in table 2.5. The complex formed was gently mixed 
with the cells and incubated for 48 hours. Control cells were transfected with 
negative control siRNA (Silencer® select negative control No.1 siRNA, Thermo 
Fisher Scientific). Following the incubation, cells were pelleted by centrifugation 
at 200 xg for 5 minutes; re-suspended to fresh complete media with antibiotics 
and centrifuged again to maximise the removal of the lipid complex. Cells were 
seeded again to the 24 well plate and incubated for an hour in the incubator to 
settle down before the LPS stimulation. Cells were stimulated with 20 ng/ml of 
LPS for 6 hours, harvested and stored at -20°C until further analysis. The only 
difference in control cells was absence of LPS stimulation. 
Table 2.5 Small interference RNA siRNA oligonucleotides 
 
siRNA IL-37a 
Target  
16-38 
nucleotides  
sense 5'- GAGGGAAACAGAAACCAAAUU-3’ 
antisense 5’- UUUGGUUUCUGUUUCCCUCUU-3’ 
Target 
 35-57 
nucleotides 
sense 5'- GGAAAGAACAGCUUUAAGAUU-3’ 
antisense 5’-UCUUAAAGCUGUUCUUUCCUU-3’ 
siRNA  IL-37 
Target 
conserved 
regions of all 
isoforms 
sense 5′-UCAAGGAUGAGGCUAAUGCUU-3′ 
antisense 5′-CAAUGUGUUUCCUGUUCUCUU-3’ 
sense 5′-UUACAAUUGCAGGAGGUGCUU-3’ 
antisense 5′-UUAUCCUUGUCACAGUAGAUU-3′ 
 
2.14.2 3T3-ms CD40L feeder cell preparation 
3T3-ms CD40L cells were cultured in complete DMEM (10% heat inactivated FBS, 
100 U/ml Penicillin, 100 µg/ml Streptomycin, 2 mM L-glutamine). 1 × 106 3T3-
msCD40L cells were seeded in T-75 cell culture flasks containing 15-20 ml of 
complete DMEM medium. When cells reached (80–90)% confluency, the culture 
medium was aspirated, the cells washed with 10 ml of PBS, trypsinized by adding 
4 ml of trypsin and incubated at 37°C for 4 minutes, and digestion stopped by 
adding 5 ml of whole medium that contains serum anti-trypsin. The cells were 
harvested into 50-ml conical tubes, centrifuged at 300 xg for 10 minutes, re-
suspended the cells at a concentration of between (5-10) x 106 cells/ml and 
irradiated at 5000 rads using an XRAD225 x-ray irradiation system (Precision X-
ray Inc). 
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2.15 Murine CD19+ B cell 
 
2.15.1 Murine CD19+ B cell isolation from Spleenocytes 
The wt and IL-37a-tg mice were sacrificed at approximately 4-6 weeks of age. 
Spleens were isolated and kept in PBS on ice until cells extraction. The spleen 
was placed into a 70 µM cell strainer, which in turn was placed in an appropriate 
petri dish with 4 ml of medium were added to it, and the spleen gently was 
mashed. The strainer was washed with media, and the cells collected in a 50 ml 
Corning tube with extra 10 ml medium, spun at 300 xg for 5 minutes at +4 ºC. 
The medium discarded; and 3 ml of pre-warmed lysing buffer added, and the 
mixture  incubated on ice for 5 minutes to lyse red blood cells.  Following the 
incubation, 40 ml of cold 1X PBS were added, and spun at 300 xg for 5 minutes 
at +40 ºC; the PBS discarded and the cells pellet re-suspended in 5 ml of media 
and mix well; keep on ice until proceeding to Magnetic activated cell 
sorting (MACS) separation.  
Using murine CD19 magnetic micro beads, B cells were separated from the 
spleenocytes by following the standard manufacturer’s instructions. 
Spleenocytes were washed with cold MACS buffer (PBS pH 7.2, 0.5% (v/v) bovine 
serum albumin, and 2 mM EDTA); centrifuged at 300 xg for 10 minutes; and the 
buffer was aspirated; the cells counted and re-suspended in 90 ul of MACS buffer 
per 107 cells with addition of 10 ul of CD19 micro beads per total 107 cells; 
mixed well and incubated in the  refrigerator for 15 minutes at +40 ºC. After 
that, cells were washed with 2ml MACS buffer per 107   cells; centrifuged for 10 
minutes at 300 xg; re-suspended in 500 ul; mixed well; applied to LS separation 
column that was placed in an appropriate magnetic field of the suitable MACS 
separator rinsed previously with 3 ml of MACS buffer. The unlabelled cells were 
collected from the column and the column washed three times with 3 ml of 
MACS buffer. The column was removed from the magnetic separator and placed 
on a suitable tube; 5 ml of MACS buffer were added to the column and the 
labelled cells flushed out by firmly pushing the plunger into the column.   
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2.15.2 Primary culture of murine CD19+ B cells 
Murine CD19+ B cells that had been separated previously by MACS technique, 
cells were cultured in PRMI 1640 containing 100 units/ml penicillin, 100 μg/ml 
streptomycin. 
2.15.2.1 Murine CD19+ B cells 
Murine CD19+ B cells cultured in complete PRMI 1640 medium at concentration of 
(106 cells/ml), cells were stimulated with different stimuli (LPS (10 ug/ml), 3T3 
cells (15 x 104 cells/ml), rIL37a (50 ng/ml), rIL-37b (50 ng/ml) in 24 well plate 
for different time according to the experiment condition. The supernatant 
collected for antibody estimation using ELISA technique; and the cells harvested 
for gene expression by qPCR 
2.16 Human CD19+B cell isolation 
To isolate B cells, peripheral blood mononuclear cells (PBMCs) were isolated 
from buffy coat and purified by standard manufacturing procedures using 
Histopaque-1077 (Sigma, USA). Heparinized venous blood was collected from the 
healthy donors, the collected blood diluted 1:1 with DPBS 3 ml of Histopaque 
added to the 15 ml centrifuge tube and 10 ml of diluted bloodcarefully layered. 
After centrifuging, at 400 xg for 30 minutes at (18-20) ˚C, the upper layer 
(plasma) was aspirated and the lymphocytes layer (opaque interface) then 
removed to new centrifuge tube using sterile Pasture pipette. Cells were washed 
three times in DPBS and spun at 250 xg for 10 minutes at 18-20˚C; the 
supernatant poured off, and this step repeated at least 2 times. B cells were 
separated from PBMC using CD19 magnetic micro beads, keeping cells and buffer 
cold. Following the manufacturer’s instructions; cells were counted, washed 
with 1-2 ml of MACS buffer (PBS pH 7.2, 0.5% bovine serum albumin, and 2 mM 
EDTA) per 107 PBMC cells and centrifuged at 300 xg for 10 minutes. The buffer 
aspirated and the cells re-suspended in MACS buffer(80 ul per 107 cells); with 
addition of 20 ul CD19 micro beads, the cells and the CD19 beads mixed well; 
incubated in the refrigerator for 15 minutes;  washed  after incubation with 1-2 
ml of MACS buffer per 107, centrifuged for 10  minutes at 300 xg. The cells re-
suspended in 500 ul MACS buffer per 108 cells; mixed well; and applied to LS 
separation column (Miltenyi Biotech) placed in a magnetic field rinsed previously 
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with 3 ml of MACS buffer. The unlabelled cells were collected from the column; 
and the labelled cells on the column washed three times with 3 ml/each time. 
The column removed from the magnetic field and placed quickly on a 15 ml 
tube; 5 ml of cold buffer was then added to the column and the labelled cells 
flushed out by firmly pushing the plunger into the column.   
2.16.1 Primary culture of human B cells 
Human B cells, which were separated by MACS, cultured in RPMI 1640 containing 
100 units/ml penicillin, 100 μg/ml streptomycin in 24 well plate (106 cells/ml). 
2.16.1.1 Human CD19+B cells stimulation 
CD19+ B cells cultured in complete RPMI medium, stimulated with different 
stimulators including: (CPG (3 ug/ml), 3T3 cells (15 x 104 cells/ml), CD40 Ligand 
(2 ng/ml), anti-IgM (10 ug/ml), IL-21 (50 ng/ml), IL-2 (10 ng/ml), rIL37a (50 
pg/ml and 50 ng/ml), and rIL-37b (50 pg/ml & 50 ng/ml), and cells incubated for 
different periods of time according to the experiment condition. Cells 
supernatant collected for IgG determination by ELISA; and cells pellet harvested 
for gene expression by qPCR. 
2.17 Gene expression assay 
2.17.1 Quantitative-PCR analysis 
2.17.1.1 Extraction of total RNA from cells 
A spin-column based RNA extraction kit (Qiagen, Germany) was used for this 
purpose. All procedures were conducted according to manufacturer’s instruction 
manuals. Briefly, add 350 μl of Buffer RLT to lyse cells up to 5 x 106, then 
transfer the lysate directly into a QIA shredder spin column placed in a 2 ml 
collection tube; and centrifuge for 2 minutes at 6500 xg. Transfer flow-through 
to an RNeasy spin column placed in a 2 ml collection tube, centrifuge for 15 
seconds at 4000 xg. Discard the flow-through; add 700 μl Buffer RW1 to RNeasy 
spin column, centrifuge for 15 seconds at 4000 xg, discard the flow-through; 
wash RNeasy spin column twice with 500 μl Buffer RPE, centrifuge at 4000 xg 
rpm for 15 seconds the first time and 2 minutes the second time. Discard the 
flow-through; place the RNeasy spin column in a new 1.5 ml collection tube, add 
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40 μl RNase free water directly to RNeasy spin column membrane, centrifuge for 
1 minute at 4000 xg to elute the RNA. 
2.17.1.2 Reverse Transcription 
Reverse Transcription (RT) of RNA into cDNA was carried out using High-Capacity 
cDNA Reverse Transcription Kits according to manufacturer’s protocol (Applied 
Biosystems, US). Dilute RNA samples to 1.5 μg per 10 μl using nuclease-free 
water. Prepare 2X reverse transcription master mix, each 10 μl mix containing 
2.0 μl of 10X RT Buffer, 0.8 μl of 25X dNTP Mix, 2.0 μl of 10 RT Random Primers, 
1.0 μl of MultiScribe reverse transcriptase and 4.2 μl of nuclease-free water. For 
a 20 μl RT reaction; mix 10 μl of 2X reverse transcription master mix with 10 μl 
of RNA samples in individual PCR tube, briefly centrifuge the tubes to eliminate 
any air bubbles; load the tubes in thermal cycler (Eppendorf, UK). Perform 
reverse transcription reaction in the following conditions: 25 ℃ for 10 minutes, 
37 ℃ 120 minutes, 85℃ for 5 seconds and 4℃ to stop the reaction. The cDNA 
samples were kept at -20 ℃ until further experiments.  
 
2.17.1.3  Real-time PCR 
Real-time polymerase chain reaction (RT-PCR) was performed using Fast SYBR 
Green master mix (Applied Biosystems, USA): pipette 10 μl of 2X Fast SYBR 
Green master mix, 1 μl of each forward and reverse PCR primers (Table 2.7).  2 
μl of cDNA samples, and 7 μl of nuclease-free water into each well of a 96-well 
reaction plate; briefly centrifuge the plate to eliminate any air bubbles; load the 
plate into an Applied Biosystems real-time quantitative PCR instrument; set the 
thermal cycling condition: 95 ℃ 20 seconds; 95 ℃ 3 seconds, 60 ℃ 30 seconds, 
repeat 40 cycles; calculate the results using ΔΔCT method (Livak and 
Schmittgen, 2001, Giulietti et al.,2001). The primers (Integrated DNA 
Technologies, USA) were synthesized according to the sequences in Tables 2.6 
and 2.7. 
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Table 2.6 Real-time PCR primers 
 
Human 
 
Forward 
 
Reverse 
 
GAPDH 
 5’- GAGCCACATCGCTCAGACAC  
-3’ 
 5’- CATGTAGTTGAGGTCAATGAAGG 
 -3’ 
IL-1F7a 
 5’- GGGAAACAGAAACCAAAGGA 
 -3’ 
 5’- CCCAGAGTCCAGGACCAGTA 
 -3’ 
IL-1F7b 
 5’- 
ATGTCCTTTGTGGGGGAGAACTCAG -
3’  
 5’- 
TGCTATGAGATTCCCAGAGTCCAGGACC -3’ 
IL-1F7c 
 5’- CCCCACCATGAATTTTGTTC 
 -3’ 
 5’- CCTTTAGAGACCCCCAGGAG 
 -3’ 
IL-1F7d 
 5’- AACCCCAGTGCTGCTTAGAA 
 -3’ 
 5’- CCCAGAGTCCAGGACCAGTA 
 -3’ 
IL-1F7e 
 5’- AACCCCAGTGCTGCTTAGAA 
 -3’ 
 5’- CCTTTAGAGACCCCCAGGAG 
 -3’ 
IL-18R1 
 5’- CCCTGGGCAAAATCTCCACAGCA 
 -3’ 
 5’- ACGCCGAGTTGAAGATCAGGGGT 
 -3’ 
SIGIRR 
 5’- GTACCAGAGCAGCACGTTGA 
 -3’ 
 5’- TCAGTGGCTCTGAACTGCAC 
 -3’ 
TNFA 
 5’- CAGGGCAATGATCCCAAAGT 
 -3’ 
 5’- TCAATCGGCCCGACTATCTC 
 -3’ 
IL10 
5’-TCCTCCTGCTTGTCATAGTC 
-3’ 
5’-CACCCATTTCTTGAAGTCTCC 
-3’ 
IFNB 
5’-GCGACACTGTTCGTGTTGTC 
 -3’ 
5’-GCCTCCCATTCAATTGCCAC 
-3’ 
IFNG 
5’-TCA GCT CTG CAT CGT TTT GG 
-3’ 
5’-GTT CCA TTA TCC GCT ACACTGAA 
-3’ 
IL12A 
5’-TTCGCTTTCATTTTGGGCCG 
 -3’ 
5’-ATCAGCTTCTCGGTGACACG 
-3’   
IL13 
5’-AACCAGAAGGCCTCCGCTCTGC 
-3’ 
5’-GGCACTGCAGCCTGACACGTT 
-3’ 
IL1A 
5’-ACTGCCCAAGATGAAGACCA 
-3’ 
5’-CCGTGAGTTTCCCAGAAGAA 
-3’ 
IL6 
5’-TGCAATAACCACCCCTGACC 
-3’ 
5’-AGCTGCGCAGAATGAGATGA 
-3’ 
TGF 
5’-TACCTGAACCCGTGTTGCTCTC 
-3’ 
5’-GTTGCTGAGGTATCGCCAGGAA 
-3’ 
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Table 2.7 Real-time PCR primers 
  
 
 
 
 
 
 
 
Murine 
 
Forward 
 
Revers 
 
IL-1F7a 
 
5’- GGGAAACAGAAACCAAAGGA 
 -3’ 
 
5’- CCCAGAGTCCAGGACCAGTA  
-3’ 
 
Tgfb1 
5'-CACCGGAGAGCCCTGGATA 
-3' 
 
5'-TGTACAGCTGCCGCACACA 
-3'  
 
Sigirr 
 
5'-GGTGGCAGTCGTGACTCAG 
-3’ 
 
5'-CTGGCTCCCTGTAATGG 
-3’ 
 
Il18r1 
 
5'-CTTCGTCTTGGTGAGAAAAGAAATA 
-3’ 
 
5'-TGTCACAGCAGCATATTACCTG 
-3’ 
 
Gapdh 
5'-GGCATGGACTG GGTCAT GAG 
-3’ 
 
5'-TGC ACC ACC AAC TGCTAGC 
-3’ 
 
IFNγ 
5'-TTCTTCAGCAACAGCAAGGC 
-3’ 
 
5'-TCAGCAGCGACTCCTTTTCC 
-3’ 
 
Il10  
5'-AAC AAA GGA CCA GCT GGA CAAC 
-3’ 
 
5'-CTT GAT TTC TGG GCC ATG CTT 
-3’ 
 
Il13 
 
5'-GCAGCATGGTATGGAGTGTG 
-3’ 
 
5'-TGGCGAAACAGTTGCTTTGT 
-3’ 
 
Tnfsf13 
(APRIL) 
 
5'-CAGTCCTGCATCTTGTTCCA 
-3’ 
 
5'-GCAGATAAATTCCAGTGTCCC 
 -3’ 
 
Inpp5d 
(SHIP) 
 
5'- ACTCTGCGTGCTGTTCCGGA 
-3’ 
 
5'-CCTTCGGATGCCTGAACAGTG 
-3’ 
 
Lyn  
5'CTATCCCGTCGCGTGAAC 
-3’ 
 
5'-CATCCCATATTTCTCGCTCGT 
-3’ 
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2.18 Measurement of B cell proliferation 
The measurement of DNA replication determined by the incorporation of 5-
bromo-2-deoxyuridine (BrdU) (Roche, UK) wasused to measure the cellular 
proliferation. Briefly human B cells were grown in 96 -well flat bottom plates 
(105 cells/well) for 3, 4, 7 days; and the cellular proliferation was determined by 
incorporation of BrdU. 0.1 ul of BrdU labling reagent (10 mM 5-bromo-2- 
deoxyuridine in PBS, pH 7.4 was added per well for a 96 well plate for B cells 
cultured 2, 3, 6 days before the end of the experiments. After 24 hours of BrdU 
addition, the plate was centrifuged at 300 xg for 10 minutes, and the medium 
removed by flicking off or aspiration; and following the same step, the cells 
were washed with 150 ul of cold PBS added by multi-channel pipette to remove 
the excess of BrdU reagent. The plate dried in the incubator at 37 ⁰C without 
CO2. Next, 200 ul of the FixDenat reagent were added to each well; incubated at 
room temperature for 2 hours; then removed by flicking off and tapping; 
followed by addition of 100 ul of anti-BrdU-POD solution incubated for 3 hours. 
Finally, the anti-BrdU-POD solution was removed by flicking off; the wells 
washed with 300 ul of PBS; 100 ul of the substrate added per well; incubated for 
5-20 minutes until colour development. 25 ul of the stop solution (1 M H2SO4) per 
well added, and the plate read with ELISA reader at 450 nm after 1 minute 
shaking at 200 xg 
2.19 Enzyme linked immunoassay (ELISA) 
Murine IL-6 cytokine and IgG isotype were analysed by ELISA, using IL-6 ELISA kit 
(R&D system) and mouse IgG kit (affymetrix, eBioscience). All mice ELISA 
experiments were conducted according to the manufacturer՚s protocol.  
1- Murine IgG: The ELISA plate (Costar 9018, Corning, USA) was coated with 100 
µl of capture antibody diluted (1:250) in 1X coating buffer (1X PBS in 
deionised water); the plate sealed and incubated in the fridge over-night at 
4º C. The wells were aspirated, washed twice with 400 ul/well with wash 
buffer (1X PBS, 0.05% Tween-20); and the plate blocked with 250 µl/well 
assay diluent 2X (1X PBS, 10% BSA, 1% tween-20) that supplemented the kit, 
and incubated at room temperature for 2 hours, washing as step 2. 2 fold 
serial dilutions in 1X blocking buffer of the standard were prepared for the 
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standard curve. The cell culture samples were pre-diluted 2X in 1X blocking 
buffer in triplicate wells; followed by addition of 50 ul of the detection 
antibody to all wells; the plate covered, sealed and incubated at room 
temperature for 3 hours on a microplate shaker at 200 xg. The wells were 
aspirated and the plate washed as step 2 for total wash of 4 times. 100 ul of 
the substrate solution added and incubated for 15 minutes; followed by the 
addition of 100 ul of stop solution to each well; and the plate read at 450 
nm and the values of 570 subtracted from those of 450 nm; data were 
analysed using Excel. 
2- Human IgG isotype levels: ELISA 96 well plate (Costar 9018, Corning, USA) 
was coated with 100 μl/well of cells supernatant, and 100 μl per well of 2-
fold serial dilutions of the top standard IgG, added  to make the standard 
curve and blanks (PBS buffer or media, respectively) as control. The plate 
was incubated at 4°C overnight. After incubation, the plate was washed 4 
times with > 300 μl/well wash buffer (1X PBS, 0.05% tween-20), blotted on 
absorbent paper to remove any residual buffer; and the wells blocked with 
200 μl/well assay diluent (1X PBS, 10% FBS), incubated over-night at 4°C and 
washed as step 2. Then, 100 μl/well of Biotin-conjugated detection antibody 
diluted in Assay diluents were added and incubated at room temperature for 
1 hour. Washing as previous steps. 100 μl per well of Avidin-HRP diluted in 
assay diluent and incubated at room temperature for 30 minutes. The plate 
was washed for a total wash of 7 times. The 100 μl of Substrate Solution 
(Tetramethylbenzidine Substrate Solution) were added to each well and 
incubated at room temperature for 15 minutes. The reaction was stopped by 
adding 100 μl per well of Stop Solution (1 M HCl). Plates were read using an 
ELISA reader (Tecan, Switzerland) at 450 nm and the value read at 570 nm 
subtracted. The OD was measured against the reagent blanks, standards and 
testsamples, and obtained the relative sample concentration by 
interpolating the readings to the Standard Curve.  
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2.20 Next generation sequencing 
2.20.1 Microarray 
Murine spleenocytes cells were purified and cultured in RPMI, stimulated with 
500 ng/ml of LPS for 4 hours, cells harvested and RNA extracted, converted to 
cDNA, and microarray performed in China by Dr.Xu lab. 
Normalization was achieved after importing the Output_fused. The data was 
statistically analyzed using one way ANOVA. False discovery rate given %5 false 
genes as it was set to the p-value 0.05 followed by applying multiple correction 
method using a Benjamini and Hochberg False Discovery Rate. Bio Venn 
programme used to discriminate each group of genes by Biovenn programme 
(Elure figures), each group of genes compared with innate immune genes, using 
IDB web site, and KEGG analysis pathways enrichment     
2.21 Statistical analyses 
All statistical analyses were performed with Excel software. Different analysis 
strategies were used depending on the data being investigated. Depending on 
the normal or skewed distribution of the data, either a T-test or a Mann-Whitney 
test was used respectively when comparing two sets of data. A one-way ANOVA 
(or non-parametric equivalent) was used for the comparison of three or more 
groups. Figure legends state the statistical test used for the analysis of each 
data set. P values of < 0.05 were considered to be statistically significant and 
illustrated in graphs as * = p< 0.05, ** = p< 0.01, *** = p< 0.001. Data in graphs 
are shown as mean ± SD. 
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Chapter 3 
Production, purification and 
Crystallization of recombinant human 
IL-37a and IL-37b  
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3 Production, purification and Crystallization of 
recombinant human IL-37a and IL-37b 
3.1 Introduction 
IL-37 gene encodes five-transcript variants (IL-37a-e) due to alternative RNA 
splicing. While the function of IL-37b has been widely studied and identified as 
an important immune regulatory cytokine, the functions of the other IL-37 
isoforms are largely unknown. The focus of this study is the IL-37a isoform, 
which was compared with IL-37b. The basis for this was that (1) our preliminary 
results showed that IL-37a expression is highly inducible in human macrophages 
by inflammatory stimuli, compared to other IL-37 isoforms (Chapter 4, Fig 4.2). 
This suggests that IL-37a may also play an important role in the inflammatory 
response; (2) IL-37a has an N-terminal region that is not homologous to IL-37b, 
suggesting that IL-37a may have unique biochemical features and functions.   
The pro or full length IL-37b is the longest transcript variant among the IL-37 
isoforms and is composed of 218 amino acids. It contains caspase-1 cleavage 
sites at its N-terminus for maturation (Fig 3.1) (Kumar et al, 2002; Sharma et al, 
2008; Boraschi et al, 2011; Afonina et al, 2015). The C-terminal of mature 
protein IL-37b consists of 12 β-strands forming the β-trefoil structure, which is 
characteristic of IL-1 family cytokines (Fig 3.1). This domain is responsible for 
these cytokines in order to bind to their receptor and trigger signal transduction 
(Boraschi et al, 2011; Zhao et al, 2018). IL-37a is shorter than IL-37b and is 
composed of 192 amino acids (Kumar et al, 2000; Boraschi et al 2011). It has a 
unique N-terminal region containing a putative nuclear location sequence (NLS) 
for protein translocation into the nucleus (Taylor et al, 2002; Boraschi et al, 
2011). A putative elastase cleavage site down stream of the NLS has also been 
identified (Boraschi et al, 2011; Abulkhir et al, 2016). This specific N-terminal 
region may offer IL-37a unique biochemical features, cellular location and 
biological function.  Like other IL-1 family members, IL-37a also possesses the 12 
β-strand forming β trefoil domain. This suggests that IL-37a and IL-37b bind to 
the same receptor for signalling. 
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Figure 3.1 The key sites and domains of IL-F7a and IL-1F7b pro-protein. 
IL1F7 gene has six exons. A) represents the IL1F7 gene and the five isoforms; the 
coloured boxes are the exons with their numbers, and the size of each exon is 
indicated just below the exon boxes; while the size of the intervening introns 
are at the top of each intron. B) Represents IL-1F7b or IL-37b isoform structure, 
and illustrates the caspase-1 cleavage site in exon 1, followed by the pro 
peptide domain; the rests are exons 2, 4, 5, and 6.  
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Cytokines produced recombinantly in bacteria can be a valuable tool for studying 
human protein function although these recombinant proteins will lack post-
translational modifications such as glycosylation that may be present in the 
human derived protein. FL and mature human IL-37b proteins have been 
produced in E. coli by several laboratories and companies (Gu et al, 2015; Li et 
al, 2015). IL-37b constructs have been expressed both in a soluble form in the E. 
coli cytoplasm and in inclusion bodies (Carrió and Villaverde, 2001; Yang et al, 
2011; Singh et al, 2015). 
 In most reports, the recombinant protein has first been purified by nickel 
affinity chromatography, using Ni-affinity chromatography, followed by gel-
filtration chromatography (Stuehr et al, 1991; Harood, 1996; Kaur and Reinhardt, 
2012). Ni-affinity chromatography is one of the immobilized, metal affinity 
chromatography (IMAC) approaches for efficient purification of engineered 
proteins that carry polyhistidine-tags. The histidine-tags bind to the divalent 
metal (Ni+2, CO+2 or Cu+2) attached to the agarose resin and can be eluted by 
adding imidazole (Mooney et al, 2014). 
Contaminating endotoxins from E.coli can be removed from recombinant 
proteins using different techniques including EndoTrap® affinity chromatography 
(Guillou et al, 2015). IL-37b purified by this method is bioactive, and can 
suppress inflammatory responses in vitro and in disease models in vivo (Gu et al, 
2015). Furthermore, both FL and mature IL-37b are bioactive and share similar 
bioactivity in vitro (Kumar et al, 2002). Since bacteria cannot provide the 
correct glycosylation of human protein this also suggests that glycosylation of IL-
37 is not required for human IL-37b bioactivity. However, it is still unknown if IL-
37a can be produced in a similar way in E. coli and whether IL-37a produced in 
this way is bioactive.  
Hypothesis: The difference in N-terminal sequence between IL-37a and IL-37b 
influences the structural and biochemical features of these isoforms. 
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The aim of the work in this chapter was to take the first steps to understand the 
biological function, structure and importance of IL-37a in biology and in disease. 
To achieve this, recombinant IL-37a and IL-37b were produced and differences 
between the IL-37 isoforms in terms of protein structure and biochemical 
features were studied. This was achieved by:  
 
1- Expression of human recombinant IL-37a and IL-37b protein in E. coli. 
2- The development of a purification protocol for IL-37a and IL-37b proteins     
using multiple chromatography techniques. 
3- Structural studies using crystallization.  
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3.2 Results 
3.2.1 Differences between IL-37a and IL-37b at the amino acid level 
and biochemical parameters. 
Understanding of the difference between the two IL-37 isoforms at the amino 
acid level can provide important information for protein purification and for 
assessing protein stability and solubility. The differences of the two isoforms at 
the amino acid level were analysed using Protparam from Expasy (extensible and 
integrative portal accessing (Boraschi et al, 2011). The differences at amino acid 
level between IL-37a and IL-37b isoforms showed in Tables (3.1) and (3.2).  
IL-37a has 9 positively charged arginine and 22 lysine residues. Together they 
comprise 16.2% of the total protein, while isoform b has 5 arginine and 20 lysine 
(11.5%). Levels of negatively charged amino acids (glutamate and aspartate) are 
higher in IL-37b than IL-37a; 12.9% in IL-37b and 11.5% in IL-37a. There is no 
marked difference between IL-37a and IL-37b protein in the percentage of 
aliphatic amino acids (Table 3.2). Consequently, there is a clear difference 
between the two isoforms in their isoelectric point (pI) 9.23 and 6.09 for IL-37a 
and IL-37b, respectively.  
3.2.2 Production of recombinant IL-37b 
In order to investigate the structure and biological function of IL-37a, large 
quantities of recombinant protein may be required. To determine whether IL-
37a and IL-37b are different in bioactivity, FL-IL-37a and IL-37b were produced 
in E. coli. The strategy was used to produce recombinant human IL-37a and IL-
37b is shown in (Fig 3.2).  
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Table 3.1 Amino acid composition of human IL-37a and IL37b 
Amino 
acids 
IL-37a  IL-37b  
 
Number 
of amino 
acids 
Percentage 
of amino 
acids % 
Number of 
amino 
acids  
Percentage 
of amino 
acids % 
Ala (A) 12 6.2 13 6 
Arg (R) 9 4.7 5 2.3 
Asn (N) 9 4.7 10 4.6 
Asp (D) 9 4.7 11 5 
Cys (C) 7 3.6 8 3.7 
Gln (Q) 6 3.1 7 3.2 
Glu (E) 13 6.8 17 7.8 
Gly (G) 11 5.7 13 6 
His (H) 5 2.6 6 2.8 
Ile (I) 8 4.2 8 3.7 
Leu (L) 15 7.8 17 7.8 
Lys (K) 22 11.5 20 9.2 
Met (M) 4 2.1 6 2.8 
Phe (F) 11 5.7 12 5.5 
Pro (P) 11 5.7 17 7.8 
Ser (S) 21 10.9 25 11.5 
Thr (T) 4 2.1 4 1.8 
Trp (W) 2 1 3 1.4 
Tyr (Y) 3 1.6 3 1.4 
Val (V) 10 5.2 13 6 
 
(Gasteiger et al, 2005) 
(https://web.expasy.org/protparam) 
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Table 3.2 Parameters for human IL-37a and IL-37b based on their primary 
sequence 
Parameter 
 
 
IL-37a IL-37b 
Molecular weight (kDa)a 
 
 
21.5 
 
24.1 
 
Theoretical iso electric  
point (pI) 
 
9.2 
 
6.1 
 
Number of amino 
 Acids 
 
192 
 
218 
 
negatively charged 
 amino acids % 
 
11.5 
 
12.9 
 
positively charged  
amino acids % 
 
16.2 
 
11.5 
 
Nonpolar aliphatic 
 amino acids % 
 
34.8 
 
33.6 
 
Polar amino acids % 
 
27.6 
 
28.9 
 
Aromatic amino acids % 
 
8.4 
 
8.3 
 
 
a: kilo Dalton  
 
(Gasteiger et al, 2005). 
(Compute pI/Mw. http://web.expasy.org/compute_pi) 
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Figure 3.2 Strategy were used to produce human IL-37a and IL-37b 
recombinant proteins 
The expression vector of each IL-37 isoform was transformed into E. coli BL21 
(DE3) pLysS. Protein expression is induced by the addition of IPTG. The 
recombinant His-tag proteins are purified initially by Ni-NTA chromatography and 
then gel filtration. LPS is removed by Endotrap column. The purity, and 
specificity of the protein are confirmed by SDS-PAGE gel, western blotting, and 
mass spectroscopy respectively. 
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3.2.2.1 Plasmid construction for the expression of IL-37b in E. coli. 
The plasmid encoding full length human recombinant IL-37b protein was 
generated by Dr Jiangning Liu in Dr Xu’s lab (unpublished results). The plasmid 
pET-28/IL-37b contains human IL-37b gene fused with a DNA sequence that 
encodes 6histidine amino acids under T7 promotor at the C-terminal. Restriction 
sites includes the Xho I and NdeI for insertion of the gene of interest. Kanamycin 
sequence inserted as a selection marker (Fig 3.3). 
 
 
 
Figure 3.3 Schematic representation of pET-28a/IL-37b vector for IL-37b 
expression. 
PET-28 a (+) construct was used to express recombinant IL-37b as N-terminal His-
Tag fusion protein under T7 promoter. The vector contains the following 
elements or encoding sequences: replication origin (Ori); kanamycin resistant 
gene coding sequence; T7 promoter region; His-tag coding sequence; Lac I 
coding sequence; IL-37b cDNA was inserted into the plasmid between Nde I and 
Xho I sites. 
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3.2.2.2  Test expression of IL-37b  
IL-37b was successfully produced in E. coli. Briefly, E. coli BL21 (DE3) pLysS 
transformed with the pET-28a/IL-37b vector, and the confirmed clone cultured 
overnight in a medium supplemented with kanamycin. To optimise expression 
recombinant IL-37b expression in bacteria cultured in log-growth phase induced 
with IPTG for vary time (from 1-7) hours. The levels of expression determined by 
SDS-PAGE as indicated in (Fig 3.4) by comparison to the non-induced bacterial 
culture. Accordingly, the best expression induction time for IL-37b was between 
(4-5) hours, and when the incubation time exceeded 5 hours; the yield of the 
product decreased significantly.  
Recombinant protein expressed in E. coli can be soluble or insoluble 
(Sorensen and  Mortensen, 2005). Recombinant cytokines expressed in E. coli are 
insoluble in inclusion bodies and this may make purification more complex. In 
order to purify the protein, the inclusion body has to be isolated and the protein 
solubilised by denaturation. Then after purification, the denatured proteins have 
to be renatured by removal of the denaturing agents (Sørensen and  
MortensenMany, 2005). Therefore, I further tested the expressed IL-37a and IL-
37b proteins expressed in our E. coli system to determine if the expressed 
protein was produced in a soluble form. Briefly, the IL-37 expressing strains 
cultured and IPTG induced for 5 hours as above. The cell pellet was re-
suspended in lysis buffer supplemented with lysozyme and protease inhibitors 
and sonicated until the solution was no longer viscous. The cell lysate 
centrifuged at 5000 xg for 30 min at +4 °C to separate the soluble and insoluble 
cell fraction. The IL-37a and IL-37b levels in the two fractions, respectively, 
determined by SDS-PAGE. While both fractions contained the 21 and 24 kDa 
bands, respectively, the majority of IL-37 proteins were found in the soluble 
fraction (data not shown). Thus, most IL-37a and IL-37b proteins expressed in 
this system are soluble. 
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Figure 3.4 Test expression of recombinant IL-37b in E. coli. 
The IL-37b expression induced in bacteria by 1 mM IPTG at 37°C for different 
times. The total bacteria were lysed, the protein separated by SDS-PAGE and the 
gel stained with Coomassie blue. Lane M indicates the markerbands in kilo 
Dalton, lanes numbered with (1, 2, 3, 4, 5, 6, 7) indicate the bacterial 
expression of IL-37b with or without IPTG; the arrow refere to rIL-37b band 
expression which is ecpected to be about 25 kDa. The result is representative of 
three independent experiment. 
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3.2.2.3  Purification of IL-37b by Ni-NTA chromatography 
Detailed methods for the purification can be found in Chapter 2. Briefly, the 
bacteria expressing IL-37a were re-suspended in binding buffer supplemented 
with lysozyme and protease inhibitor. Bacteria were lysed by sonication and the 
cell debris removed by centrifugation. The supernatant containing the His-
tagged IL-37b was loaded to the Ni-NTA column equilibrated previously with 
binding buffer for line A and elution buffer (binding buffer with 500 mM 
imidazole) for line B. The unbounded proteins (without His-tag) removed using 
binding buffer for 35 minutes (Fig 3.5a). The bound His-tagged-IL-37 proteins 
eluted with a sharp peak using elution buffer containing 500 mM Imidazole for 25 
minutes (Fig 3.5a). The IL-37b expression and purity checked by SDS-PAGE (Fig 
3.5b). The bands at 25 kDa seen clearly in the fraction number 15-20 (Fig 3.5b). 
The protein markedly enriched in the eluted fractions compared to the loading 
and unbound samples. Thus, the results demonstrated that the His-tagged IL-37 
proteins can be effectively produced in E. coli and successfully purified by Nickel 
Nitrilo-triacetic Acid (Ni-NTA) chromatography. 
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         a) 
 
                 
                  b) 
 
Figure 3.5 Nickel affinity chromatography for IL-37b purification. 
6His-IL-37b was purified with His-Trap column (5ml) using the AKTA system. (a) 
35 ml of soluble bacterial containing 6His-tagged-IL-37b extract loaded to the 
Ni-column at a flow rate of 1ml/minute and the UV absorption monitored at 280 
nm; the IL-37b was eluted from the column using imidazole, as the  peak with 
red brackets shows rIL-37b. (b) is SDS-PAGE gel. Fractions numbered (15 to 20) 
were collected, and re-suspended in SDS-PAGE loading buffer, heated at 95 Cº 
for 10 minutes; separated on 15% SDS-PAGE. The gel stained with Coomassie 
Brilliant Blue R-250 solution, and de stained with de stain buffer. Lane M is the 
protein marker; Line Ft is the flow throw; load represents the bacterial extract 
contaning rIL-37b; Lanes numbered (15-20) elution fractions of rIL-37b eluted by 
imidazole. 
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3.2.2.4  Confirmation of the His-tagged IL-37b by western blot 
The identity ofpurified IL-37b was confirmed by western blot. As no commercial 
anti-IL-37 antibody was available for western blot, a well-characterised anti- 
6His-tag monoclonal antibody was employed for the purpose. The different 
fractions of IL-37b eluted by Nickel affinity chromatography were separated by 
SDS-PAGE, and transferred to a nitrocellulose membrane. The proteins were 
then labelled with conjugated anti-6His-tag monoclonal antibody and detected 
by western blotting. As shown in (Fig 3.6), a single band with molecular weight 
of His-tagged IL-37b clearly detected in the samples, indicating that the purified 
protein is His-tagged IL-37b.  
3.2.2.5  Purification of IL-37b proteins by gel filtration 
To further purify IL-37b collected from IMAC affinity chromatography the protein 
was dialysed in (50 mM Tris and 200 mM NaCl; pH 7.5) and loaded on an 
Superdex-75 SEC column equilibrated in the same buffer and separated with flow 
rate 1.5 ml/minute (Fig 3.7a). The fractions (A10-15, B15, B14, and B4) were 
collected  and analysed by SDS-PAGE (Fig 3.7b). 
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Figure 3.6 Confirmation of the His-tagged IL-37b by western blotting 
The protein fractions from Ni-NTA affinity chromatography run by SDS-PAGE, 
transferred onto nitrocellulose membrane, and detected using conjugated anti 
6His-tag antibody. The first line (M) indicates the molecular weight marker. Lane 
(load) is the loading sample before the Nickeled column; lane (Fth) is the 
unbound protein flow through the Nickel column. Lanes (15-20) are different 
fractions of 6His-tagged-IL-37b eluted from Ni-NTA column. The fractions 
numbers are the same as in the (Fig 3.5b). The experiment repeated three 
times. 
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a) 
 
b) 
             
 
Figure 3.7 Purification of IL-37b by Gel filtration. 
The Ni-NTA purified IL-37b samples are further purified by gel filtration. a) 
Dialysed IL-37b was loaded onto a Superdex-75 column; the protein separated in 
the column with a flow rate of 1.5 mi/minute. b) Fractions collected to terst 
purity using SDS-PAGE; the collected fractions from gel filtration assessed by 15% 
SDS-PAGE and Coomassie blue staining. Lane (M):  is the protein marker; Lane 
load: is the loaded sample and the band with the star represents rIL-37b; Lane 
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ft: washed away proteins. Lanes (A10, A12, A14, A15, B15, B14, and B4) are the 
protein fractions collected from the column (as in fig 3.7a). The experiment 
repeated three times. 
3.2.2.6 IL-37b Circular Dichroism (CD) 
Circular dichroism (CD) is a form of light absorption spectroscopy that measures 
the difference in absorbance of left handed and right handed circularly polarized 
light. This technique depends on the interaction between polarized light and an 
optically active matter (Greenfield, 2006). 
First, plane polarised light is composed of two circularly polarised components 
that have equal magnitude, one of them is left handed light and the other is 
right handed light. Second, an optically active matter or chiral chromophore is 
an atom or molecule, which rotates polarised light in either a right hand 
(Dextro) or a left hand (Levo) direction. A chromophore to be chiral for these 
reasons: 
1-Intrinsically chiral because of its structureis for instance an atom bound to 
fourdifferent groups or disulphide bound, because of the di hedral angles.  
2- The chromophore bound to a chiral centre. 
3- The chromophore is in an asymmetric environment.    
A chiral centre absorbs left and right-handed circularly polarized light 
differently, a phenomenon that exploited in CD spectroscopy for rapid 
determination of stability, structure of proteins, nucleic acids, and lipids. In 
proteins, the presence of peptide bond (absorption below 240 nm) make them 
optically active in addition to disulphide bonds (absorption around 260 nm). 
Different types of protein secondary structure give rise to CD in the far UV (180-
260) nm. Structural information can be obtained at atomic level of resolution 
using nuclear magnetic resonance techniques (NMR) or X-ray crystallography, 
however; NMR needs high concentration of proteins (0.5 mM), high temperature, 
acidic pH, long time, and also it is limited to small proteins < 40 kDa. X-ray 
crystallography needs time for crystals to grow. In addition, it cannot be applied 
to membrane proteins, wherase CD takes 30 minutes (Kelly et al, 2005; Micsonai 
et al, 2015). There are some factors, which should be taken in account for 
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structural studies. Preparation of fused protein is of high importance since 
addition of tags can be problematic, some molecules affect the absorbance 
signal for instance glutathione –S-transferase (GST) or maltose binding protein 
(MBP) because they are big moieties of 26 kDa and 40 kDa respectively.  The 
presence of nucleic acids, and protein aggregates in the CD samples also distort 
the magnitude of the signal. Reliable estimation of protein secondary structure 
by CD depends on accurate concentration and instrument calibration (Kelly et al, 
2005). CD at different temperature is also an informative tool for protein 
stability.  
Far-UV circular dichroism (CD) used to analyse protein secondary structure and 
the use of CD at different temperatures is an informative tool to analyse protein 
stability. The technique was applied to recombinant IL-37b after purification 
(Fig 3.8a and b). The secondary structure prediction from circular dichroism 
indicated that the IL-37b does not contain significant stretches of α-helix and 
the protein showed aggregation after 40 ◦C.   
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             a) 
 
                b) 
 
Figure 3.8 Far UV CD spectrum of IL-37b 
a) Spectra were recorded on a Jasco J-710 spectropolorimeter in a 0.02 cm path 
length cell at 20 degrees C. UV A280 0.3678:  Protein concentration 0.437 
mg/ml. Mean residue weight concentration = 0.437/mrw (111.88) = 3.90597e-
3M. b) Thermal melting of IL-37b. Spectra were recorded at 5 °C intervals from 
5 to 80 degrees C. Data were plotted using the ellipticity value at 206nm. Note 
the increase in HT (High Tension) values above 40 degrees C. This increase is 
indicative of light scattering as the protein begins to aggregate. The decrease in 
HT at temperatures above 60 °C reflects the movement of the scattering 
particles out of the light path. 
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3.2.3 Production of recombinant IL-37a 
3.2.3.1 Plasmid construction for the expression of recombinant IL-37a in E. 
coli. 
The plasmid encoding FL human recombinant IL-37a in E.coli was generated by 
Dr Jiangning Liu in Dr Xu’s lab (unpublished results). The plasmid pET-21a/IL-37a 
(Fig 3.9) encodes human IL-37a fused with a sequence encoding 6 histidine 
amino acids at the 5’-end, inserted via the restriction enzymes Xho I and NdeI 
cutting sites at the 3’ and 5’ end, respectively. The plasmid contains an 
ampicillin resistant gene for selection and preventing of bacterial 
contamination.  
3.2.3.2  Test expression of IL-37a in E. coli 
While the recombinant IL-37b expression successfully produced in E. coli, 
whether recombinant IL-37a produced in E. coli is unknown. The plasmid pET21 
a/IL-37a construct (Fig 3.9). The IL-37b construct used as a positive control; and 
the same steps to the BL21 (DE3) pLysS strain transformed with pET21/IL-37a 3-
3-2 Test expression of IL-37b. The levels of expression determined by SDS-page 
electrophoresis as indicated in (Fig 3.10), compared to the non-induced bacterial 
controls. The size of the protein was approximately 21 kDa, which is compatible 
with the theoretical molecular weight of human IL-37a. The kinetics of study 
indicates that the IL-37a expression was induced 1 hour after the addition of 
IPTG; and the optimal induction time was between 4-5 hours; which is not 
different from IL-37b.   
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Figure 3.9 Schematic representation of pET- 21a/ IL-37a construct. 
The pET- 21 a (+) vector used to express recombinant IL-37a as N-terminal His-
tag fusion protein under T7 promoter. The vector contains the following key 
elements and encoding sequences: replication origin(Ori); ampicillin resistant 
gene coding sequence; T7 promoter region; IL-37a gene; 6His-tag coding 
sequence; LacI coding sequence; IL-37a cDNA was inserted into the plasmid 
between Nde I and Xho I sites.  
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Figure 3.10 Test expression of recombinant IL-37a in E- coli 
The IL-37a expression induced in bacteria by 1 mM IPTG at 37 ◦C for different 
periods. The total bacteria lysed, and soluble proteins separated by SDS-PAGE 
electrophoresis and the gel stained by coomassie brilliant blue. Lane M indicates 
the marker used in kilo Dalton (kDa) illustrated at the left; lanes numbered with 
(1, 2, 3, 4, 5, 6, 7) indicate the bacterial expression of rIL-37a with or without 
IPTG; the arrow refere to rIL-37a band expression which is expected to be about 
22 kDa. The experiment repeated five times. 
 
 
 
 
 
 
 
 
3.2.3.3  Purification of IL-37a by Ni-NTA chromatography 
The bacterial pellet expressing IL-37a, re-suspended in binding buffer 
supplemented with lysozyme and protease and the supernatant containing the 
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His tag-fusion IL-37a protein loaded to the Ni-NTA column (Fig 3.11a). The same 
IL-37b His-tag procedure used for the purification of IL-37a by Ni-NTA 
chromatography. However, the time used for the purification of IL-37b was much 
shorter than that of IL-37a. The washing step in IL-37a purification completed 
within 60 to 120 minutes; and the bound His-tagged-IL-37a protein eluted within 
120-190 minutes.  Based on the protein optical density (OD) and experiences, 
the fractions of the protein elution from 17-26 were collected. 
3.2.3.4  Confirmation and purity of the His-tagged IL-37a protein by SDS-PAGE 
I next checked if the eluted protein fractions (17-26) contain IL-37a protein, and 
what is the purity using SDS-PAGE (Fig 3.11b). The result showed that the 
protein with the molecular weight about 21 kDa in the bacterial extract could 
bind to Ni-NTA and eluted by imidazole, indicating that it is the 6His-tagged IL-
37a protein. While this protein band seen in all the collected fractions (number 
17, 19, 22, 23, 24, 25, and 26), the majority of the proteins existed in the 
fractions 17, 19 and 22. Compared to the loading samples, the Ni-NTA 
chromatography effectively enriched the recombinant protein from the bacterial 
lysis. However, this protein seen in the unbound fractions (line 3) or the flow 
throw from the column, this suggests that the loading quantity and condition 
were further optimised.  
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a) 
 
 
b) 
 
Figure 3.11 Nickel affinity chromatography for IL-37a purification. 
a) IL-37a- 6His-tagged protein purified with His-Trap (5ml volume column) using 
the AKTA system. 35 ml of soluble bacterial containing IL-37a- 6His-tag extract 
loaded to the Ni- column, with 1ml/min flow rate; and the absorption monitored 
at 280 nm; the peak with the red brackets is IL-37a protein. b) SDS-PAGE gel. 
Fractions numbered (17 -26) collected and re-suspended in SDS-PAGE loading 
buffer, heated at 95 Cº for 10 minutes; then separated on 15% of SDS-PAGE gel. 
The gel stained with 0.1% Coomassie Brilliant Blue R-250 solution and de stained 
with de stain buffer. The first line (M) is the marker with the molecular weight 
on the left, lane (load) is the protein extract loaded, and lane (ft) is the  
unbound flow throw proteins out from the column, respectively. Lane numbered 
(17, 19, 22, 23, 24, 25, and 26) correspond to 6His-tagged- IL-37a.  
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3.2.3.5  Confirmation of the His-tagged IL-37a proteins by western blot 
Since the protein size in (Fig 3-12) can only suggest, but not ensure that the 
purified protein is IL-37a-His protein, I next confirmed this by western blot. As 
the same was done for IL-37b His-tag in section 3.3.5, the different fractions of 
His-tag IL-37a protein eluted by Nickeled affinity chromatography separated by 
SDS-PAGE and transferred onto nitrocellulose membrane. The protein was 
labelled with conjugated anti-6His-tag monoclonal antibody, and detected by 
western blotting. As shown in Fig 3.12, a single band with molecular weight of 
His-tagged IL-37a clearly detected in the samples, further; suggesting that the 
proteins is His-tagged IL-37. 
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Figure 3.13 Confirm the His-tagged IL-37a by western blotting. 
The protein fractions from Nickel affinity chromatography run by SDS-PAGE, 
transferred onto nitrocellulose membrane, and the His-tag IL-37a was detected 
using conjugated anti 6His-tag antibody. The first line (M) indicates the marker 
with the molecular weight (kDa); the second lane (rIL-37a) is recombinant IL-37a 
used as positive control, lane (load) is the loading sample on the Nickeled 
column before purification; lane (Fth) is the unbound proteins flow throw 
through the Nickel column. Lanes (25, 24, 23, 22, 19, and 17) are different 
fractions of rIL-37a eluted from the Nickeled column. The fractions numbers are 
the same as in the (Fig 3.11b). The experiment repeated three times. 
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3.2.3.6  Purification of IL-37a proteins by gel filtration  
As seen in (Fig 3.11), while the Nickel affinity chromatography was effective in 
the enrichment of recombinant IL-37a protein, many contaminating proteins 
were still present in the protein preparations. Next, the contaminants of 
proteins were further removed by size exclusion chromatography (SEC). The 
separation with SEC performed under native conditions to preserve the biological 
activity of the protein.  
After the successful purification of IL-37b, however, the nickel purified IL-37a 
proteins precipitated during the dialysis, which were seen by naked eyes. The 
precipitation of the protein led to the loss of considerable amount of IL-37a (up 
to 50%). Several dialysis conditions were developed to overcome this problem 
(Section 3.5.1).  
IL-37a was further purified by SEC; using the same conditions as IL-37b described 
above. As shown in the (Fig 3.13a), a clear protein peak was detected after the 
sample loaded; and the protein fractions correlated to the protein peak 
collected for the purity checking using SDS-PAGE as before. 
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           a) 
 
             b) 
 
Figure 3.14 Purification of rIL-37a by Gel filtration 
The Nickeled purified IL-37a samples were dialysed in 50mM tris and 200 mM 
NaCl, and loaded onto gel filtration column. a) The proteins were separated 
using S-75 sephadex column with 1.5 ml/minute flow rate; and the protein peak 
fractions collected for SDS-PAGE gel. b) Represents collected fractions from gel 
filtration assessed by 15% SDS-PAGE; Line M: the protein marker. Line load: 
loaded sample. Lanes (A9, A10, A11, A12, A13, and B14) are the protein 
fractions collected from the column. 
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3.2.3.7  Identity confirmation of purified IL-37a by mass spectrometry 
Mass spectrometry (MS) is a powerful technique with different applications in 
chemistry, biology and clinical medicine.  It determines the molecular weight of 
compounds by separating molecule ions based on their mass and charge. 
Recently MS has become one of the most important methods for proteins studies 
in term of identification and sequencing. 
The mass spectrometry strategy composed of three main steps:  
1- Analyte ionization: ionization converts the molecule to ions. Electrospray 
ionization (ESI), matrix-assisted laser desorption and ionization (MALDI) 
are the most commonly used methods in proteomics. 
2- Analysis of mass: molecules separated according to their mass/ charge 
ratio (m/z), in proteomics the mass analyser can be an ion trap, an 
fourier transform ion cyclotron resonance (FTICR), hybrid of the 
aforementioned a or a quadrupole analysers. 
3- Detection of the output: signal is recorded at the detector, and results 
can be m/z vs intensity plot, or a mass spectrum. The detector is 
normally an electron multiplier. The mass analyser and detector are 
always within the high-vacuum region (Zhu et al, 2010; Ilavenil et al, 
2016). 
Whereas the results of SDS-PAGE and western blot using anti-6His-tag antibody in 
(Fig 3-11b and 3-12); indicated that the purified proteins were IL-37a, this result 
is still unable to define the protein identity. Next, we decided to determine the 
protein identity by MS. IL-37a band with molecular weight of IL-37a in (Fig 3.11) 
was cut out from the SDS gel. The protein in the gel pieces was enzymatically 
digested using trypsin into peptide fragments. The protein sequence of the 
protein fragments was determined by mass spectrometric analysis (Sutton et al, 
1995). MS demonstrated that the resulted peptide sequences covered 84.375% of 
the published human IL-37a sequence (Accession number (Q9NZH6-2) with 100% 
homology (Table 3.3 and data not shown). Thus, the purified protein is human 
IL-37a. Amino acids sequences detected by MS, also confirmed that the purified 
protein is human IL-37a (Table 3.3).  
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Table 3.3 Mass Spectroscopy confirms the protein sequence of purified 
human IL-37a. 
Accession 
Q9NZH6-
2 score/ 6616.46 Coverage/84.38% 
A2 Sequence # PSMs 
High VLVLDSGNLIAVPDK 44 
High NYIRPEIFFALASSLSSASAEK 44 
High VLVLDSGNLIAVPDKNYIR 2 
High AQVGSWNLESAAHPGWFIcTScNcNEPVGVTDKFENR 7 
High AQVGSWNmLESAAHPGWFIcTScNcNEPVGVTDK 3 
High NYIRPEIFFALASSLSSASAEKGSPILLGVSK 7 
High LAAQKESAR 1 
High VLVLDSGNLIAVPDKNYIRPEIFFALASSLSSASAEK 12 
High HIEFSFQPVcK 23 
High GSPILLGVSK 14 
High FSIHDQDHKVLVLDSGNLIAVPDK 1 
High GSPILLGVSKGEFcLYcDK 2 
High AQVGSWNMLESAAHPGWFIcTScNcNEPVGVTDK 2 
High AQVGSWNmLESAAHPGWFIcTScNcNEPVGVTDK 3 
High GEFcLYcDKDK 8 
High GEFcLYcDK 2 
High HIEFSFQPVcKAEmSPSEVSD 1 
High KHIEFSFQPVcK 2 
High GEFcLYcDKDKGQSHPSLQLK 5 
High KFSIHDQDHK 1 
High AEmSPSEVSD 1 
High AQVGSWNMLESAAHPGWFIcTScNcNEPVGVTDKFENR 1 
High KFSIHDQDHKVLVLDSGNLIAVPDK 1 
High AQVGSWNmLESAAHPGWFIcTScNcNEPVGVTDKFENR 3 
High DKGQSHPSLQLK 1 
Medium GSPILLGVSKGEFcLYcDKDK 1 
Medium RPFIFYR 5 
Medium GQSHPSLQLK 2 
Medium DKGQSHPSLQLKK 1 
High AEMSPSEVSD 2 
High AEmSPSEVSD 2 
Medium AQVGSWNMLESAAHPGWFIcTScNcNEPVGVTDKFENRK 1 
Medium GQSHPSLQLKK 1 
Medium VKNLNPK 1 
 
The protein sequences identified by mass spectroscopy matched with the known 
protein sequence of human IL-37a (Q9NZH6-2).  
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Mass spectroscopy analysis confirmed that the protein was intact, and covers 
84.38% of human IL-37a sequence. The sequence below shows human IL-37a 
amino acids sequences and the highlighted sequences with red indicate similarity 
between the sequences in Table 3.3 with human IL-37a (Q9NZH6-2).   
  
 
MSGCDRRETETKGKNSFKKRLRGPKVKNLNPKKFSIHDQDHKVLVLDSGNLIAVPDKNYIRPEIF
FALASSLSSASAEKGSPILLGVSKGEFCLYCDKDKGQSHPSLQLKKEKLMKLAAQKESARRPFIFY
RAQVGSWNMLESAAHPGWFICTSCNCNEPVGVTDKFENRKHIEFSFQPVKAEMSPSEV SD. 
 
 
3.2.4  Optimisation of IL-37a and IL-37b protein purification 
3.2.4.1  Dialysis conditions  
In initial experiments, Ni-NTA purified IL-37a precipitated extensively during 
dialysis, led to loss of protein; to overcome this drawback, I tried several dialysis 
conditions inan attempt to improve solubility, and to prevent protein 
precipitation (Table 3.4). The protein showed great stability in dialysis buffers 
contains (250 mM NaCl Tris 50 mM) with pH= 7.5, and less precipitation noticed.    
Table 3.4 Dialysis conditions used to improve IL-37a solubility 
Conditions used for dialysis   concentration 
 
 
  before 
dialysis   
After 
dialysis  
250 mM NaCl+ Tris 50 mM (pH=7.5) 
 1.191 1.065 
 500 mM   NaCl+ Tris 50mM (pH=7.5) 
 1.191 1.001 
(1mM   DTT) + (250 mM   NaCl) + Tris 50Mm 
(pH=7.5) 
 1.191 0.978 
(1mM   DTT) + (500 mM   NaCl) (pH=7.5) 
 1.191 0.905 
(Glycerol 5%) + (250 mM NaCl) (pH=7.5) 
 1.191 0.94 
(Glycerol 5%) + (500 mM NaCl) (pH=7.5) 
 1.191 0.901 
PBS (137 mM NaCl; 2.7 mM KCl; 8 mM 
Na2HPO4; 
and 2 mM KH2PO4, pH=7.5) 1.191 0.552 
Tris buffer (pH=7.5) 
 1.191 0.993 
111 
 
3.2.4.2  Assess the efficiency and yield of recombinant IL-37 purification 
The quantity and yield of the proteins in each of the purification steps of the 
production process was also determined and showed in the (Table 3.5) below. 
Nickel affinity chromatography was most the effective step that removed most 
of the contaminating proteins.The final yields of IL-37a and IL-37b were 1.2 mg 
and 2.4 mg, respectively.  
Table 3.5 Recombinant IL-37a and IL-37b production yield after each 
purification step. 
 
 
 
 
 
 
 
The result is representative of 6 independent experiment. 
 
3.2.4.3  Endotoxin removal  
LPS, or (endotoxin), is an abundant surface component of gram-negative 
bacteria. It is also a powerful immune activator and can trigger and exacerbate 
many inflammatory and autoimmune disorders (Dullah and Ongkudon, 2016). 
Bacterial LPS contamination in recombinant protein preparation is a potential 
problem in the application of the protein agent. Thus, the contaminated 
endotoxin was removed.Endotoxin in the purified IL-37a and IL-37b samples was 
removed with polymyxin B columns following the manufacturer’s instruction. 
Levels of endotoxin in the IL-37 proteins preparations was measured before and 
after the LPS removal, using Limulus amebocyte lysate (LAL) QCL-1000 pyrogen 
test kit (Chapter 2). Before LPS removal, the level of LPS in IL-37a and IL-37b 
were 0.83 EU/µg and 0.861 EU/µg of protein respectively, and after LPS 
removal, the level of LPS in both proteins were less than 0.01 EU/µg. This level 
of LPS in the cytokine preparations as acceptable for the bioactivity studies.  
Cytokine 
IL-37a 
(mg)  
IL-37b  
(mg)  
Yield of protein after Ni-column 10.3 14.6 
Yield of protein after  gel filtration 3.03 5.37 
Yield of protein after LPS removal  1.2 2.4 
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3.2.5 Crystallization of IL-37a and IL-37b protein 
Protein structure prediction with experimental methods is determined by using 
X-ray crystallography (Gromiha M, 2004). Protein crystallization includes the 
creation of a supersaturated solution in conditions where do not perturb the 
proteins natural state. The production of super saturated conditions can be 
achieved through: 1) the addition of mild precipitating agent such as salts or 
polymers. 2) The use of various parameters; including pH, temperature; and 
ionic strength. Crystallization proceeds in two distinct inseparable steps; the 
first step is   nucleation and the second step is growth. A variety of methods 
developed to affect and promote crystallization including dialysis, vapor 
diffusion, batch and liquid–liquid diffusion (Luft et al, 2014). 
IL-37b isoform purified previously by Nickeled column and gel filtration in 
sections 3.3.3 and 3.3.5, dialysed in PBS buffer (Table 3.5); in which the protein 
remained stable and soluble. IL-37b protein was concentrated into 14 mg/ml 
using Sartorius Vivaspin (50 m tube from thermos Fisher Company); the protein 
kept on ice until processed to crystallization screen. Next, two different 
concentrations (14 mg/ml and 7.5 mg/ml diluted in PBS buffer) of IL-37b were 
used with different high throughput crystallization screens including JCSG-plus-
HT-96, MIDAS-96; Morpheus- HT-96; and PACT premier-HT-96 (Molecular 
Dimensions Company). The screens were monitored every week for crystals 
formation by light microscopy. Most of the wells resulted in phase separation 
(Fig 3.14). 
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Figure 3.15 The results from IL-37b crystallization screens. 
IL-37b was prepared for crystallization with two different concentrations (14 and 
7.5 mg/ml), diluted in PBS buffer. a) granular precipitate(JCSG- plus-HT-96 
screen with 14 mg/ml), b) granular precipitate (PACT premier-HT-96, with 14 
mg/ml), c) granular precipitate (MIDAS-96, with 14 mg/ml), d) phase separation 
(Morpheus- HT-96, with 14 mg/ml), e) granular precipitate (JCSG- plus-HT-96 
screen, with 7.5 mg/ml), f)  phase separation (Morpheus- HT-96, with 7.5 
mg/ml, with 7.5 mg/ml).  
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3.3 Discussion 
Plasmids for the expresiion of IL-37a and IL-37b were successfully constructed 
and purification methods for the recombinant IL-37a andIL-37b were established. 
Both of these His-tagged proteins were successfully purified to a high level of 
purity with good yeild. The choosing of of BL21(DE3) pLysS as a host expression, 
resulting in good expression to give a final yield of purified protein of 10-13 
mg/5L of culture. 
The expression of the protein was not problematic, but  IL-37a precipitation 
during diyalysis was noticed. Several conditions were used to overcome IL-37a 
precipitation (Table 3.3) to optimse purification. 
IL-37a is less soluble compared to IL37b, and it was suggested that may was due 
to the isoelectric point (PI) of IL-37a which is 9.2 in comparison with IL-37b (PI 
6.1). However, the buffer used was pH 7.5, which was at least one unit far from 
9.2 to avoid protein precipitation. Therefore, I tried different salts 
concentrations with the same Ph 7.5. Finally, by reducing the salt concentration, 
the protein exhibited stability in 250 mM NaCl with a very small amount  of 
precipitation. 
Western blotting was used to confirm the identity of the His-tagged proteins. 
The protein purity after Ni-column was relatively high and the remaining 
contaminants were removed by gel filtration. IL-37a after gel filtration had not 
shown clear dimerization, while  dimerization of IL-37b was noticed. Fractions of 
IL-37b after gel filtration were tested with SDS-PAGE to check the purity and 
monomer fractions collected separately from the dimerised fractions.  
IL-37b dimerization due to two main chains of hydrogen bonds formed between 
Tyr85 and Arg87 from each IL-37b monomer, and this interaction is protected by 
conserved ionic interactions between Lys83 and Asp73, in addition to extra  
hydrogen bonds formed between Ile86 main-chain carbonyl group and Arg87  side 
chain of of each monomer. Tyr85 mutation at the hydrophobic core is disrupted 
the dimer formation completely and results in a variant with a MW of ~18,000 
kDa, suggesting that Tyr85 is highly conserved and is  a key role in  the dimer 
stabilization; however, mutation of Asp73  affect the ionic interactions gate of 
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the interface; thus, Asp73  mutation moderately destabilizes IL-37b dimerization 
(Ellisdon et al, 2017).  
Circular dichrosim confirmed that the protein secondary structure of IL-37b 
seems to be unfolded at its native conditions, and the protein aggregated at 
temperatures above 40°C.  
Mass spectrometry determination confirmed the IL-37a identity, and showed that  
IL-37a was intact and had not suffered from degradation during the purification 
process.    
Crystalisation method was established, however, the protein was not crystallized 
before, I selected several screening conditions which were reported by Krumm 
et al (2015) to crystalize IL-18 cytokine, as IL-18 cytokine belong to the same 
family of IL-37b; but, IL-37b did not yield crystals, and most of the conditions 
gave phase separation (Krumm et al, 2015). IL-37 crystallization reported by 
Ellisdon et al (2017) ,while I was trying to find the suitable conditions for IL-37b 
crystallization. This group used hanging-drop vapor diffusion in (2.1 M 
ammonium sulfate , 0.1 M sodium acetate at pH 4.5), and the IL-37b  crystals 
were grown at +20°C  in flash cooled in liquid nitrogen (Ellisdon et al, 2017), 
while we were growing crystals at  +17 ºC in the incubator.  
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4 Expression and function of IL-37a and IL-37b in 
immune cells 
4.1 Introduction 
The optimal and preferential induction of IL-37 isoforms in immune cells is still 
poorly understood. There is one report, which shows that IL-37 isoform 
expressions in total human PBMCs are differently regulated by TLR stimulation 
within 8 hours (Rudloff et al, 2016).  TLR1, 2, 3, 4, 5, 6, and 9 ligands upregulate 
IL-37b and c in these experimental condition and the most effective TLR ligand 
that induces IL-37 isoform expression is LPS (TLR4 ligand). TLR7/8 agonists had 
no effect on the induction of IL-37 expression. IL-37c expression is 
predominantly induced by PAM3 (TLR2 ligand), while IL-37a and e are not 
upregulated with these stimuli. However, the time effect beyond 8 hours has not 
been studied. Furthermore, this study also shows that monocytes comprise the 
main source of IL-37 (73%), followed by myeloid dendritic cells (mDCs) (12%), B 
cells (0.556%) and T cells (0.46%). Stimulation with LPS did not affect IL-37 
expression in the cell populations (Rudloff et al, 2016). While this information is 
valuable, the relative expression of IL-37 isoforms in these immune cells is 
unknown.  In addition, the details of qPCR primers for each of the IL-37 isoforms 
used in the study were not provided.  
While the function of IL-37b has been well studied, the effect of other isoforms 
on immune response is still unknown.  IL-37b are inflammatory signal an induced 
and feedback suppresses ongoing inflammatory response (Nold et al, 2009; Li et 
al, 2017; Zhan and Zeng, 2017). Whereas mice do not express IL-37, they express 
IL-1R8 and IL-18Ra; the IL-37 receptors can response to human IL-37 (Wang et al, 
2018). This has made mouse a useful model system to study human IL-37 
function in vitro and in vivo. Taking this advantage, human IL-37b transgenic 
mice have been developed and facilitated to study human diseases in vivo 
(McNamee et al, 2011; Davis et al, 2017; Liu et al, 2018) 
Since IL-37 receptors are widely expressed on immune cells, IL-37b has profound 
effect on a wide range of innate and adaptive immune cells, including 
monocytes, macrophages, epithelial, NK, mast and T cells (Fehervari, 2014; 
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Zhao et al, 2014; Shuai et al, 2015; Wu et al, 2015; Wang et al, 2016; Zhang et 
al, 2017; Conti et al, 2018). However, its effect on mature B cells has not been 
studied, while it shown that IL-37 may prevent B cell progenitors to develop into 
B lymphopoiesis by reducing inflammation in bone marrow of aging mice (Henry 
et al, 2015).  
B cells are the important lymphocytes in immunity. The main function of B cells 
is to produce antibody and mediate humoral immune responses (Amlot et al, 
1985; Cerutti and Cols, 2013; Tsiantoulas et al, 2014). However, B cells can also 
serve as a professional APC to present antigen to T cells (Rivera et al, 2001; 
Rodríguez-Pinto, 2018). Furthermore, B cells after activation can also regulate 
other cell function by secreting a range of cytokines and chemokines (Fillatreau 
et al, 2002; Shen et al, 2014; Lino et al, 2015; Shen and Fillatreau, 2015; 
Vazquez et al, 2015).   
The activation and differentiation of naive into effector B cells requires at least 
three signals: the BCR/antigen interaction, co-stimulation from T cells, in 
particular CD40/40L ligation, and cytokines from other cells and the B cell itself 
(Nonoyama et al, 1993; Parker, 1993; Wortis et al, 1995; Dorner and Radbruch, 
2007). The CD40/CD40L ligation can induce resting B cells proliferation and 
differentiation into Ig secreting plasma cells in the presence of IL-4 (Nakanishi et 
al, 1996; Rush and Hodgkin, 2001; Linterman and Beaton et al, 2010). 
B cells also express several TLRs and TLR, especially TLR4 and TLR9 signals, can 
induce polyclonal B cell activation and function (Bernasconi et al, 2003; Bourke, 
2003; Ruprecht and Lanzavecchia, 2006; Richard et al, 2008). Human and mice B 
cells respond to TLR4 and TLR9 signals differently. Murine B cells stimulation 
with LPS induces polyclonal expansion, antibody isotype switching and 
differentiation to plasma cells (PCs), while stimulation with CPG can induce only 
proliferation but less IgG production (Bernasconi et al, 2003; Lanzavecchia and 
Sallusto, 2007; Richard et al, 2008). TLR9 is expressed at high levels in naive and 
memory human B cells compared to that in murine (Bourke et al, 2003; Ruprecht 
and Lanzavecchia, 2006); and CPG is an excellent agent to induce human B cell 
proliferation and antibody production (Krieg, 2000; Rupercht and Lanzavecchia, 
2006). CPG/TLR9 signals also enhance APC function of B cell by upregulating 
surface CD40, CD80 and MHC-II expression (Jiang and Lederman et al, 2007). 
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To date, it is unclear whether IL-37a is bioactive and whether IL-37a and IL-37b 
isoforms are different in expression and function. Based on the structural study 
in Chapter 3 and the similarity between IL-37a and b in the IL-1-like receptor-
binding domain, I hypothesised that IL-37a is bioactive and can also bind to and 
signal via the same receptor. However, the two isoforms also possess different 
N-terminal sequence that may offer them unique biological features in cellular 
location and function. Thus the main aims of this chapter are: 
1- To investigate the induction and regulation of IL-37 isoforms and receptor 
expression in human cells.  
2- Determine the bioactivity of endogenous and exogenous IL-37a in the regulation 
of human cell functions. 
3- Compare the similarity and difference between IL-37a and IL-37b isoforms in the 
regulation of immune cell functions.    
 
4.2 Results 
4.2.1 IL-37 isoform expressions levels are differently regulated in 
human monocytes. 
To understand the induction and regulation of IL-37 isoforms in immune cells, we 
sought to investigate IL-37 isoform expression in human monocyte THP-1 cells. 
Monocytes were cultured in RPMI medium; and stimulated with or without 
different doses of LPS for 16 hours. Cells were harvested and the IL-37 isoform 
expressions determined by qPCR. We found that different doses of LPS had 
different effect on the expression of IL37 isoforms. 100 ng/ml of LPS markedly 
induced the expression of all isoforms, compared to the controls (Fig 4.1). The 
IL-37a, IL-37c and IL-37e expressions were higher than IL-37b and IL-37d. At the 
higher dose (200 ng/ml), LPS mainly induced the expression of IL-37d, not the 
other isoforms.   
Next, we investigated the time effect of LPS on the induction of IL-37 isoforms 
expression. THP-1 cells were stimulated with fixed dose of LPS and the IL-37 
isoform expressions were determined by qPCR over the times indicated. As 
shown in (Fig 4.2); the kinetics of induction of the isoform expressions were 
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varied; the expression of IL-37a, c, d and e reached to peak at 16 hours after 
LPS stimulation and then declined. In contrast, IL-37b was induced in a time 
dependent manner, at 24 hours when all other isoform expressions were 
declined, the expression of IL-37b still went up (Fig 4.2). 
These results suggest that the expression of IL-37 isoforms is differently 
regulated and IL-37a is one of the highly induced isoforms. 
4.2.2 IL-37a is an immune suppressive cytokine. 
I next investigated if the IL-37a is bioactive and whether it has same or different 
bioactivity in immune cells compared to IL-37b.  
In order to understand the function of the endogenous IL-37a, we studied its 
function in human monocyte in vitro. We firstly knockdown the RNA of IL-37a or 
total IL-37 isoforms as well by using specific siRNAs that target exon 3 for IL-37a 
and the common exon 5 for all the IL-37 isoforms respectively. The human 
monocyte cell line THP1 cells were transduced with the specific and control 
siRNA for 48 h and then the cells were stimulated with LPS for 6 hours followed 
by the determination of IL-37 isoforms, TNF-α and IL-1α expression by qPCR. As 
shown in (Fig 4.3), knockdown of IL-37a alone significantly enhanced the 
expression of LPS-stimulated inflammatory cytokine TNF-α, which was further 
enhanced by the knockdown of total IL-37 isoforms. The knockdown of both IL-
37a and total IL-37 also significantly elevated the expression of LPS-induced IL-
1α with the similar effect. These siRNAs also selectively abolished the expression 
of IL-37a and total IL-37 (Egle Katkeviciute, data not shown). Thus, this result 
suggests that endogenous IL-37a is bioactive and may serve as an 
immunosuppressive cytokine. 
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Figure 4.1 Dose-dependent effect of LPS in the induction of IL-37 isoforms 
expression in THP-1 cells. 
THP-1 cells (106/ml) were stimulated with different doses of LPS as indicated for 
16 hours then the RNA extracted for qPCR with specific primers for all the IL-37 
isoforms. Data are mean ± SD, *P< 0.05 compared to controls, which is THP-1, 
cells alone or treated with LPS. This figure represents three independent 
experiment.  
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Figure 4.2 Time effect of LPS on the induction of IL-37 isoform expression 
THP-1 cells (106/ml) were stimulated with 100 ng/ml of LPS, the RNA were 
extracted and the expression levels of IL-37 isoforms monitored at 3, 16 and 24 
hours by qPCR using specific primers. Data are mean ± SD, *P< 0.05 compared to 
controls which is THP-1, cells alone or treated with LPS. This figure represents 
three independent experiment.  
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Figure 4.3 Knockdown of IL-37a and total IL-37 by specific siRNA increases 
LPS stimulated inflammatory cytokines production in THP-1 cells. 
The RNA of IL-37a and total IL-37 isoforms in THP1 cells were knocked down first 
using specific siRNAs; the cells (106/ml) was then stimulated with LPS for 12 h; 
and the expression of IL-1α and TNF-α was determined by qPCR. Data are mean 
± SD, **P< 0.01, and ***P< 0.001. This figure represents two independent 
experiment.  
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In chapter 3, I purified FL-IL-37a and IL-37b proteins by Ni column and gel 
filtration. I next tested their bioactivity in the mouse macrophage (RAW 264.7 
cell line) which lack IL-37 gene expression but possess both receptors (IL-18Ra 
and IL-1R8) for signalling of IL-37 (Bulau et al, 2014; Li et al, 2015). This cell line 
has been used to test IL-37b activity (Bulau et al, 2014). RAW 264.7 cells 
cultured in DMEM medium were stimulated with LPS in the presence or absence 
of different doses of recombinant IL-37a and IL-37b. These proteins were 
purified by Ni-NTA column (Fig 4.4 A and B) or by both Ni chromotography and 
gel filtration (Fig 4.4 C and D) as described in Chapter 3; the cells were then 
harvested 24 hours after the culture and IL-6 levels in culture supernatants were 
measured using ELISA. I found that both rIL-37a and rIL-37b proteins purified by 
Ni column alone were sufficient to suppress the LPS-induced IL-6 production in 
macrophages, and IL-37a was more suppressive than IL-37b in this condition (Fig 
4.4 A and B). The inhibitory effect of both proteins on IL-6 production was dose-
dependent, with the lower doses (50-25 ng/ml) more suppressive than the higher 
ones. This is consistent with the report that IL-37b can form homodimer at 
higher concentration and homodimer is less suppressive than monomer in 
inflammatory cytokine production (Ellisdon et al, 2017). Compared to the Ni 
column purified proteins, I also found that the inhibitory capacity of IL-37a and 
IL-37b proteins purified by both Nickeled-column and gel filtration was more 
pronounced, and again, IL-37a was more suppressive compared to IL-37b (Fig 4.4 
C and D). To confirm the differences between IL-37a and IL-37b in bioactivity, 
we next compared the ability of both proteins in the suppression of IL-6 
production in LPS-stimulated macrophage. As shown in (Fig 4.5). IL-37a was 
more suppressive than IL-37b in IL-6 production in macrophages in a dose-
dependent manner.  
I further assessed the regulatory effect of IL-37a on other key cytokines 
production in LPS-stimulated monocytes. I found that IL-37a could also suppress 
LPS-induced expression of TNF-α and IL-1α, the important inflammatory 
cytokines; however, it had no effect on the inhibition of regulatory cytokine IL-
10 expression in the condition (Fig 4.6). Together, all the data demonstrated for 
the first time that both the endogenous and recombinant IL-37a are functional 
and able to suppress LPS-induced cytokine production in human monocyte and 
murine macrophages, the important innate immune cells. 
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Figure 4.4 Bioactivity of recombinant IL-37a and IL-37b in LPS-stimulated 
murine macrophage. 
Murine RAW 264.7 cells (106/ml) were stimulated with LPS (100 ng/ml) and 
treated with different dose of rIL-37a and rIL-37b purified by different columns. 
Cells were harvested after 24 hour culture, and ELISA used to mesure IL-6 levels 
in cells supernatant. (A and B) represent the activity of rIL-37a and rIL-37b 
purified by Nickeled-column. (C and D) are the bioactivity of rIL-37 after gel 
filtration and LPS removal. Data are mean ± SD,*P< 0.05, **P< 0.01, and ***P< 
0.001 compared to control (RAW 264.7 cells alone or treated with LPS). This 
figure represents two independent experiment. 
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Figure 4.5 Comparison between recombinant IL-37a and IL-37b bioactivity in 
murine macrophage RAW264.7. 
Murine RAW cells (106/ml) were stimulated with LPS (100 ng/ml) and treated 
with different doses of rIL-37a and rIL-37b for 24 hours; and IL-6 level in culture 
supernatant was measured by ELISA. Data are mean ± SD, *P< 0.05 and **P< 0.01 
compared to control (RAW264.7 treated with LPS). This figure represents three 
independent experiment. 
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Figure 4.6 Effect of rIL-37a on the regulation of cytokine expression. 
THP-1 cells (106/ml) were stimulated with LPS (100 ng/ml), in the presence of 
rIL-37a (50 ng/ml); the cells were harvested for RNA extraction after 16 hours 
culture. TNF-α, IL-1α and IL-10 expressions were determined by qPCR. Data are 
mean ± SD; *P< 0.05, **P< 0.01, and ***P< 0.001 compared to control (NC: THP-1 
cells only) or LPS treated THP-1 cells.  This figure represents three independent 
experiment.  
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4.2.3 The regulatory effect of IL-37a and IL-37b on murine B cell 
function 
4.2.3.1 IL-37a and IL-37b increase antibody production in B cells 
After finding thatIL-37a and IL-37b isoforms suppress pro-inflammatory cytokines 
production in innate immune cells, we decided next to investigate the role of IL-
37 in adaptive immune cells. While the effect of IL-37b on the regulation of T 
cell function has been studied (Shuai et al, 2015; Wang et al, 2016), the role of 
IL-37a and IL-37b in B cells is unknown.   
B cells represent one of the major arms of adaptive immunity and have three 
functions; they serve as professional APC, producing cytokine; but their main 
function is antibody production in humoral immune responses. Therefore, we 
sought to investigate the effect of IL-37 on B cell function; the first step was to 
check the effect of IL-37a and IL-37b on antibody production in murine B cells. 
Murine CD19+ B cells were isolated from spleenocytes by MACS using anti-CD19 
antibody conjugated on magnetic beads for positive selection (Abts et al, 1989). 
CD40 ligand on T cells plays a co-stimulatory role in B cell activation and 
antibody production by interacting with CD40 receptor on B cells and triggering 
signalling (Parker, 1993; Smith et al, 2000; Elgueta et al, 2009; Zotos et al, 
2012). We then assessed the regulatory effect of IL-37 on the CD40-mediated B 
cell activation and antibody production. The B cells were co-cultured with 3T3 
cells that over-express transgenic CD40 ligand, and then treated with 50 ng/ml 
of rIL-37a and rIL-37b for 3, 4 and 7 days. Supernatants were collected for the 
detection of IgG level in the cultures by ELISA. As reported, CD40 signals 
significantly enhanced B cell IgG production from 3 days culture (Fig 4.7 A.C). 
Unexpectedly, rIL-37a further increased the IgG production in CD40-activated B 
cells 7 days after the culture (Fig 4.7C). This was also the case in the rIL-37b 
treated B cells (Fig 4.8). Furthermore, rIL-37b was more effective than rIL-37a in 
the enhancement of B-cell IgG production (Fig 4.7 and 4.8). 
I sought next to confirm the phenomenon by using B cells isolated from the 
human IL-37a transgenic (IL-37a-tg) mice which constantly express IL-37a (Dr Xu, 
unpublished result). CD19+ B-cells were isolated from wt and IL-37a transgenic 
C57BL/6 mice as above and co-cultured with CD40L expressing 3T3 cells for 3, 4 
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and 7 days as before (Fig 4.7 and 4.8). Consistent with the results with rIL-37 
protein, the B cells from IL-37a transgenic mice also showed an increased IgG 
production compared to the wt B cell control, 7 days after the culture (Fig 4.9)  
TLR signals also play an important role in B-cell activation and antibody 
production, in particular TLR4 and TLR9 signals (Jiang et al, 2007; Quintana et 
al, 2008; Boeglin et al, 2011). I then determined whether IL-37a and IL-37b can 
also potentiate the TLR4 agonist, LPS-mediated antibody production in B cells.  
CD19+B cells were isolated from spleenocytes of C57BL/6 mice and stimulated 
with LPS (10 ug/ml) in the presence or absence of rIL-37. As seen in Fig 4.10 and 
4.11, both rIL-37a and rIL-37b increased LPS-induced IgG production in B cells. 
The effect was more pronounced in IL-37b than IL-37a treated B cells (Fig 4.10 
and 4.11). 
Furthermore, B cells from IL-37a-tg mice also markedly enhanced IgG production 
in the LPS-stimulated B cells from 3 days after the culture (Fig 4.12). At day 7, 
the antibody level in the tg cells were about 5 times higher than that in wt 
control cells. Thus, both IL-37a and IL-37b are able to promote antibody 
production in the CD40 or TLR activated B cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
130 
 
 
Figure 4.7 IL-37a enhanced IgG production in CD40-stimulated B-cell. 
Wild type CD 19 murine B cells (106 cell/ ml) were cultured with 3T3 (15 x 104 
cells/ml), and treated with 50 ng/ml of rIL-37a, and incubated for 3, 4, and 7 
days, IgG levels in the culture supernatant was measured using ELISA. A, B, and 
C are IgG levels at days 3, 4, and 7. Data are mean ± SD; *p≤ 0.05, **P< 0.01 and 
***P< 0.001 compared to control (CD19+ cells only) or to CD40 treated cells. This 
figure represents five independent experment. 
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Figure 4.8 IL-37b enhanced IgG production in CD40 stimulated B-cell. 
 
Wild type CD19+ murine B cells (106 cell/ ml) were cultured with 3T3 cells (15 x 
104 cells/ ml), and treated with 50 ng/ml of recombinant IL-37b, cells were 
incubated for 3, 4, and 7 days. ELISA used to measure IgG levels in the culture 
supernatant. The experiment was repeated more than five times. A, B, and C 
are IgG levels at days 3, 4, and 7. Data are mean ± SD; NS represents non-
significant, and *P< 0.05, **P< 0.01 and ***P< 0.001 compared to control or CD40L 
treated cells. This figure represents five independent experment. 
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Figure 4.9 IL-37a-tg mice elevate IgG production in CD40-stimulated B-cell 
compared to wt cells. 
CD 19+ murine B cells (106 cell/ml) from wt and tg-mice were cultured with 3T3 
for 3, 4, and 7 days. IgG level in the culture supernatant measured by ELISA. 
Experiment was repeated more than 5-8 times. A, B, and C are IgG levels at days 
3, 4, and 7. Data are mean ± SD; NS represents non-significant, and *P< 0.05, 
**P< 0.01 and ***P< 0.001 compared to control or CD40. This figure represents 
five independent experment. 
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Figure 4.10 IL-37a enhance IgG production in LPS-stimulated murine B-cell. 
Wild type CD19+ murine B cells was cultured (106 cell/ml) in RPMI,and treated 
with 10 ug/ml of LPS, followed by 50 ng/ml rIL-37a for 3 and 7 days. IgG level 
measured from the supernatant of the cultured cells by ELISA. A and B are IgG 
levels at different days. Data are mean ± SD; NS represents non-significant, and 
*P< 0.05, **P< 0.01, and ***P< 0.001 compared to control or LPS CD19+ treated 
cells. This figure represents seven independent experment. 
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Figure 4.11 IL-37b enhance IgG production in LPS-stimulated murine B-cell. 
 
Wild type CD19+ murine B cells were cultured (106 cell/ml) in RPMI, and treated 
with 10 ug/ml of LPS, followed by 50 ng/ml of rIL-37b for 3 and 7 days. IgG level 
measured from the supernatant of the cultured cells by ELISA. A and B are IgG 
levels at different days. Data are mean ± SD; *P< 0.05, **P< 0.01 and ***P< 0.001 
compared to control or LPS treated cells. This figure represents three 
independent experiment. 
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Figure 4.12 IL-37a-tg mice increase IgG in  LPS-stimulated  murine B-cells. 
Wild type and tg- CD19+ murine B cells were cultured (106 cell/ml), treated with 
10 ug/ml of LPS  for 3, 4, and 7 days. IgG level were measured from supernatant 
of the cultured cells by ELISA. Data are mean ± SD; *P< 0.05, **P< 0.01, and ***P< 
0.001 compared to wild type cells stimulated with LPS. This figure represents 
three independent experiment. 
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4.2.3.2  IL-37 promotes B-cell proliferation 
I next studied the possible mechanism by which IL-37 enhances B cell antibody 
production. First, I assessed the possibility that IL-37 may promote antibody 
production by inducing B-cell proliferation. The CD19+ B cells were isolated from 
spleenocytes of wt and IL-37a-tg C57BL/6 mice and cultured with or without LPS 
(10 ug/ml) as before for 2, 4 and 7 days. B-cell proliferation was determined by 
Brdu cell proliferation assay as described (Löfdahl etal, 2018). As illustrated in 
the (Fig 4.13), without LPS, IL-37a-tg cells exhibited a slight but significantly 
enhanced cellular proliferation compared to that in the wt cells. While LPS alone 
had little effect on the B-cell proliferation in wt group in this condition, it 
markedly enhanced cell proliferation in IL-37a-tg cells. The rIL-37a and rIL-37b 
also enhanced proliferation in murine B cell isolated from wt mice with or 
without LPS in vitro (data not shown). This result suggests that IL-37a can 
promote B cell proliferation, alone or with LPS. 
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Figure 4.13 IL-37a transgenic B cells enhance proliferation compared to wild 
type B cells. 
CD19+ murine B cells from wt and tg- mice were stimulated with or without LPS 
(10 ug/ml). Brdu 0.1 % (v/v) was added to the cell cultures at days 1, 3, and 6, 
incubated for 15 hours from the addition, and the cells harvested for 
proliferation mesuerment. Proliferation were measured at 450 nm. Data are 
mean ± SD, *P< 0.05, **P< 0.01, and ***P< 0.001 compared to control (wt cells 
treated with LPS). This figure represents three independent experiment. 
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4.2.3.3  IL-37a regulates cytokine and signalling molecule expressions in 
activated murine B cells 
B-cell activation and antibody production process is regulated by signalling 
pathways elucidated by BCR, co-stimulatory molecules and cytokines (De Silva 
and Klein, 2015; Wu et al, 2016). Cytokines play different but crucial roles in B 
cell differentiation, antibody class switching and proliferation, including IL-10, 
TGF-, IFNγ and IL-13 (Jurado et al, 1989; Cocks et al, 1993; Abed et al, 1994; 
Defrance, 1994; Gros et al, 2008). I therefore investigated next whether IL-37 
enhances B cell function by the regulation of different cytokine expression. 
CD19+B cells were isolated from wt and IL37a-tg spleenocytes by MACS. The B 
cells (106/ml) were cultured with or without 10 ug/ml of LPS for different times 
and cytokine gene expression determined by qPCR. First, we checked IL-10, 
which can enhance B cell antibody production by preventing B cell apoptosis 
(Gary-Gouy, 2002). I found that 1 day after culture; IL-10 expression was 
markedly enhanced in tg-mice, compared to that in wt cells (Fig 4.14). However, 
the IL-10 expression was significantly reduced after 3 and 7 day cultures 
compared to wt control cells. The expression of antibody isotype class switching 
cytokines (TGF-, IFN-ϒ, IL-13) in LPS-stimulated B cells was also determined by 
qPCR (Fig 4.15). The expression of TGF- was markedly enhanced (245 fold) in 
LPS-stimulated IL37a-tg B cells compared to wt cells. The expression levels of IL-
13 were also elevated, while the IFNγ was significantly reduced in IL37a-tg cells 
compared to wt cells (Fig 4.15). 
We also checked the expression of another three genes, phosphatidylinositol-3, 
4, 5-trisphosphate 5-phosphatase 1 (Inpp5d) or called SHIP (SH2 domain-
containing inositol 5’ phosphatase), tyrosine-protein kinase (Lyn), and tumor 
necrosis factor ligand superfamily member 13 (Tnfsf13) or (April). SHIP knock 
out (SHIP−/−) mice display high serum IgG (Helgason et al, 2000; Maeda and 
Mehta et al, 2010), referring that SHIP is critical in the limitation of B cell 
responsiveness to antigen stimulation. Lyn can enhance or reduce antigen B cell 
receptor–mediated signals (Yamanashi et al, 1993; Kurosaki et al, 1994; 
Sidorenko et al, 1995; Tezuka et al, 1996; Wang, 1996; Chan et al, 1997; 
Yamanashi et al, 1997). Lyn deficiency causes lupus-like autoimmune disease 
and B cell hyperactivity (Lamagna et al, 2013). April (A proliferation-inducing 
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ligand), plays a key role in peripheral B survival, maturation, and 
differentiation. April-/- mice have normal B lymphocyte development and 
proliferation in vitro, but high level of IgG (Castigli et al, 2004). We noticed that 
B-cells from IL-37a-tg mice significantly decreased the expression of SHIP with or 
without LPS, but increased expression of Lyn after LPS stimulation (Fig 4.16). 
The expression level of April was similar between IL-37a-tg and wt B cells in the 
presence or absence of LPS. 
These results suggest that IL-37-induced B cell antibody production and 
proliferation in mice may also be attributed, in part, to its ability to induce and 
regulate the expression of key cytokines and signalling molecules. 
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Figure 4.14 IL-37a-tg B cells alter IL-10 expression. 
CD 19+ cells (106/ml) from IL-37a-tg, and wt mice were cultured and stimulated 
with 10 ug/ml of LPS for 1, 3 and 7 days; the RNA extracted and qPCR performed 
to determine the IL-10 level. Data are mean ± SD, **P< 0.01 and ***P< 0.001 
compared to control or (wild type LPS stimulated CD19+). Both wt and tg 
stimulated with LPS are normalised to non-treated wt and tg cells respectively, 
thus the comparision here is only between treated wt and tg-cells. The figure 
represents three independent experiment.  
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Figure 4.15 IL-37a-tg B cells alter antibody isotype switching cytokine 
expression upon stimulation with LPS compared to wt mice. 
CD19+ cells (106/ml) from IL-37a-tg and wt mice were cultured and stimulated 
with LPS (10 ug/ml) for 3 days; RNA extracted and qPCR performed to detect the 
expression of A) Tgfb, B) Ifng and C) Il13. Data are mean ± SD, *P< 0.05 and ***P< 
0.001 compared to control (wild type). The figure represents three independent 
experiment. 
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Figure 4.16 Role of IL-37a in the regulation of the expression of Tnfsf13, Lyn 
and Inpp5d in transgenic B-cells compared to wt controls. 
CD19+ cells (106/ml) from IL-37a-tg and wt mice were cultured and stimulated 
with LPS (10ug/ml) for 3 days; RNA was extracted and qPCR performed to detect 
the expression of: A) Tnfsf13 or April; B) Lyn and C) Inpp5d or SHIP. Data are 
mean ± SD, **P< 0.01 and ***P< 0.001 compared to control (wild type). The figure 
represents three independent experiment. 
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4.2.4 Effect of recombinant IL-37a and IL-37b on human B cells 
4.2.4.1  The effect of rIL-37a and rIL-37b on human B cells antibody 
production 
Since the most dramatic effect of IL-37 in murine B cells is the promotion of 
antibody production, we next sought to confirm the effect of IL-37 in human B 
cells. 
It is known that while both CpG and LPS can enhance antibody production in B 
cells, B-cells from human and mouse are different in their response to the two 
TLR agonists (Richard et al, 2008).  Human B cells response to CpG but not LPS; 
while murine B cells prefer LPS stimulation (Lutzker et al, 1988; Severinson et 
al, 1990; Berkeredjian-Ding et al, 2002; Hornung et al, 2002; Wangner et al, 
2004). Therefore, Cytosine-phosphate-guanine class B or (CpG (ODN 2007)), was 
used to study antibody induction in human B cells (Malaspina et al, 2008) 
The CD19+ cells were purified from PBMC of buffy-coat human blood cells using 
MACS by positive selection (Chapter 2). The purity of B cells was about 98% of 
total cells, as determined by flow cytometry using anti-CD20 antibody (Fig 4.17). 
The B cells were cultured in complete RPMI medium and stimulated with CpG (3 
ug/ml) in the presence or absence of different doses of rIL-37a and rIL-37b (Fig 
4.18), for 4, 7 and 9 days. The cells were harvested for gene expression by qPCR, 
and the supernatants for IgG measurement using ELISA. The ELISA results 
revealed that, as expected, CpG induced B cell antibody production from day 4, 
however, 50 pg/ml of IL-37a and IL-37b only enhanced CpG-induced IgG 
production at 4 days after culture, not at day 7 and day 9 (Fig 4.18). Increasing 
the doses of IL-37 from 50 pg and 50 ng failed to further enhance the antibody 
production at all the tested time points (Fig 4.18). 
To understand if the weak efficacy of IL-37 in human B cell antibody production 
is due to the lost bioactivity of the recombinant proteins or due to IL-37 having 
different effect between human and murine B cells, I then assessed the cytokine 
expression level in the cultured B cells, including the Th1, Th2 and Treg 
cytokines. I found that IL-37a alone significantly inhibited the expression of Th1 
cytokines, IL-12, IFN and TNF-α, but not IFNγ, compared to cell only control 
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(Fig 4.19) IL-37b alone significantly decreased IFNϒ, IL-12a but not the IFN and 
TNF-α. CpG alone downregulated all 4 cytokine at this condition, compared to 
the cell control. IL-37a and CpG further down regulated all the cytokines, except 
the IFNϒ compared to CpG alone. IL-37b and CpG further suppressed all 4 
cytokines compared to CpG control (Fig 4.19). 
I further checked the regulatory effect of IL-37a and IL-37b on the expression of 
Th2 (IL-13, IL-6) and Treg (TGF- and IL-10) cytokines in human B cells with or 
without the stimulation of CpG. As shown in the (Fig 4.20), IL-37a alone 
significantly reduced the expression of TGF-, IL-10 and IL-6, but enhanced the 
expression of IL-13, compared to cell alone control. IL-37b alone had no effect 
on the expression of TGF- and IL-10, while, as IL-37a, it also enhanced IL-13 but 
reduced IL-6 expression. CpG alone markedly increased TGF- and IL-10 but 
decreased IL-13 and IL-6 expression compared to control. While CpG together 
whith IL-37a and IL-37b further enhanced TGF- and IL-10, but reduced, IL-13 
and IL-6 expression compared to CpG and cell alone controls (Fig 4.20). 
Thus, the recombinant IL-37 proteins were bioactive and could potentiate CpG-
mediated regulatory effect on Th1, Th2 and Treg cytokine expressions in B cells. 
Furthermore, IL-37a and IL-37b alone can differently influence these cytokine 
expressions in human B cells. 
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Figure 44.17 The purity of isolated human B cells determined by flow 
cytometry 
Human CD19+ B cells were isolated from PBMC by MACS using anti-CD19 beads. 
The B cells were then labelled with anti-CD20 antibody conjugated with FITC to 
check the purity of the isolated B cells by flow cytometry. The figure shows B 
cells purity which is 98.8% of.   
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Figure 4.18 The effect of IL-37a and IL-37b on IgG production in human B-
cells. 
Human CD19+ B cells were isolated from PBMC, cultured in RPMI, and stimulated 
with CpG (3 ug/ml) in the presence or absence of rIL-37a and rIL-37b. Two doses 
(50 ng and 50 pg) of rIL-37a and rIL-37b were used. The IgG levels in the culture 
supernatants were measured by ELISA at day 3, 4 and 7. Data are mean ± SD, *P< 
0.05, **P< 0.01, and ***P< 0.001 compared to control (non-stimulated or CPG 
stimulated cells). The figure represents three independent experiment. 
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Figure 4.19 IL-37 regulates Th1 cytokine expression in human B cells 
stimulated with CpG. 
Human CD19+ B cells were isolated from PBMC and stimulated with CPG (3 
ug/ml) in the presence or absence of IL-37a and IL-37b (50 pg/ml). Cells were 
harvested after 3 day culture for TNF-α, IL-12 a, IFNand IFNγ gene expression 
using qPCR. Data are mean ± SD, *P< 0.05, **P< 0.01, and ***P< 0.001 compared 
to control (non-stimulated or CPG stimulated cells). The figure represents three 
independent experiment. 
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Figure 4.20 Effect of IL-37 on the regulation of T-reg and Th2 cytokine 
expressions in human B cells stimulated with CpG. 
Human CD19+ B cells were isolated from PBMC and stimulated with CpG (3 
ug/ml) in the presence or absence of IL-37a and IL-37b (50 pg/ml).  Cells 
(106/ml) were harvested after 3 day cultures for TGF-, IL-10, IL-13 and IL-6 
gene expression using qPCR. Data are mean ± SD, *P< 0.05, **P< 0.01, and ***P< 
0.001 compared to control. The figure represents three independent 
experiment. 
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4.2.4.2  Role of recombinant IL-37a and b in human B cellproliferation 
As IL-37 can induce murine B cell proliferation, alone or in the presence of TLR 
signals, we investigated the effect of IL-37a and IL-37b on human B cell 
proliferation under different stimulus. B cell activation and proliferations 
require three signals from BCR, co-stimulation and cytokines (Nonoyama et al, 
1993; Wortis et al, 1995; Dörner and Radbruch, 2007). Different cytokines may 
have different impact on B cell functions, including proliferation. Il2−/− mice 
have an age-related decrease in B lymphocytes number (Schultz et al, 2001); 
while IL-21 is pivotal for normal plasma cell formation; as IL-21 deficiency 
affects affinity maturation production in germinal centre B cells (Linterman et 
al, 2010). We therefore compared the effect of the three signals, alone or in 
combination, on B cell proliferation. Here, we used anti-IgM, which cross-links 
the BCR to mimic the BCR activation, the co-stimulation signal of CD40L from T 
cells was provided from a fibroblast cell line 3T3 expressing transgenic CD40 
ligand (Liebig et al, 2009). Cytokines, IL-2 and IL-21 that promote B cell 
proliferation and differentiation into plasma cells were also included in this 
study. 
CD19+ B cells were isolated from human PBMCs, and cultured with different 
stimulators (IL-2, IL-21, CD40 and IgM), alone or in different combinations in the 
presence or absence of IL-37a or IL-37b for 3 days. B cell proliferation was 
measured by Brdu proliferation assay. I found that IL-37a and IL-37b alone 
slightly but significantly reduced human B cell proliferation (Fig 4.21). IL-2, anti-
IgM antibody alone could enhance B cell proliferation, whereas IL-21 and CD40 
alone had little effect on B cell proliferation in this experimental condition. 
However, the combination of two or three stimuli dramatically triggered B cell 
proliferation (Fig 4.21). I next determined the effect of IL-37a and IL-37b on the 
B cell proliferation induced by two or three of the activation signals as indicated 
in (Fig 4.22). The CD19+ B cells were isolated and cultured with different 
stimulators (IL-2, IL-21, CD40 and IgM), alone or in different combinations in the 
presence or absence of IL-37a or IL-37b for 3 and 5 days before the measurement 
of B cell proliferation. While IL-2 plus IL-21 failed to induce B cell proliferation, 
the presence of IL-37a but not IL-37b in this condition significantly enhanced B 
cell proliferation at day 3 but not day 5 culture. Anti-IgM and CD40 significantly 
induced cellular proliferation, however IL-37a and IL-37b failed to further 
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enhance the effect.  Anti-IgM, CD40 and IL-21 induced significantly higher levels 
of proliferation in B cells, which, again, could not be further enhanced by IL-37a 
and IL-37b (Fig 4.22). In summary, in contrast to murine B cells, IL-37a and IL-
37b have little effect on the human B cell proliferation. This is consistent with 
the failure of IL-37 in the induction of antibody production in human B cells. We 
also found that rIL-37a and rIL-37b had no influence on BCR, CD80/86 and CD40 
expression on human B cells determined by flow cytometry (data not shown). 
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Figure 4.21 Set up and comparison the human CD19 B cells proliferation 
conditison induced by different stimuli 
Human CD19+ B cells were isolated from PBMC and cells (106/ml), and cells were 
stimulated with anti-IgM (10 ug/ml), IL-2 (10 ng/ml), IL-21 (50 ng/ml), CD40 
ligand (2 ug/ml), alone or in combination. In some samples, IL-37a and IL-37b 
(50 pg/ml) were also added into the B cell culture.  Cells were harvested after 3 
days cultures for proliferation assay using Brdu kit. Data are mean ± SD, *P< 
0.05, **P< 0.01 and ***P< 0.001 compared to control (B cells alone). The figure 
represents three independent experiment. 
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Figure 4.22 Role of IL-37a and IL-37b in the human B cells proliferation 
induced by different stimuli. 
Human CD19+ B cells were isolated from PBMC and cells (106/ml) were 
stimulated with (anti-IgM, IL-2, IL-21, CD40) in different combinations in the 
presence or absence of IL-37a and IL-37b (50 pg/ml).  Cells were harvested after 
3 and 5 days cultures for proliferation assay using Brdu kit. Data are mean ± SD, 
*P< 0.05 and **P< 0.01 compared to control (IL-2, IL-21, anti-IgM/ CD40 or anti-
IgM/ CD40/IL-21). The figure represents three independent experiment. 
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4.2.4.3  The expressions of IL-37 isoforms and receptors in human cells are 
regulated by immune activation signals and IL-37 it self 
In order to reveal the mechanism underlying the failure of IL-37 in the induction 
of human B cell antibody production and proliferation, we next examined IL-37 
isoforms and receptor expression and regulation in human B cells. Little is known 
how IL-37 isoform and receptor expressions are regulated in immune cells. We 
sought to study this in resting and activated B cells. CD19+ B cells were isolated 
from human PBMCs, cultured in medium only without treatment with 
stimulators. The RNA was extracted for the detection of IL-37 isoform expression 
by qPCR. We found that resting B cells did express all IL-37 isoforms (Fig 4.23). 
The cycle threshold (CT) value indicated that the relative expression level of IL-
37a was the lowest and the IL-37b the highest among the isoforms in this 
context. 
I next assessed if IL-37 can regulate its own expression in B cells. The B cells 
were cultured with or without rIL-37a or rIL-37b in culture for 10 days and the 
expression level of IL-37 isoforms detected by qPCR (Fig 4.24). Compared to the 
cell alone control, rIL-37a significantly downregulated all isoform expression, in 
particularly its own expression. In contrast, rIL-37b selectively suppressed IL-
37a, IL-37c and IL-37e, but enhanced IL-37d expression. Intriguingly, rIL-37b has 
no effect on its own expression (Fig 4.24). 
I further studied the regulation of IL-37 isoform expression in B cells activated 
with IL-2/IL-21 with or without rIL-37. Compared to the cell only control, B cell 
treatment with IL-2/IL-21 dramatically down regulated the expression of all IL-
37 isoforms (Fig 4.25). IL-37a and IL-37b had minor effect on the IL-2/IL-21-
mediated down regulation, with slightly enhanced IL-37b but reduced IL-37e 
expression in activated B cells (Fig 4.25). This was also the case in anti-IgM and 
CD40 signals activated B cells. Anti-IgM and CD40 treatment almost completely 
abolished all IL-37 isoform expressions and rIL-37 had little influence on this 
effect (Fig 4.26). 
I next studied the regulation of IL-37 receptors, IL-1R8 and IL-18Ra expression in 
B cells. B cells cultured with or without rIL-37a, rIL-37b, IL-2/IL-21, anti-
IgM/CD40 or CpG in the culture for 10 days and the expression level of IL-1R8 
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and IL-18Ra were detected by qPCR. As shown in Fig 4.25 and 4.26, rIL-37a 
slightly but significantly down regulated the expression of both receptors. On 
the other hand, rIL-37b reduced IL-1R8 but enhanced IL-18R expression. This was 
also the case in the CpG-activated B cells (Fig 4.26 and 4.27). The IL-2/IL-21 and 
anti-IgM/CD40 stimulation dramatically down regulated the expression of all the 
receptors (Fig 4.27 and 4.28). To support this finding, we found that IL-1R8 
expression in B cells from wt and IL-37a-tg mice was also down regulated by LPS-
stimulation (Fig 4.29).  
To further support this finding, we also have evidence showing that activation 
signals and rIL-37 can also down regulate both IL-37 receptor expressions in 
human monocytes (Egle Katkeviciute, data not shown). Since IL-1R8 is a specific 
signalling receptor for IL-37 and can be down regulated by all the tested 
activation signals and IL-37 itself in B cells it is likely that all these signals can 
subsequently affect IL-37 signalling and function. This suggests that IL-37 
expression and function are highly controlled in immune cells. 
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Figure 4.23 IL-37 isoforms expression in human CD19+ B cells 
Isoforms at steady state; the graph shows all the five isoforms in CT value. 
Human CD19+ B cells were isolated from PBMC by MACS and cultured for long 
term 11 days, cells harvested and qPCR performed to mesure IL-37 isoforms 
expression level. Human CD19+ cells express IL-37 isoforms at steady state; the 
graph shows all the five isoforms in CT value.  
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Figure 4.24 IL-37a and IL-37b regulation of IL-37 isoforms expression in 
human B cells. 
Human CD19+ B cells (106/ml) were isolated from PBMC and cultured with 
recombinant IL-37a and IL-37b (50 pg/ml) for 10 days. The cells were then 
harvested for IL-37 isoform expression by qPCR. Data are mean ± SD, *P< 0.05 
and **P< 0.01 compared to control (B cells only). The figure represents three 
independent experiment. 
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Figure 4.25 Regulation of IL-37 isoforms expression by IL-2/IL-21 in human B 
cell. 
Human CD19+ B cells were stimulated with IL-2 (10 ng/ml) and IL-21 (50 ng/ml) 
followed by treatmet with (50 pg/ml) of rIL-37a or b. After 10 days, cells were 
harvested for isoforms expression checking by qPCR. The figures shows that IL-
2/IL-21 down regulate IL-37 isoforms. Using rIL-37a and rIL-37b with IL-2/IL-21 
did not show any significant upregulation, except that, isoform b and c can be 
up regulated by IL-37a and IL-37b respectively. Data are mean ± SD, NS 
represents (non-significant), *P< 0.05, **P< 0.01 and ***P< 0.001 compared to 
control (B cells only or B cells treated with IL-2/IL-21).  
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Figure 4.26 Regulation of IL-37 isoforms expression by IgM/CD40 in human B 
cells. 
Human CD19+ B cells were stimulated with recombinant IgM/CD40L (10 ug/ml, 20 
ng/ml) respectively, and IL-37 (50 pg/ml) for 10 days, the cells were harvested 
for IL-37 isoforms expression by qPCR. Data are mean ± SD, *P< 0.05, **P< 0.01, 
and ***P< 0.001 compared to control (B cells only or treated with IgM/CD40). The 
figure represente three independent experiment. 
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Figure 4.27 Regulation of IL-1R8 chain expression in human B cells. 
Human CD19+ B cells were stimulated with or without rIL-37 (50 pg/ml), IL-2/IL-
21 (10, 50 ng/ml) respectively, anti-IgM(10 ug/ml), CD40 (20ng/ml), CpG (3 
ug/ml) for 10 days. The cells then were harvested and the expression level of IL-
1R8 determined by qPCR. NC-CD19 represents B cells only or negetive control. 
Data are mean ± SD, *P< 0.05, **P< 0.01, and ***P< 0.001 compared to control. 
The figure represents three independent experiment. 
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Figure 4.28 Regulation of IL-18Ra chain expression in human B cells. 
Human CD19+ B cells were cultured with or without rIL-37, (50 pg/ml), IL-2/IL-21 
(10, 50 ng/ml), anti-IgM/CD40 (10 ug/ml, 20 ng/ml), CpG (3 ug/ml) for 10 days. 
The cells then were harvested and the expression level of IL-1R8 determined by 
qPCR. Data are mean ± SD, *P< 0.05 and **P< 0.01 compared to control (B cells 
only). The figure represents three independent experiment. 
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Figure 4.29 LPS regulates IL-1R8 expression in murine B cells. 
CD19+ B cells were isolated from the spleen of wt and IL-37a-tg mice, and 
stimulated with LPS (100 ng/ml) for 3 days. The cells were then harvested for 
the detection of IL-1R8 expression by qPCR.  Data are mean ± SD, *P< 0.05 
compared to control. The figure represents three independent experiment. 
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4.3 Discussion 
As a first step toward the understanding of the function and importance of all IL-
37 isoforms in immunity and disease, this study investigated the induction and 
bioactivity of IL-37a in human and mouse innate and adaptive immune cells. The 
preliminary results from this project demonstrated for the first time that: 1) the 
expressions of IL-37 isoforms are differently regulated in immune cells, 
depending on the activation conditions and also the dose and time of stimuli. IL-
37a is one of the highly induced isoforms in human monocytes. 2) IL-37a is 
bioactive and a novel immunoregulatory cytokine. 3) While sharing functional 
similarity, IL-37a and IL-37b are different in the regulation of some cytokine 
productions. 4) IL-37 is not only immunosuppressive but may also be 
immunoactive, for instance in B-cell antibody production and proliferation. 5) 
The expression and function of IL-37 isoforms in immune cells are highly 
regulated by immune activation signals and by IL-37 itself. Thus, it is likely that 
IL-37a is an important IL-37 isoform and differs from IL-37b in the regulation of 
immune response in health and disease. 
 
While the function of IL-37b as an important immunosuppressive cytokine has 
been well studied, the functions of IL-37a and other IL-37 isoforms are largely 
unknown. Using several in vitro experimental approaches, including IL-37a RNA 
knockdown, recombinant protein and transgenic cells, we demonstrated that IL-
37a is bioactive and can regulate the expression of several TLR-induced 
inflammatory cytokines in macrophage, monocytes and B cells. Thus, IL-37a is a 
novel immunoregulatory cytokine in the IL-37 family and contributes to the IL-
37-mediated immunoregulation and immunotolerance. However, the effect of IL-
37a on health and disease is still unknown and currently under investigation in 
our laboratory using human IL-37a transgenic mice in vivo.  
We also found that IL-37a and IL-37b share functional similarity in the tested 
experimental conditions; suppress the same cytokine expressions and with the 
similar effect. Whereas it is known that IL-37b triggers its anti-inflammatory 
signals through a receptor complex consisting of IL-18Rα and IL-1R8 (Nold-Petry 
et al, 2015), how IL-37a signals is unknown. Given IL-37a and IL-37b share the 
common IL-1 like domain for receptor binding and signalling is likely that both 
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the isoforms signal via the same receptor. Our preliminary results demonstrated 
that anti-IL-1R8 blocking antibody or Sigirr-/- mice could abolish the IL-37a-
mediated effect in vitro, suggesting that rIL-37a also signals via the same 
receptor as IL-37b (D. Xu, unpublished result).   
Intriguingly, FL-IL-37a is different from FL-IL-37b in the regulation of some 
cytokine gene expressions, including IL-37 (Fig 4.3, 4.6, 4.18 and 4.23). 
Furthermore, FL-IL-37a is more effective than FL-IL-37b in the suppression of 
LPS-induced IL-6 production in macrophages (Fig 4.4 and 4.5). The reason is still 
unclear and under investigation. Since IL-37a and IL-37b are completely different 
in their N-terminal sequences, which are encoded by exon 3 and exon 1 and 2, 
respectively, it is possible that the functional difference between the two 
isoforms may be attributed to their difference in N-terminal sequence. To 
support this, we found in Chapter 3, that IL-37a and IL-37b vary in their 
chemical features, including PI, molecular weight, and amino acids percentage, 
and IL-37a is less soluble compared to IL-37b. This may influence their receptor 
binding affinity and protein stability, thereby the bioactivity.  
Another important difference between the two isoforms is that, IL-37a but not 
IL-37b possesses a NLS n the protein N-terminal. NLS is able to translocate 
proteins from cytoplasm to the cell nucleus where the protein can regulate gene 
expression (Jans and Hubner, 1996; Yoneda et al, 1997). It has been known that 
IL-1α but not IL-1b carries NLS and can regulate immune response in the cell 
nucleus (Luheshi et al, 2008). Further works needed to reveal whether IL-37a is a 
nuclear protein and whether it is capable of in the gene regulation in the 
nucleus. In Chapter 5, I analysed and identified the common and specific genes 
and signal pathways regulated by IL-37a and IL-37b in LPS-induced inflammatory 
response by RNA-sequence and bioinformatics. This will further enhance our 
understanding of the common and different between the two isoforms in 
immunoregulation and tolerance. 
How the expressions of IL-37 isoforms are induced, and regulated in an immune 
cell population in a given condition is poorly understood. Since we have 5 IL-37 
isoforms with possibly different functions it is important to know whether they 
are equally or differently induced and regulated in immune cells. Our results 
here demonstrated that IL-37 isoform expression is activation signal induced in 
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immune cells, including TLR signals. In addition, among the three isoforms (IL-
37a, b, d) that possess the full IL-1-like domain and may have cytokine activity, 
IL-37a and IL-37b are highly induced compared to IL-37d isoforms. This suggests 
that IL-37a and b may be the dominant IL-37 isoforms with cytokine activity. We 
also noted that IL-37c and IL-37e are the most inducible IL-37 isoforms compared 
to others with IL-1-like domain. The reason is unclear, may be in part due to the 
IL-37e and c are shorter in gene and protein sequence compared to the others; 
and long or multi introns may cause delay in gene expression time. Since the two 
isoforms lack the full IL-1-like domain and are unlikely to have cytokine activity 
it has been suggested that IL-37c and e may interfere with other IL-37 cytokine 
expression by competing with RNA splicing and/or cleaving enzymes for 
maturation (Boraschi et al, 2011). 
We also demonstrated that IL-37 isoform induction and regulation in human 
monocytes is dose and time-dependent; the lower dose LPS (100 ng/ml) and 
short activation time (within 16 hours) can upregulate the expression of IL-37 
isoforms. In contrast, the higher dose LPS (200 ng/ml) and longer time 
stimulation may lead to the down regulation of IL-37 expression. This was also 
the case in the persistently activated human B cells. The reduced IL-37 
expression in these conditions was not due to TLR-induced cell apoptosis and 
stress since the cells produced more inflammatory cytokines compared to the 
cells stimulated with lower LPS dose or shorter times (data not shown). The 
immunological and physiological meaning of the reversed association between 
immune cell activation and IL-37 expression is not yet fully understood. Given 
the main function of IL-37 is to suppress immune activation and inflammation; it 
is possible that the immune cell has to abolish IL-37 expression and function first 
in order to initiate an optimal immune activation and cellular proliferation.  
How the strong activation signals down regulate IL-37 expression is unknown. 
Our preliminary results suggest that IL-37, in particularly IL-37a, can regulate 
the expression of all IL-37 isoforms. In addition, IL-37 and activation signals can 
also down regulate the IL-37 receptor expression in immune cells. Together, the 
two pathways will abolish IL-37 function by preventing the further production of 
endogenous IL-37 and shutting down exogenous IL-37 signalling. While the 
impact of the regulation on immune response is still largely unknown, these 
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results suggest that IL-37 function is carefully regulated in immune cells in order 
to achieve an appropriate level of immune response, for instance in B cell 
antibody production. B cells play an important role in immunity and in disease 
by presenting antigen, producing antibody and cytokines (Amlot et al, 1985; 
Rivera et al, 2001; Vazquez et al, 2015). Thus, B cell function must be tightly 
checked. The effect of IL-37b on innate immune cells and T cells has been 
studied and current evidence suggests that IL-37b is an immunosuppressive 
cytokine on these cells. However, its function in B cells has not been studied; I 
therefore studied the effect of IL-37a and IL-37b on mouse and human B cells. 
The most dramatic finding was that IL-37 is able to increase, not decrease, IgG 
production in murine, to a lesser extent, in human B cells.   
The antibody enhancement effect of IL-37 was observed in several experimental 
conditions with both recombinant IL-37a and b and transgenic IL-37a in the LPS 
or CD40-stimulated B murine B cells, suggesting that it is a general function of 
IL-37.  
The precise mechanism by which IL-37 promotes antibody production in B cells is 
still unknown. Since IL-37 can enhance B cell number in a proliferation assay, it 
is possible that IL-37 may promote antibody production by enhancing cell 
number. However, it is unclear at this stage whether the enhanced B cell 
number by IL-37 is really due to enhanced cellular proliferation or preventing B 
cell apoptosis. Cytokines play an important but different role in B cell 
proliferation and apoptosis (Itoh and Heroheta, 1995). Th1 and Th2 cytokines, IL-
12, IFNϒ and IL-13 have similar helping effect on B cell expansion and antibody 
production (Smith and Pottage et al, 2000). However, in our case, both Th1 and 
Th2 cytokines were down regulated by IL-37, suggesting that these cytokines are 
not responsible for the IL-37-induced B cell proliferation. Regulatory cytokine IL-
10 can prevent B cell apoptosis and promote B cell antibody production via 
STAT3 (Itoh and Heroheta, 1995; Ding et al, 2016), and we found that IL-37 can 
enhance IL-10 production in both murine and human B cells. STAT3 deﬁciency in 
B cells promotes germinal centre (GC) B cell apoptosis (Ding and Chen et al, 
2016). It has been reported that IL-37b upregulates STAT3 in IL-1R8 dependent 
pathway, which is critical for IL-10 signal (Nold-Petry et al, 2015); therefore, it 
is possible that IL-37 may promote B cell proliferation and IgG production by 
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inducing IL-10 production, which keeps B cell survival and differentiation. 
However, IL-10 was only enhanced one day, but not after that, by LPS 
stimulation in IL-37 transgenic B cells. TGF-can also be enhanced by IL-37 in 
murine and human B cells. GC B cells differentiate into memory-like B cells and 
plasma cells dependent on endogenously secreted IL-10 and TGF- (Durand et al, 
1993). However, TGF- can also suppress mature B cell proliferation (Tsuchida et 
al, 2017). Its role in IL-37-induced B cell proliferation and antibody production is 
unclear. 
We also assessed the expression of key B cell signalling molecules in IL-37-
mediated B cell proliferation and antibody productions, Lyn, SHIP-1 and April 
(Muta et al, 1994; Brauweiler et al, 2000). Our results showed that IL-37 signals 
increased the expression of Lyn but decreased SHIP-1 and had no significant 
effect on April. SHIP-1 plays a regulatory role in B cell signaling. Inpp5d −/− mice 
exhibit enhanced survival and are hyperresponsive to BCR stimulation, and 
elevated serum Ig (2, 3, and 4). Studies have showed that SHIP-1 promotes NF-κB 
dependent cytokine and MAP kinase activation exploiting TLR4-independent 
PI3K/Akt pathway; therefore, decrease in SHIP-1 was accompanied with 
increased survival and reduced inflammatory response (Brauweiler et al, 2000; Li 
et al, 2016). Thus, down regulation of SHIP may contribute to IL-37-enhanced 
antibody production and proliferation in B cells. However, the underlying 
mechanism by which IL-37 downregulates SHIP in B cells is currently unknown.  
Current evidence suggests that Lyn is a dual functional enzyme, which can 
positively and negatively regulate B cell function (DeFranco et al, 1998). Lyn 
depletion in B cells results in a lupus-like autoimmune disease (Lamagna et al, 
2013; Li and Fang et al, 2016). Its role and down regulation in IL-37-mediated B 
cell activation need to be further studied. 
Because the marked effect of IL-37 on IgG production in murine B cells we 
further studied the effect of IL-37 on human B cells. I found that, different from 
in murine B cells, rIL-37 only had minor effect on human B cell antibody 
production. The effect was only seen in earlier (day 4), but not later (day 7 and 
9) cultured B cells and only induced by lower but not higher dose of rIL-37 (Fig 
4.17). Inconsistently, the minor effect of IL-37 on antibody production was 
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accompanied by minor or no effect for IL-37 on the B cell proliferation induced 
by different stimulus (Fig 4.17). The reason for the contrary effect of IL-37 on 
antibody production in human and murine B cells is understood. As IL-37 induced 
similar cytokine profiles in human as murine B cells, reduced Th1 and Th2 
cytokines but enhanced regulatory cytokine IL-10 and TGF-, thus, it is unlikely 
that cytokine profiles are responsible for the controversy. Because the main 
difference between human and murine B cells in this cellular context is that 
human but not murine cells express IL-37 isoforms, we sought to see if it is due 
to the dysregulation of endogenous IL-37 and receptors. We found that rIL-37a 
can down regulate the expression of all IL-37 isoforms, including its own 
expression, in the cultured B cells. In addition, rIL-37 and activation signals can 
also down regulate the IL-37 receptor IL-1R8 expression in both murine and 
human cells. Together, the two pathways may abolish IL-37 signalling and 
function in B cells, including antibody production. While this may provide a 
possible explanation for the low efficiency of IL-37 on human B cell antibody 
production, it can still not explain why IL-37-mediated effect on cytokine 
production in human B cells was not affected. This may be because the IL-37 and 
receptor induction is time-dependent enhanced first, then down regulated and 
the induction of cytokine expression is much quicker (within 24 hours) than 
antibody production (3-7 days). More detailed kinetic study of the induction of 
IL-37 and receptor expression may help to answer the question, another question 
is, if this is the case, why cannot the IL-37a and receptor expression be 
regulated in mouse B cells? This may be due to the follow reasons: 1) since mice 
do not have IL-37 gene it is possible that mice may also lack the regulatory 
system for the control of IL-37 expression; 2) it is also possible that IL-37 
receptor system is less regulated in mouse compared to that in human cells. 
Nevertheless, our results suggest that IL-37 has potential to promote B cell 
antibody production. Since overproducing antibody, in particular autoantibody is 
dangerous to the host, the production and function of IL-37/receptor system 
must be carefully controlled. Thus, it is worthwhile to study in detail how IL-
37/receptor system is regulated in human B cells and whether the dysregulation 
of IL-37/ receptor expression may lead to autoimmune disease, such as SLE. 
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5 Determine the difference betweenIL-37a and IL-
37b in the regulation of transcriptome 
5.1 Introduction 
The studies in Chapter 4 have demonstrated that IL-37a is bioactive and is a 
novel immune regulator.It suppresses LPS-stimulated inflammatory cytokine 
expression in monocytes and macrophages. In contrast, it also enhanced LPS-
induced IgG production in B cells. In addition, IL-37a and IL-37b exhibit similarity 
and difference in biology and function. However, the molecular explanation for 
their similarity and difference in bioactivity is still lacking. In this chapter, using 
LPS/TLR4-induced inflammatory response in spleenocytes as a cellular model, I 
performed transcriptomic experiment to reveal the common and unique aspects 
of IL-37a and IL-37b in signalling and gene regulation of the LPS response. This 
part of the workwas aimed to reveal some molecular explanations for their 
regulatory role in the LPS/TLR4 signalling-mediated effect on macrophages and 
B cell functions described in Chapter 4. 
TLR4 signalling in innate immune cells including macrophages has been studied, 
and described in detail in (Chapter1). Briefly (Fig 5-10), TLR4 signals via a 
MYD88-dependent and TRIF-dependent pathway. The former is triggered by an 
agonist binding to the cell surface TLR4 complex, and the recruitment of MYD88 
and adaptor TIRAP (MAL), and the activation of signalling cascades nuclear 
factor kappa-light-chain (NF-κB), and mitogen-activated protein (MAP) kinases; 
resulting in inflammatory gene expression. The latter is elicited when the TLR4 
is internalised into cell plasma and the recruitment of TRAM and adaptor TRIF 
leads to the activation of IFN response factors (IRFs) and subsequent type I IFN 
expression. 
 
BCR signalling is triggered by the antigen-BCR interaction; three important 
protein tyrosine kinases (PTKs) are then activated, the Src-family kinase SYK, 
Lyn and the TEC-family kinase BTK (Fig 5-11). The deletion of either SYK or Lyn 
is sufficient to largely abolish BCR signalling (Gross et al, 2011; Ackermann et al, 
2015). Lyn is the predominant Src-family tyrosine kinase in B cells. Current 
evidence suggests that Lyn is a dual functional enzyme, which can positively and 
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negatively regulate B cell function (Nishizumi et al, 1998). Lyn deletion in B cells 
results in enhanced cell proliferation and lupus-like autoimmune disease (Li and 
Fang et al, 2016). These tyrosine kinases will then activate downstream BCR 
signalling effectors, including the important PI3K and phospholipase C-gamma 2 
(PLC-r2) and B-cell linker protein (BLNK). This signalling ultimately results in the 
activation of calcium signalling, MAPK and NF-κB pathways and the expression of 
genes involved in B cell proliferation, differentiation, cytokine and Ig production 
as well as other functions (Fig 5-11) (Nishizumi et al, 1998; Li and Fang et al, 
2016). BCR signalling is tightly regulated, primarily by SHP-1 and SHIP (O'Neill et 
al, 2011; Getahun et al, 2016). Both inhibitors share regulatory function in BCR 
signalling, but via different acting mechanisms (O'Neill et al, 2011). SHP-1 is a 
protein tyrosine phosphatase that counters BCR signalling at early stages by 
dephosphorylating activating signalling molecules, such as Spleen tyrosine kinase 
(SYK), and BLNK (Adachi et al, 2001). SHP-1 deficiency results in increased 
serum levels of IgM, IgG1, and IgG3 (Alsadeq et al, 2014). Furthermore, in mice, 
B cell-specific loss of SHP-1 leads to an accumulation of B-1a cells and systemic 
autoimmunity (Pao et al, 2007). SHIP is a lipid phosphatase that removes the 
signalling lipid phosphatidylinositol 3, 4, 5-trisphosphate (PIP3), and thereby 
impairs BCR signalling pathway (Baracho et al, 2011). SHIP-1 deficiency mouse 
had elevated IgG serum Abs, and developed lupus-like phenotypes (O'Neill et al, 
2011; Chen et al, 2017). Thus, SHP-1 and SHIP are required for B cell tolerance 
and the prevention of the development of B-cell mediated autoimmunity 
(Getahun et al, 2016).  
 
While TLR ligands have a profound effect on B cell proliferation, differentiation 
and antibody production, the precise mechanism and signalling pathways are 
still not known.  Recent evidence suggests that TLR4 signals in B cells through 
two distinct pathways, one via the BCR leading to activation of SYK, ERK, and 
AKT and this pathway is independent of MYD88 (Schweighoffer et al, 2017). In 
addition, the MYD88-independent pathway leads to the B cell proliferation and 
activation (Yanagibashi et al, 2015). The other pathway through MYD88 leads to 
activation of NF-κB (Bekeredjian-Ding and Jego, 2009; Schweighoffer et al, 
2017). However, the function of the MYD88-dependent pathway in this context 
has not been investigated. In another report, it has been suggested that 
MYD88 and TRIF pathways regulate B cell response differently; 
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immunization induced IgG1 production was impaired in Ticam2−/−mice, 
while the antibody was enhanced in Myd88−/−mice (Pihlgren et al,2012; 
Yanagibashi et al, 2015). Furthermore, the T-cells ID antigen IgG 
response was strictly dependent on TLR4 and BCR signals and the IgG 
class switch was mediated by TRIF, but not by MyD88 (Pihlgren et 
al,2012). However, whether IL-37 regulates BCR and TLR signalling in B cells is 
unknown, and the understanding of IL-37b signalling may help to understand IL-
37a signalling in immunoregulation. 
Current evidence suggests that IL-37b signals with the receptor-dependent and 
independent pathways in gene regulation (Chapter 1). In brief, the extracellular 
IL-37b can bind to and signal via the receptor complex consisting of IL-18Rα and 
IL-1R8 (Nold-Petry et al, 2015). The same as other members in the IL-1 family, 
the IL-37 receptor-mediated signalling pathway is also MYD88 dependent (Nold-
Petry et al, 2015). The receptor-independent pathway is less understood. It 
takes place intracellularly and may be via Smad3 and TGF signalling pathway 
(Luo et al, 2017). While the study of IL-37 signalling transduction has just 
started, one report has revealed the difference between the two pathways in IL-
37b-mediated gene regulation (Nold-Petry et al, 2015). The spleenocytes RNA 
was isolated from wild type, IL-37b-tgand IL-37b-tg/sigirr-/- mice, 3 hours after 
intraperitoneal injection of LPS, and the immune gene profiles were analysed by 
RNA-sequencing along with the Innate Immune Database (IDB). About 2,000 
genes associated with innate immune response have been identified and the 
genes regulated by receptor-dependent and independent pathway of IL-37b were 
further identified by comparing the gene profiles among the wt, IL-37tg and IL-
37b-tg/sigirr-/- mice groups. The results indicate that: 1) IL-37b not only 
suppresses, but also enhanced gene expressions compared to the wt control with 
the suppression effect dominant; 2) in the receptor-dependent manner, IL-37b 
primarily inhibited genes that are largely associated with inflammatory 
response, including inflammatory cytokines, mediators and signalling molecules. 
In addition, the receptor-dependent manner, IL-37b induced some genes with 
immunoregualatory property; but also some inflammatory genes; 3) in the 
receptor-independent fashion, IL-37  inhibited and enhanced the expression of 
many genes including the genes involved in inflammation, metabolism, signalling 
transduction and chemokines; 4) IL-37b seems to have a wide ranges of effects 
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on the regulation of genes in different pathways. The wide regulatory effects of 
IL-37b have been further confirmed totally and by phosphorylated protein arrays 
with isolated macrophages and DCs from the spleens of wt, IL-37tg and IL-37b-
tg/sigirr-/-mice (Nold-Petry et al, 2015). This work has established IL-37b 
signalling and function in gene regulation. However, how IL-37a signals in gene 
regulation is unknown and the research in IL-37b signalling is helpful for the 
understanding of IL-37a signalling and the difference between the two isoforms. 
Based on all the results from our own and from other labs, I propose that: the 
functional similarity and difference between IL-37a and IL-37b can be attributed 
to their difference in protein sequence and signalling transduction. Using their 
shared C-terminal protein sequence containing IL-1-like domain for receptor 
binding and signalling, IL-37a and IL-37b may regulate common signalling 
pathways and genes. However, given their difference in N-terminal sequence, 
they may regulate different pathways and genes. The overall aim in this chapter 
was to test this hypothesis using LPS/TLR4 activated murine spleenocytes to 
understand how IL-37a and IL-37b regulate TLR signalling transduction and what 
is common and different between the two IL-37 isoforms in gene regulation. 
The aims of the project are: 
1. Identify the different expressed genes regulated by IL-37a and IL-37b with 
microarray and bioinformatics assay 
2. Assess the immune genes/signalling pathways, whichare commonly 
regulated by both IL-37a and IL-37b. 
3. Identify the immune gene/pathways specifically regulated by IL-37a or IL-
37b. 
4. Reveal the possible molecular mechanism by which IL-37a and IL-37b 
regulate LPS/TLR4-mediated inflammatory response from the 
transcriptomic. 
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5.2 Results 
5.2.1 Identifying the LPS-induced genes differentially regulated by IL-
37a and IL-37b 
To understand the common and variable effect of IL-37a and IL-37b in gene 
regulation, we next systematically identified and compared genes regulated by 
IL-37a and IL-37b using transcriptomic analysis of RNA. Briefly, spleenocytes 
from wt, IL-37a-tg and IL-37b-tg mice (n=3) were stimulated with LPS (500 
ng/ml) for 4 hrours. Total RNAs from each mouse were isolated and cDNA 
synthesised by reverse-transcription. The gene profiles were performed using 
microarray (Chapter 2), and analysed using the Database for Annotation 
Visulalization and Integrated Discovery (DAVID)/bioinformatics) 
http://david.abcc.ncifcrf.gov).  
In order to identify the differentially expressed genes between IL-37a and IL-
37b, we initially identified global differentially expressed genes (DEG) between 
LPS-stimulated wt and IL-37a-tg or IL-37b-tg spleenocytes. Firstly, the global 
DEG between IL-37a-tg and wt control were identified (Fig 5.1). Euler diagrams 
show (A) the down and (B) upregulated genes by IL-37a compared to wt control 
cells. Overall, 2905 genes were significantly down regulated by IL-37a (Fig 5.1a). 
Unexpectedly, 2881 genes were also upregulated by IL-37a versus the wt control 
(Fig 5.1b). By using the same strategy, the global DEG between IL-37b-tg and wt 
control were also identified (Fig 5.2). Compared to the control, 5263 genes were 
down regulated by IL-37b (Fig 5.2A). Compared with the control, 4666 genes 
were also upregulated by IL-37b (Fig 5.2B). 
Next, the common and specific genes between IL-37a and IL-37b groupswere 
identified by comparing the IL-37a and IL-37b specific DEG identified above. As 
illustrated in the (Fig 5.3A), among the downregulated DEG between the IL-37a 
and IL-37b gene pools, 1723 DEG were the common genes that were down 
regulated by both IL-37a and IL-37b (27%, common genes/total genes). 1182 
genes were found to be specifically down regulated by IL-37a and 3540 genes 
were specifically down regulated by IL-37b (Fig 5.3A). 
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By comparing the upregulated DEG of IL-37a and IL-37b identified above, we 
found that 1356 genes (about 22%) were shared by the two IL37 isoforms (Fig 
5.3b). 1525 genes were specifically upregulated by IL-37a and 3310 by IL-37b.  
Furthermore, it was noted that IL-37b regulated more genes than IL-37a in the 
experimental conditions; with 2.17 folds more in the down regulated genes and 
2.99 folds more in the upregulated genes. Thus, IL-37a and IL-37b are largely 
different in gene profiling, while sharing some gene profiles.  This is consistent 
with the results in Chapter 3 and Chapter 4, that IL-37a and IL-37b share C-
terminal protein sequence but are different in N-terminal sequence and display 
functional similarity and verity in biology. 
5.2.2 Revealing the common signalling pathways/genes regulated by 
both IL-37a and IL-37b 
In order to understand the molecular mechanism by which IL-37a and IL-37b 
regualted innate and adaptive immune cell function performed in Chapter 4, I 
next assess the gene function by associating the IL-37a and IL-37b regulated 
immune genes with signalling pathways. IDB has been selected for this purpose, 
which was generated from several major databases and focused on, but not 
limited to the innate immunity by curating experimentally validated human and 
mouse interactions from the biomedical literature (Lynn et al, 2010). It provides 
a manually curated knowledge base of the genes, proteins, and particularly, the 
interactions and signalling pathways involved in mammalian immune response, 
including TLR-mediated response (Lynn et al, 2008; 2010; Breuer et al, 2012). 
Since TLR, cytokines and B-cells were involved in Chapter 4, the TLR siganlling 
and related cytokine/chemokine, JAK-STAT, NOD and B cell pathways were 
further studied in detail. Firstly, gene ontology of these common regulated 
genes by both IL-37a and IL-37b identified in (Fig 5.3) was assessed using IDB, 
and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. The 
results revealed that IL-37a and IL-37b significantly repressed genes associated 
with 20 signalling pathways and the number one pathway suppressed by both the 
cytokines was the TLR signalling pathway (Fig 5.4A). Both the cytokines also 
significantly upregulated genes in 10 pathways (Fig 5.4B). The top enhanced 
pathway was the cytokine-cytokine receptor interaction. The key and related 
signalling pathways/genes were studied in more detail (Table 5.1A and B). 
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Agreeing with my previous results in Chapter 4, showing that IL-37a and IL-37b 
inhibited TLR4-induced inflammatory cytokine production in macrophages, here 
both the cytokines also suppressed several signalling components in the TLR 
pathway (Table 5.1A and fig 5.5A).  
These included important TLR4 co-receptor CD14 and MyD88 adaptor protein 
TIRAP, that play an initial role in TLR signalling (Zanoni et al, 2011), and the 
downstream signalling molecules MAPK3 and 14 that encode p38α, NF-κB 
elements and Pik3cd (Table 5.1A). The Nod1 in Nod-like receptor (NLR) pathway 
were also inhibited, which is required for the inflammasome formation and IL-1β 
and IL-18 maturation and secretion (Kavathas et al, 2012; Moreira and Zamboni, 
2012). Agreeing with the TLR signalling inhibition and our results in Chapter 4, 
IL-37a inhibited a number of inflammatory cytokine/receptor genes, including 
Il1b, Il18, Il17a, Ifnar1 (encoding Ifn alpha/beta receptor alpha chain), Kdr 
(encoding VEGF receptor), Tnfrsf1a (encoding Tnfa receptor 1), Ltbr (encoding 
lymphotoxin B receptor) and several chemokines/receptors. Furthermore, IL-37a 
impaired the expression of key genes in MAPK signal pathway, including Map3k5; 
MAP3k7; Mapk14; Mapk3 and Pla2g4a encoding cytosolic phospholipase A2 for 
the metabolic production of leukotrienes and prostaglandins (Zhu et al, 2001). 
Somegs in BCR signalling pathway, Mapks, Rac1, Nfkb1, Pla2g4a and Plcg2 were 
also inhibited. The Ptpn6 gene encodes the Src homology region 2 domain-
containing phosphatase-1 (SHP-1), genetically loss of SHP1 leads to the 
development of B lymphopoiesis and systemic autoimmunity (Cyster and 
Goodnow, 1995; Pao et al, 2007). Interestingly, Ptpn6 was also suppressed by 
both IL-37 isoforms. This may provide some explanation for the IL-37-enhanced B 
cell antibody production in mice (Chapter 4, fig 4.10 and fig 4.11). 
IL-37a also enhanced the expression of some immune genes in associated 
pathways (Table 5.1B and fig 5.5B). Both isoforms also elevated the expression 
of some cytokines/chemokines/receptors and related JAK -STAT pathway: Il4ra 
encoding IL-4 receptor and IL-4 protects from LPS shock in mice (Grohmann et 
al, 2000); Il12a encoding IL-12a chain may have regulatory effect on IL-12 
function (Presky et al, 1998). However, while the impact is still unknown, some 
inflammatory cytokine and chemokine receptor expressions were also enhanced 
by IL-37, including IL-19, an inflammatory cytokine, IL-6st encoding IL-6 Signal 
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transducer and 3CXC chemokine receptors. The enhanced expression of 
cytokines/chemokines was also accompanied by the increased expression of 
STAT3 and STAT6 in JAK-STAT pathway. Whereas MYD88 adaptor protein TIRAP 
was inhibited, both isoforms enhanced expressions of Ticam1 encoding TRIF and 
also Tlr6 and Tlr7 signalling with TRIF pathway, suggesting that both isoforms 
may promote TRIF-dependent TLR pathway (Nold-Petry et al, 2015). It was noted 
that MYD88 expression was also enhanced by IL-37, while MYD88 adaptor TIRAP 
was reduced by the two isoforms as described above; the biological meaning is 
still unclear.  
5.2.3 Identifying the signalling pathways/genes specific regulated by IL-
37a only 
Next, the IL-37a specifically regulated genes identified in (Fig 5-3) were further 
analysed for their association with signalling pathways as above. While IL-37a 
specifically inhibited 1182 but enhanced 1525 genes compared with IL-37b (fig 
5.3A and B), it inhibited more signalling pathways than it enhanced (Fig 5.6A, B). 
As shown in (Fig 5-6), IL-37a significantly down regulated more than 20, but only 
enhanced 10 pathways. The most significantly inhibited pathway was TLR (Fig 5-
6A and table 5.2A). The most enhanced pathway was PPARγ (Fig 5.6B and table 
5.2B). The related key pathways/genes were further analysed (Table 5.2A and 
Fig 5-7A). IL-37a specifically down regulated TLR1 and 2 expressions in TLR 
pathway, suggesting that IL-37a can also suppress other TLR functions, beyond 
TLR4 and TLR9. Intriguingly, while it enhanced TRIF and TLR6 and TLR7 
expression, it suppressed the expression of downstream TLR signalling pathway 
elements Irf7 (Interferon regulatory factor 7), a transcription factor of the INF 
regulatory factor family which is involved in the type I INF production in both 
the MYD88 and TRIF-dependent TLR pathways and also Ifnb1 encoding IFNβ1 
(Uematsu and Akira, 2007). Furthermore, the Ifnb1 down regulation was also 
accompanied by the down regulation of Jak2 in Cblc in JAK-STAT pathways.  
IL-37a also specifically inhibited cytokine Il15 and Il1r2 (IL-1 receptor) in 
cytokine–cytokine receptor interaction pathway. 2 genes in BCR signalling 
pathway; glycogen synthase kinase 3(Gsk3b), a metabolic sensor that promotes  
gthe survival of naive recirculating B cells by restricting cell mass 
accumulation,and Phosphoinositide-3-kinase adaptor protein1 (Pik3ap1), a 
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signalling adapter linking BCR signalling to the PI3K-Akt signalling pathway. The 
genes/pathways specifically enhanced by IL-37a were also identified (Fig 5.6B, 
table 5.2B and fig 5.7b). IL-37a increased expression of several 
immunoregulators with known anti-inflammatory activity in TLR4 signalling, such 
as Pltp in peroxisome proliferator-activated receptors (PPARγ) pathway, which is 
a LPS binding protein and blocks LPS function (Hailman et al, 1996; Gautier et 
al, 2008). PPARγ, which inhibits TLR4-mediated inflammation (Appel et al, 
2005), Fzd1 encoding Frizzled-1, which induces Wnt/beta-catenin signalling to 
promote anti-inflammatory function in macrophages (Neumann et al, 2010). IL-
37a also enhanced expression of the type II cytokine IL-13 which protects mice 
from LPS-induced lethal endotoxemia (Muchamuel et al, 1997). Altogether, these 
effects may ameliorate LPS and TLR-mediated inflammatory response 
thereafter-enhancing LPS tolerance and survival.  
5.2.4 Identifying the specific signalling pathways/ genes regulated by IL-
37b 
The IL-37b specifically down regulated (3540) and upregulated (3310) genes (Fig 
5-3) were analysed for the signalling pathways as above. The result showed that 
IL-37b significantly inhibited but also enhanced more than 20 signalling pathways 
(Fig 5.8A, and B). The most significantly down regulated pathway by IL-37b was 
the cytosolic DNA-sensing pathway (CDSP) which is used by cytoplasm PRRs to 
detect foreign double-strain DNA from microbes and trigger innate immune 
responses to produce typeI INF and inflammatory cytokines. The most 
upregulated pathway was TLR pathway (Fig 5.8 A and B). Intriguingly, its 
signalling enhancement effect was greater than its inhibitory effect (log 10 p-
value= 10 vs log 10 p-value= 4) (Fig 5.8A and B). The detailed analysis (Table 5.3A and 
Fig 5.9A) revealed that IL-37b selectively suppressed 4 genes in TLR pathway, 
including the important transcription factors Akt1 and Irf3. The expression of 5 
genes in the CDSP and 3 genes in NOD-like receptor (NLR) signalling pathway was 
also inhibited by IL-37b in the LPS-stimulated cells. While suggesting that IL-37b 
may also be able to regulate other pathogen pattern recognition pathways, its 
impact on LPS/TLR4 signalling needs to be evaluated. 
IL-37b also specifically suppressed 3 important genes in BCR pathway, Akt1, Lyn 
and Inp5d encoding SHIP, a negative regulator of BCR. The down regulation of 
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SHIP by IL-37 is consistent with the result in B cells in Chapter 4. IL-37b also 
repressed 4 different genes in JAK-STAT pathway and related cytokine IFNϒ, IL-
12α, and alsoIL-1R1, Tnfsf9 encoding 4-1BBL (4-1BB ligand), a co-stimulatory 
molecule. Socs1 is an important cytokine regulator, but also suppressed by IL-
37b. 
The genes/pathways specifically upregulated by IL-37b are shown in (Table 5.3B) 
and (Fig 5-9B). In TLR pathway, IL-37b enhanced expression of 10 genes 
including Tlr4, Irak4, 3Mapk members and pik3cg. In cytokine/receptor 
interaction pathway, IL-37b increased transcription of cytokine/chemokine 
genes, including Csf2, Il21, Il2rb,Tnf, and Vegfc encoding Vascular endothelial 
growth factor C (VEGF-C); Tnfsf11 encoding receptor activator of nuclear factor 
kappa-Β ligand (RANKL); and Chemokine (C-X-C motif) ligand 2 (Cxcl2). The Csf2, 
Il21 and Il2rb are associated with the JAK-STAT pathway. In BCR pathway, the 
Mapk1 and Neuroblastoma Ras vial oncogene homologe (Nras), a member of Ras 
family in MAPK pathway, and Nfatc2 in calcium signalling pathway were also 
down regulated (Table 5.3B and fig5.9B). 
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Figure 5.1 Identification of the differentially expressed genes regulated by 
IL-37a in LPS stimulated spleenocytes 
Spleenocyte cells from wt and IL-37a-tg mice were stimulated with LPS for 4 
hours; total RNAs from each group were isolated for microarray. The differential 
expressed genes identified using bio Venn programme and visualised by the area-
proportional and overlapping using bioven Euler graphs. A) shows differentially 
expressed genes (DEGs) that are specifically down regulated by IL-37a (the red 
area) compared with wt control; while the green area are genes that are not 
affected by IL-37a. B) The red area shows DEGs that are specifically upregulated 
by IL-37a; the overlap area are the common genes between IL-37a and wt; while 
the green are genes that are not affected by IL-37a. 
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Figure 5.2 Identification of the differentially expressed genes regulated by 
IL-37b in LPS stimulated spleenocytes. 
Spleenocyte cells from wt and IL-37b-tg mice were stimulated with LPS for 4 
hours; total RNAs from each group were isolated for microarray. A) Shows 
differentially expressed genes (DEGs) that are down regulated by IL-37b (the red 
area); the overlap area is common genes between IL-37b and wt; while the 
green area are genes that are not affected by IL-37b. B) The red area shows 
DEGs that are specifically upregulated by IL-37b; the overlap area are the 
common genes between IL-37b and wt; while the green are genes that not 
affected by IL-37b. 
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Figure 5.3 Identification of common and specific genes differentially 
regulated by IL-37a and b in LPS stimulated spleenocytes 
Spleenocyte cells from wt, IL-37a-tg and IL-37b-tg mice were stimulated with 
500 ng LPS for 4 hours; cells harvested and RNA isolated for microarray assay. A) 
represents the genes that are down regulated by IL-37a and b; the pink area are 
genes down regulated by IL-37a only; the overlap area shows the genes that are 
down regulated by both IL-37a and b; while the blue area represents the genes 
that are down regulated by IL-37b only. B) shows the set of genes that are 
upregulated by IL-37a and b; specific genes upregulated by IL-37a shown in pink 
area; the overlap area are common genes, which are upregulated by both IL-37a 
and b; the blue area are genes that are upregulated specifically by IL-37b. 
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Figure 5.4 The signalling pathways regulated by both IL-37a and b in LPS 
stimulatedspleenocytes. 
The signalling pathways of the common genes regulated by both IL-37a and IL-
37b in LPS-stimulated cells identified by the enrichment analysis on IDB and 
KEGG. The x-axis indicates the pathway name ; the y-axis is associated p-value 
presented by (log10^ pvalue), the blue line implies the cut-off p-value (0.05). A) 
Represents common pathways down regulated by IL-37a and b. B) are the 
common pathways upregulated by IL-37a and b. 
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Table 5.1a Common pathways and related genes downregulated by both IL-
37a and b 
Pathway Name 
 
 
Pathway 
Id 
 
Pathway 
uploaded 
gene 
count 
Genes in 
IDB for 
this 
entity 
Pathway 
 p-value 
 
Pathway 
 p-value 
(corrected) 
 
Genes 
 
Toll-like receptor 
signalling pathway 699 13 100 2.92E-12 2.30E-10 
Cd14; Cxcl10; Ifnar1; 
Il1b; Map3k7; MAPK14; 
MAPK3; Nfkb1; Nfkbia; 
Pik3cd; Rac1; TIRAP; 
Tollip;  
NOD-like receptor 
signalling pathway 8111 8 57 3.13E-08 5.18E-07 
Il18; Il1b; Map3k7; 
MAPK14; MAPK3; Nfkb1; 
Nfkbia; Nod1;  
MAPK signalling 
pathway 728 12 253 2.02E-06 1.67E-05 
Cd14; Daxx; Il1b; 
MAP3k5; Map3k7; 
MAPK14; MAPK3; Nfkb1; 
Pla2g4a; Rac1; Relb; 
Tnfrsf1a;  
B cell receptor 
signalling pathway 790 7 72 3.08E-06 2.42E-05 
MAPK3; Nfkb1; Nfkbia; 
Pik3cd; Plcg2; PTPN6; 
Rac1;  
Chemokine signalling 
pathway 4351 9 195 5.30E-05 2.93E-04 
Cxcl10; Cxcl16; Cxcr2; 
JAK3; MAPK3; Nfkb1; 
Nfkbia; Pik3cd; Rac1;  
Cytokine-cytokine 
receptor interaction 604 10 264 1.05E-04 5.27E-04 
Cxcl10; Cxcl16; Cxcr2; 
Ifnar1; Il17a; Il18; Il1b; 
Kdr; Ltbr; Tnfrsf1a;  
mTOR signalling 
pathway 
 743 4 61 0.002048 0.00602944 
Igf1; Mapk3; Pik3cd; 
PTEN 
 
The key pathways selected from the Pathways analysis presented in figure 5.4 A; 
these pathways are presented here in detail. Pathway Id is the number of the 
pathway in KEGG system; the name and number of the genes that are down 
regulated by IL-37a and b and involved pathway with P values.         
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Table 5.1b Common pathways and related genes upregulated by both IL-37a 
and b  
Pathway Name 
 
 
Pathway 
Id 
 
 
Pathway 
uploaded 
gene 
 
Genes in 
Innate DB 
for this 
entity 
 
Pathway 
p-value 
 
 
Pathway  
p-value 
(corrected) 
 
 
Gene Symbols 
 
 
 
Cytokine-cytokine 
receptor interaction 604 8 264 5.52E-06 1.60E-04 
Csf1r; Cxcr3; Cxcr4; Cxcr6; 
Il12b; Il19; Il4ra; Il6st;  
JAK-STAT signalling 
pathway 651 6 154 2.36E-05 3.05E-04 Il12b; Il19; Il4ra; Il6st; Stat6;  
Toll-like receptor 
signalling pathway 699 5 100 3.71E-05 3.58E-04 
Il12b; MYD88; Ticam1; TLR6; 
TLR7;  
NOD-like receptor 
signalling pathway 8111 3 57 0.001345 0.00410596 Casp1; Naip2; Nlrp3;  
Chemokine signalling 
pathway 4351 4 195 0.006492 0.01234527 Cxcr3; Cxcr4; Cxcr6; Stat3;  
 
The key pathways selected from the pathways analysis presented in figure 5.4B; 
these pathways are presented here in detail. Pathway Id is the number of the 
pathway in KEGG system; the name and number of the genes that are 
upregulated by IL-37a and b and involved pathway with P values.         
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Figure 5.5 Heat maps presentation of the common genes regulated by IL-37a 
and b compared to wt control. 
The representative common regulated genes by IL-37a and b selected from 
Tables 5.1 and 5.2 displayed in heat maps. The genes were analysed by 
microarray assay in triplicates. A) The representative genes (Table 5.1) that are 
down regulated by IL-37a and b; B) the representative genes (Table 5.2) that are 
upregulated by IL-37a and b compared with wt controls.  
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Figure 5.6 The signalling pathways selectively regulated by IL-37a in LPS 
stimulated spleenocytes. 
The signalling pathways of the genes selectively regulated by IL-37a in LPS-
stimulated cells identified by the enrichment analysis on Innate DB and KEGG. A) 
Represents signalling pathways down regulated by IL-37a. B) The pathways 
upregulated by IL-37a.    
187 
 
Table 5.2 Signalling pathways and related genes specifically regulated by IL-
37a. 
 
 
The key pathways selected from the Pathways analysis presented in figure 5.6; 
Pathway Id is the number of the signalling pathway in KEGG system; the name 
and number of the genes in related pathway that are down regulated by IL-37a 
(A) and upregulated by IL-37a (B) with P values.      
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Figure 5.7 Heat maps presentation of the genes regulated specifically by IL-
37a compared to wt control. 
The representative genes specifically regulated by IL-37a selected from table 5.2 
and displayed in the heat maps. The genes were analysed by microarray assay in 
triplicate. A) The representative genes from table 5.2A that are down regulated 
by IL-37a; B) the representative genes from table 5.2B that are upregulated by 
IL-37a compared with wt controls.  
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Figure 5.8 The signalling pathways selectively regulated by IL-37b in LPS 
stimulated spleenocytes. 
The signalling pathways of the genes selectively regulated by IL-37b in LPS-
stimulated cells identified by the enrichment analysis on Innate DB and KEGG. A) 
Represents signalling pathways upregulated by IL-37b. B) The pathways down 
regulated by IL-37b.   
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Table 5.3 Signalling pathways and related genes specifically regulated by IL-
37b 
 
The key pathways selected from the Pathways analysis presented in figure 5.8; 
pathway Id is the number of the signalling pathway in KEGG system; the name 
and number of the genes in related pathway that are regulated by IL-37b and a. 
A) Pathways down regulated by IL-37b; B) pathways upregulated by IL-37a. 
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Figure 5.9 Heat maps presentation of the genes regulated specifically by IL-
37b compared to wt control. 
The representative genes specifically regulated by IL-37b selected from table 5.3 
and displayed in the heat maps. The genes were analysed by microarray assay in 
triplicates. A) The representative genes from table 5.37A that are down 
regulated by IL-37b; B) the representative genes from table 5.3B that are 
upregulated by IL-37b compared with wt controls.  
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Figure 5.10 Proposed molecular mechanism by which IL-37a and IL-37b 
regulated TLR4 signalling. 
IL-37a and b supress TLR4 signalling through gene regulation of several 
pathways. Both IL-37a and b inhibit CD14 co-receptor, TIRAP, that affect LPS 
binding to TLR4 and signal initiation respectivly, and inhibit MAPK, NF-κB, PI3K, 
and mTOR pathways ; and genes involved in Jak/STAT pathway. IL-37a 
specifically upregulate PLTP which affect LPS metabolisim ; PPARγ ; Frizzled-1, 
IL-13, and IL4r that all promote anti-inflammatory function.  
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Figure 5.11 Proposed molecular mechanism by which IL-37a and IL-37b 
regulate TLR and BCR signalling in B cells 
 
 
194 
 
5.3 Discussion 
In order to gain understanding of the similarity and difference between IL-37a 
and IL-37b in gene regulation, transcriptomic analysiswas performed with 
LPS/TLR4-stimulated spleenocytes samples from wt control and IL-37a and IL-
37b transgenic mice. The results demonstrated for the first time: 1) Compared 
to the wt control, IL-37a significantly down regulated 2905 and upregulated 2881 
genes in the LPS-stimulated cells; indicating that IL-37a has a broad regulatory 
effect on global gene expression, not only suppressing but enhancing gene 
expressions. 2) Compared to IL-37b, IL-37a specifically inhibited 1182 and 
enhanced 1525 genes, suggesting that IL-37a differs from IL-37b in gene 
regulation. 3) By comparing with IL-37b, the common regulated genes between 
the two IL-37 isoforms were also identified, explaining the functional similarity 
between the two isoforms; 4) the common and unique signalling pathways 
between the two isoforms were also revealed using Innte Data Base (IDB) and 
KEGG enrichment analysis. These have provided molecular mechanism, at least 
in part, for the IL-37-mediated regulatory effect in our previous experimental 
observations.  
Thus, the transcriptomic analysis further demonstrated that IL-37a is a 
previously unrecognised immunoregulatory cytokine and plays an important role 
in the regulation of TLR-signalling and beyond. In addition, IL-37a differs from 
IL-37b in gene regulation and signalling and may be a novel regulatory 
intervention for inflammatory diseases. 
Consistent with our results that show IL-37a and IL-37b sharing functional 
similarity in the regulation of immune cell function (Chapter 4), a considerable 
amount of genes in LPS-stimulated cells were regulated by both IL-37a and IL-
37b in the transcriptomics analysis. While the detailed mechanism still needs to 
be elucidated, because the two isoforms share the IL-1-like cytokine domain for 
receptor binding and signalling, it is mostly likely that IL-37a also signals via the 
same receptor as IL-37b and the common genes are regulated via the common 
IL-37 receptor-dependent pathway. Indeed, our recent results using IL-1R8 
deficient cells demonstrated that the same as IL-37b, recombinant IL-37a also 
requires the receptor for signalling (Y. Ji, unpublished result). Apart from the 
common regulated genes, nearly half of the genes regulated by IL-37a and the 
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majority of genes regulated by IL-37b are specifically regulated by IL-37a or IL-
37b, respectively. The result further demonstrates that IL-37a and IL-37b differ 
in gene regulation and signalling. Whereas it is poorly understood how the two 
IL-37 isoforms are differently involved in gene regulation, the unique genes may 
be largely attributed to their unique N-terminal sequence of the two IL-37 
isoforms and their difference in nuclear translocation.  
It has been shown that matured but not the FL-IL-37b is able to translocate into 
cell nucleus via Smad3 (Luo et al, 2017). Using the IL-37b transgenic mice 
lacking the IL-1R8, it was further demonstrated that nuclear located mature IL-
37b can regulate LPS response in an IL-1R8-independent manner (Nold-Petry et 
al, 2015). While the detailed mechanism is still lacking, it has been reported 
that the genes regulated by the receptor-independent pathway of IL-37b are 
largely different from the ones regulated by the receptor-dependent pathway 
(Nold-Petry et al, 2015).  
Because the FL-IL-37a contains a putative NLS and our preliminary results 
suggest that the majority FLIL-37a proteins translocate into cell nucleus via their 
NLS (R. Wei, unpublished result), we reason that the genes specifically regulated 
by IL-37a may be predominantly attributed to the nuclear FLIL-37a in a receptor-
independent manner. Further experiments are needed to define the hypothesis 
by using the IL-37a transgenic mice without the IL-1R8. While the molecular 
targets and mechanism of action of nuclear IL-37a in the nucleus are still 
unknown and currently under investigation in our lab using Chip-sequence, it is 
known that the NLS containing N-terminal of IL-1a is sufficient to regulate cell 
function by translocation to the nucleus and binding to transcription activators 
and chromatin (Werman et al, 2004b). Since the putative elastase-matured IL-
37a protein (R22-D192) shares 98% homology with the caspase-1 matured IL-37b 
(V46-D218), it is possible that after processing, matured IL-37a also translocate 
to the cell nucleus through the same Smad3-mediated mechanism as mature IL-
37b. However, our preliminary result suggests that different from the FLIL-37, 
the majority of mature IL-37a proteins are located in the cell plasma, not cell 
nucleus (Wei, unpublished result). While the reason behind this is still unknown, 
it is likely that FL but not mature IL-37a is primarily responsible for the gene 
regulation in the cell nucleus. Nevertheless, our results suggest that FL-IL-37a is 
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a dual functional regulatory molecule, which regulates genes and cell function 
by different mechanism. Different from FL IL-37b; FL-IL-37a can serve as a 
nuclear regulatory factor when translocated into the cell nucleus. Similar to IL-
37b, FL and mature IL-37a can also act as a cytokine when released from 
producing cells and trigger signalling via IL-37 receptor. Our transcriptomic 
analysis reveals that IL-37a and IL-37b control LPS/TLR4 signalling transduction 
by targeting multiple signalling pathways and via common and specific 
mechanisms (Fig 5-10): both isoforms inhibit the expression of TLR4 co-receptor 
CD14 and MyD88 adaptor protein TIRAP. IL-37a also induces the expression of 
LPS-binding protein PLTP to block LPS function; both these will prevent the 
initiation of LPS/TLR4 signalling. Both isoforms can further suppress the 
downstream TLR signalling, including MAPK, PI3K, mTOR, NF-κB and JAK-STAT 
pathways. A part of the shared capacity of gene regulation, both isoforms can 
also act independently in gene modulation and control TLR signalling by 
different mechanisms. As such, IL-37a suppresses the expression of Irf7 and Ifnb1 
in the TRIF-dependent pathway, on the other hand, IL-37b inhibited Irf3, 
altogether; this may lead to the down regulation of type I IFN production. 
Intriguingly, IL-37a, but not IL-37b, also increased expression of several 
immunoregulators with known anti-inflammatory activity, such as PPARr which 
inhibits TLR4-mediated inflammations (Wei R., unpublished) and Frizzled-1 
which induces Wnt/b-catenin signalling to promote anti-inflammatory function in 
macrophages (Wei R, unpublished). IL-37a also enhanced expression of the type 
II cytokine IL-13 and both IL-37 isoforms enhanced IL-4 receptor as well; these 
type II cytokines may counter regulate the expression and function of pro-
inflammatory cytokines (Wynn, 2015). Altogether, these effects may impair the 
LPS-induced production of inflammatory cytokines, chemokines and mediators 
and also ameliorate inflamed leucocyte migration, cell metabolic and immune 
reactions, thereafter decreasing inflammatory response. Hence, the selective 
induction of IL-37a may represent a novel strategy for improving 
immunotolerance against dysregulated inflammatory response.  In addition, this 
analysis also provides a possible molecular explanation for the IL-37-mediated 
regulatory effect on LPS-activated macrophages, monocytes and B-cells in 
(Chapter 4). 
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Our previous results showed that IL-37 signals increased IgG production and 
cellular proliferation in LPS-stimulated murine CD19+B cells (Chapter4). 
However, IL-37 inhibited inflammatory cytokine expression in murine and human 
B cells. The mechanism is still unknown (Chapter4).  
Because the murine spleenocytes contain 40% B cells and the spleenocytes used 
for the transcriptomic study were stimulated with LPS, we therefore assessed 
the regulatory effect of IL-37 isoforms on TLR-stimulated B cells by analysing 
their gene profile in B cell signalling pathways. As illustrated in (Fig 5-11), our 
results suggested that IL-37a and IL-37a also positively or negatively regulate 
TLR and BCR signalling pathways in B cells, alone or together.  
Although no clear picture can be drawn from this, probably due to the total 
spleenocytes used and the analysis being was based on the IDB in which not all B 
cell-related genes are included, the result suggests the possible mechanisms 
underlying how IL-37 isoforms regulate TLR4/BCR signalling and function in B 
cells. Regarding the different effect of IL-37a and IL-37b on the regulation of 
MYD88 and TRIF-dependent pathway in B cell function, while; the precise 
signalling pathway is still lacking. TLR4 signals in B cells through at least two 
distinct pathways, one via the BCR leading to the activation of SYK, ERK, and 
AKT independent of MYD88, and the other through MYD88 leading to the 
activation of NF-κB (Schweighoffer et al, 2017). The MYD88-independent 
pathway mainly mediated by TRIF-dependent pathway, and associated with the 
B cell proliferation and antibody production (Pihlgren et al, 2012; Yanagibashi et 
al, 2015). 
However, the function of the MYD88-dependent pathway in this context was not 
investigated, but was likely involved in inflammatory cytokine production. 
Interestingly, we found that TRIF expression was enhanced, but the MYD88 
adaptor TIRAP was inhibited by both IL-37a and b. The result suggests that IL-
37a/b may enhance antibody but decrease inflammatory cytokine production by 
differentially regulated MYD88 and TRIF-dependent pathways. This hypothesis 
needs to be defined by using the B cells from MYD88 and TRIF deficient mice. 
IL-37 may enhance B cell antibody production by suppressing the expression SHIP 
and SHP1 in B cell signalling. 
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BCR signalling is tightly regulated and mainly by SHP-1 and SHIP (Paessler et al, 
2002). Mice deficiency in SHP-1 or SHIP all enhanced antibody production and 
autoimmune disease (Pao et al, 2007; O’Neill et al, 2011; Chen et al, 2017).  We 
found that both IL-37a and b significantly suppressed the expression of PTPN6 
encoding SHP-1, and IL-37b suppressed Inpp5d encoding SHIP in LPS-stimulated 
spleenocytes (Fig 5-11). Agreeing with the SHP1 down regulation, we found that 
IL-37b also enhanced effector molecules in the TLR4/SYK/ERK and NFAT 
pathways that are responsible for the TLR4-mediated IgG production in B cells, 
including MAPK1, Nras and Nfatc2, and the Pik3cg in PI3K pathway (Fig 5-11). 
Thus, down regulation of SHP-1 and/or SHIP may contribute to IL-37-enhanced 
antibody production and proliferation in B cells. However, the impact and 
underlying mechanism by which IL-37 down regulates SHP-1 and SHIP in B cells is 
currently unknown. Further study will be important using B cells with the two 
phosphatases knock downed to evaluate the importance of the down regulation 
of the phosphatases in the IL-37-enhanced antibody production and B cell 
proliferation.  
The expression of SHIP but not SHP-1 has been examined above in Chapter 4. 
The result showed that the SHIP expression in LPS-stimulated B cells from IL-37a- 
tg mice was significantly lower than that in wt cells. While this suggests that IL-
37a can also regulate SHIP, the result is contradicted by the transcriptomic 
result. The reason is unclear, maybe due to the difference in cell population, 
the earlier study using purified B cells the later one the spleenocytes, and to 
also the culture conditions (4 hours vs 3 days).  
The possible mechanism by which IL-37 suppresses LPS-induced inflammatory 
cytokine production in B cells.  
While the down regulation of inhibitory SHP-1; and SHIP may provide, at least in 
part, explanation for the IL-37-enhanced antibody production in murine B cells, 
it fails to explain why IL-37 is still capable of inhibiting inflammatory cytokine 
production in B cells. Studies have also showed SHIP-1 defecincy elevating NF-
κB-dependent inflammatory cytokine and MAP kinase activation exploiting TLR4-
independent PI3K/Akt pathway (Li et al, 2016). By analysing the genes regulated 
by IL-37a and b in BCR signalling pathway, we found that both IL-37 are able to 
down regulate expression of key genes in NF-κB pathway in B cells, alone or 
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together: IL-37a down regulated pik3ap1 in PI3K pathway and IL-37b down 
regulated the important Lyn and Akt. Both isoforms also down regulated pik3cd 
in PI3K pathway, Nfkb1 and Nfkbia in NF-κB pathway as well as MAPK3 in MAPK 
pathway (Fig 5-11). Thus, it is possible that the subsequent increasing NF-κB 
activation resulting from the SHP-1 and SHIP down regulation by IL-37 will be 
reduced quickly by the direct inhibitory effect of IL-37 on the elements in the 
signalling pathway as did in TLR signalling. However, this needs to be confirmed 
in phosphorylated protein levels by western blot in B cells stimulated or not 
stimulated with IL-37. Based on these preliminary results, my hypothesis is that 
the down regulation of B-cell regulators SHP1 and SHIP will be mainly 
responsible for the IL-37a/b-mediated antibody response and that the 
suppression of NF-κB and MAPK pathway by IL-37a/b may result in the impaired 
inflammatory cytokine production in B cells. Obviously, it is worthwile to test 
the hypothesis in vitro and in animal model in vivo. The transcriptomic 
experiment has some limitations and could be improved; it will be ideal to have 
more LPS stimulation time points in B cells in order to see kinetic changes in 
gene expression, in particular the early time 2-3 hours after stimulation to see 
the transcriptomic changes in the initiation stage of B cell activation. The 
important differentially expressed genes need to be validated by qPCR with 
specific primers and in protein levels by western blot, FACS or ELISA. Their 
function in IL-37-mediated effect also needs to be evaluated by siRNA 
knockdown or overexpression in immune cells. The transcriptomics study also 
shows that IL-37a and b may have global regulatory effect on other diseases 
beyond LPS-induced inflammation. This will be discussed in the General 
Discussion.  
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Chapter 6 
General Discussion 
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6 General discussion 
6.1 IL-37 family: why do we need 5 isoforms? 
IL-37 is a new member of the IL-1 family and consists of 5 isoforms (IL-37a, b, c, 
d, and e). Until now, only the IL-37b isoform has been studied in detail. While 
IL-37b is important in immune regulation and tolerance, the biology and function 
of other isoforms are largely unknown. From an evolution point of view, if a 
gene is no longer needed, it will be deleted or became a pseudogene. Thus, it is 
important to know the function of other IL-37 isoforms. Based on the 
information in the general introduction of IL-37 isoforms (Chapter 1) and the 
results from our own lab, here I will mainly discuss their differences in the 
structure, induction, regulation, tissue distribution and potential function. By 
doing so, hopefully we can answer the question, at least in part, why we need 
five IL-37 isoforms. 
6.1.1 IL-37 isoforms are different in gene organisation and protein 
levels: 
IL-37 gene contains 6 exons and encodes five isoforms due to alternative gene 
splicing (Boraschi et al, 2011). Pro-IL-37a is a protein with 192 amino acids 
encoded by exon 3 to 6. It contains a unique nuclear localization sequence (NLS) 
in the N- terminal for importing from cytoplasm into the cell nucleus. The pro 
protein also contains a unique elastase cleavage site and can be digested by 
elastase to form mature protein, while the other IL-37 members carry a caspase-
1 cleavage site (Boraschi et al, 2011). Pro IL-37b is the biggest protein in the 
family consisting of 218 amino acids long encoded by all the exons, except the 
exon 3 and can be cleaved by caspase-1 to produce mature IL-37b (Pan et al, 
2000). IL-37d is encoded by exon 1 and exons 4 to 6 to give a 197 amino acid pro 
protein and canalso be processed by caspase-1. IL-37c is 178amino acid long 
encoded by exons 1, 2, 5 and 6 and IL-37e is 157 amino acids long encoded by 
exons 1,5 and 6 (Boraschi et al, 2011). Some IL-37 isoforms also contain a key IL-
1-like β-trefoil structure for receptor binding and signalling, which is encoded by 
the exons 4-6. Based on whether or not carrying the IL-1-like domain, the 
isoforms can be divided into two functional groups; the isoforms a, b, and d (i.e. 
those encoded by the complete exons 4-6 will therefore be expected to bind to 
the same receptor and trigger the same range of biological effects. In contrast, 
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IL-37c and e lack the key exon 4 and are expected to give rise to a partial IL-1-
like β-trefoil structure and their functions are unknown (Boraschi et al, 2011). 
This protein/structural evidence suggests that the isoforms may vary in induction 
and function. 
6.1.2 Difference of IL-37 isoforms in induction and expression 
One possibility for why we need five IL-37 isoforms is that these isoforms may be 
selectively expressed in different organs or differently induced in different 
cell/tissues in disease by different stimuli. Indeed, the tissue specific expression 
of the IL-37 isoforms has been reported (Taylor et al, 2002). While they are 
expressed in some common organs, IL-37a is the only isoform that is expresses in 
the brain, IL-37b is the only one present in kidney, IL-37c is the heart-specific 
isoform, IL-37d and e are only expressed in bone marrow and testis, suggesting 
that IL-37 isoforms may have different effect in organs. 
Current evidence also suggests that IL-37 gene expression is highly regulated. IL-
37 genes contain an instability element (A-rich homology box) in exon 5, this 
makes the IL-37 mRNA unstable (Bufleret al, 2004). The function of instability 
elements can be over come by inflammatory stimuli to ensure the cytokine 
genes can only be increased in inflammatory, but not in the homeostasis 
conditions. As such, resting cells only produce low levels of IL-37b proteins and 
the expression can be upregulated by an array of inflammatory stimuli and 
cytokines (TLR agonists, IL-1α, IL-18, TNF-α, IFNγ) (Nold-Petry et al, 2015). 
Thus, it is important to know how other IL-37 isoforms are regulated and 
whether they are regulated in the same or different ways in immunity and 
diseases. However, the knowledge in this area is still very poor, mainly because 
the potential importance of IL-37 isoforms has not been fully appreciated. 
There is only one report whichdetermined the expressions of IL-37 isoform in 
human PBMCs (Rudloff et al, 2016). The results show that IL-37 isoform 
expressions are differently regulated by different TLR agonists within 8 hours 
cultures. TLR4 ligand LPS upregulates IL-37b and c in this experimental 
condition. IL-37c expression is predominantly induced by pam3 (TLR2 ligand); 
while TLR7/8 agonists had no effect on the induction of IL-37 isoform 
expression. The authors also showed that the expression of IL-37a and e was not 
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upregulated with any of these stimuli in this experiment. While it was the first 
report on the regulation of IL-37 isoform expression in cell level and sheds new 
insight for the difference of IL-37 isoforms in induction, this study has some 
drawbacks; the study on time effect was not long enough, the induction of IL-37 
isoform expression beyond 8 hours has not been studied. In addition, the details 
of the qPCR primer sequence for each of the IL-37 isoforms used in the study 
were not provided; this makes it difficult to interpret the real value of the 
result. We further studied time and dose effect of TLR agonist on the IL37 
isoform expression and found that the induction of IL-37 isoforms is differing 
depending on dose and time (Chapter 4). We also found that IL-37a is one of the 
highly induced isoforms. 
6.1.3 Functional differences of IL-37 isoforms 
While IL-37 (IL1F7) gene has been identified 10 years ago, its key biological 
function has just emerged recently. So far, among the isoforms, only the 
function of IL-37b and IL-37d has been reported.  
Current evident suggests that IL-37b is a new member in the portfolio of 
classical anti-inflammatory cytokines, including IL-10 and TGF- (Conti et al, 
2016). However, different from IL-10 and TGF-, these global immune 
suppressors, IL-37bis inflammatory signal induced and feed back inhibits the 
ongoing inflammatory response in vitro and in vivo.  IL-37b is a dual functional 
cytokine and suppresses inflammatory response via the receptor-dependent and 
independent mechanisms; with the receptor-dependent manner, the secreted IL-
37b binds to receptor complex IL-18Ra and IL-1R8 and elicit anti-inflammatory 
signalling (Nold-Petry et al, 2015; Dinarello et al, 2016). With the receptor-
independent manner, the mature but not the FL-IL-37b can interact with Smad3, 
translocate into the cell nucleus and thereby facilitates the cytokine-suppressing 
properties through a Smad3-dependent mechanism. The importance and detailed 
mechanism underlying the receptor-independent regulatory effect of IL-37b is 
largely unknown, whereas the IL-37b-mediated protective effect against LPS-
induced endotoxic shock is receptor-dependent (Jia et al, 2018). 
It has been reported recently that IL-37dis also bioactive (Zhao et al, 2018). The 
same as IL-37b, IL-37d can also suppress inflammatory response via Smad3-
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dependent mechanism. However, different from IL-37b, IL-37d fails to induce 
signal via the IL-37 receptor. Since IL-37d and b share the common C- terminal 
sequence and the IL-1 like domain it is difficult to understand why IL-37d is 
unable to signal via the receptor. The function of IL-37a has not been reported 
and this is the current focus in our lab. We found so far that pro-IL-37a is also 
dual functional and can serve as a nuclear regulator in the cell and a cytokine 
when secreted out of the producing cells. Different from other isoforms, pro IL-
37a carries a unique putative NLS domain that may allow it to translocate into 
cell nucleus. Our result confirms its nuclear location; and further demonstrated 
that nuclear IL-37a can regulate gene expression (Xu, unpublished result). We 
also found that IL-37a possesses a similar C-terminal structure as IL-37b and can 
also bind to the same receptor as IL-37b and trigger the similar range of 
biological effects. However, we expect the unique dual effect of IL-37a may 
render IL-37a a super regulatory effect in immunity and disease compared to IL-
37b and d. This is currently under investigation in the lab. 
Nothing is known about the function of the two IL-37 isoforms lacking the full IL-
1-like domain. Since the 12 B-trefoils in the IL-1-like domain are required for the 
receptor bind and signal in cytokines in IL-1 family, and both IL-37c and e lack 
the first three β-strands in the β-trefoil structure, it has been speculated that 
the IL-37c and e may not be able to bind to the receptor; and therefore lack the 
cytokine activity (Nold et al, 2010; Ellisdon et al, 2017). However, they may 
regulate other IL-37 isoforms function by competing or interfering with their 
mRNA splicing.  As all pro IL-37 isoforms, except pro IL-37a, contain the caspase-
1 cleavage site and can be processed into mature protein by the same enzyme, 
IL-37c and e may also affect other isoforms maturation and function by 
competing with the enzyme in the microenvironment in vivo. To support the 
hypothesis, all cytokines in IL-1 family are self-regulated, for example, IL-1 is 
regulated by IL-1 antagonist, IL-18 is via a binding protein (IL-18 BP), and IL-33 
by the soluble IL-33 receptor (Hayakawa et al, 2007; Dinarello et al, 2013). 
Alternatively, while unable to induce receptor-dependent effect, IL-37c and e 
may also be able to regulate gene expression as IL-37b and d via Smad3 to 
translocate into cell nucleus.  
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6.1.4 Conclusion and future directions 
In summary, the five IL-37 isoforms are different in protein structure, induction 
and function as well. Three of them have been demonstrated to play an 
important immunoregulatory role in disease and tolerance. These IL-37 isoforms 
may be therapeutically important in the treatment of a broad range of chronic 
disorders, including inflammatory and autoimmune diseases. However, much 
remains to be studied: it is still unclear whether the isoforms regulate 
inflammation with same or different effect. The precise mechanisms by which 
IL-37 isoforms suppress inflammatory response are still largely unknown. The 
different involvement and interaction of IL-37 isoforms in a given disease 
context need to be determined. Furthermore, while they are likely bioactive, 
the function of IL-37c and e isoforms remains unclear. Finally, the importance 
and relationship of IL-37 with other immunoregulatory cytokine, including IL-10 
and TGF- in immune tolerance need to be evaluated in the future. 
Nevertheless, it is possible that the IL-37 isoforms will synergise, back up or 
balance each other’s function in the regulation of inflammation, thus ensuring 
that an ongoing inflammatory response is appropriately controlled. 
6.2 IL-37 an immune inhibitor or regulator? 
IL-37b has been originally characterised as a fundamental inhibitor of innate 
immune response (Nold-Petry et al, 2010). Later research confirms the 
hypothesis on innate immune cells and further reveals that IL-37 not only inhibits 
innate immune cells but also T-cells as well, indicating that IL-37 may inhibit 
both innate and adaptive immunity. Furthermore, all the current evidence 
suggests that IL-37 is an immune inhibitor and inhibits immune cell functions via 
both direct and indirect mechanisms. However, our results strongly suggest that 
IL-37 can also enhance immune cell function, at least in B cells. This has raised 
an important question: whether IL-37 is an immune inhibitor or a regulator. In 
this part of the general discussion, I sought to answer the question by collecting 
and analysing all the evidence supporting both proposals. 
6.2.1 Evidence supporting IL-37 as an immune inhibitor 
Much research supports the proposal, which demonstrated that IL-37 can inhibit 
both innate and adaptive immune cell functions. IL-37 is expressed in a wide 
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range of immune cells, including monocyte, macrophages, mast and T cells, and 
IL-37 plays an inhibitory role in the immune cell functions. It has been 
demonstrated that monocytes express highest levels of IL-37 among the human 
immune cells (Rudloff et al, 2016). This suggests that monocytes may be a 
primary source of IL-37 in immune response. It is also reported that IL-37 is 
inducible in monocytes by mycobacteria in tuberculosis (TB) patients; the 
expression is negatively correlated with the levels of inflammatory cytokines IL-
1β, IL-6 and TNF-α (Zhang et al, 2016). However, the detailed function of IL-37 
on monocytes has not been explored. Its effect on macrophages has been well 
studied, including our own study. IL-37 can effectively suppress TLR signalling 
induced inflammatory cytokine production (Nold-Petry et al, 2015; Huang et al, 
2016). In oxidized low-density lipoprotein (ox-LDL)-activation conditions, IL-37b 
effectively inhibited the production of IFNγ, TNF-α and NO in the macrophage 
(Huang et al, 2016).   
The mast cells play a pathogenic role in many conditions, including asthma, 
allergy and psoriasis (Conti, 2017). Several studies show that IL-37b is able to 
suppress mast cell migration and function in murine model of psoriasis (Teng et 
al, 2014) and asthma (Conti et al, 2016).   
The influence of IL-37b on adaptive immune cells has also been assessed and 
only T cells have been studied so far. It has been shown that IL37 is expressed by 
CD3+ and CD4+ T cells and can inhibit Th17 cell function (Ye et al, 2014). In 
Th17 polarisation condition, IL-37 effectively inhibits IL-17 expression and Th17 
cell proliferation but not the differentiation from naive human CD4+ T cells. 
The study of regulatory effect of IL-37a and IL-37d has just begun. The only 
report shows that IL-37d is expressed in peripheral blood mononuclear cells 
(PBMCs), epithelia and umbilical cord-derived mesenchymal stem cells (UCMSCs). 
IL-37d overexpression inhibits inflammatory cytokine IL-1β induced IL-6 
production in epithelia cell line and macrophages (Zhao et al, 2018). However, 
its role in the regulation of other immune cell function has not been studied yet. 
Our results demonstrated that IL-37a is also bioactive and can suppress LPS-
stimulated inflammatory cytokine production in human and murine macrophage 
and monocytes (Xu, unpublished results). IL-37a can also regulate B cell function 
and this will be discussed below. Its effect on other innate and adaptive immune 
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cell function is currently under investigation. While the precise mechanisms are 
still poorly understood, IL-37 can suppress innate and adaptive immune cell 
function directly or indirectly. 
6.2.1.1 The direct inhibitory effect of IL-37 on immune cell activity  
The direct effect of IL-37 can perform in autocrine or paracrine manner; in the 
autocrine, an immune cell produces the cytokine first, the cytokine then 
regulates the function of the producer cellvia receptor dependent or 
independent pathways. As discussed before, IL-37a, b and d can also enter the 
cell nucleus and regulate cell function asa nuclear factor without the receptor. 
However, the detailed mechanism by which nuclear IL-37 isoforms regulate gene 
function is largely unknown. In contrast, the receptor-dependent regulatory 
effects of IL-37 isoforms are relatively well studied; the secreted free IL-37 and 
IL-37a, but not IL-37d can bind to its receptor and regulate cell function via 
receptor-mediated signalling (Nold-Petry et al, 2015; Zhao et al, 2018 M). This 
was evidenced by the lost inhibitory effect of endogenous or recombinant IL-37 
in IL-37 receptor knockout mice or the mice treated with anti-IL-37 receptor 
antibody (Nold-Petry et al, 2015). 
In the paracrine, the IL-37 secreted by one immune cell type, for instance, 
monocytes can suppress the function of other surrounding immune cells that 
possess the IL-37 receptor. This will allow an enlargement of IL-37-mediated 
effect in immune response in tissue and organ. However, the indirect inhibitory 
effect mediated by IL-37 on immune cells with the indirect arm, IL-37 may 
control immune activation by downregulating antigen-presenting cell (APC) 
function and/or by inducing regulatory T cells (Treg) and tolerogenic dendritic 
cells (tDC). This could lead to a systemic impact of IL-37 on the ongoing 
inflammatory response.  
Effect on APC function: DC is a key APC in tissues and plays an important role in 
the initiation of immune response. It has been shown that IL-37 can inhibit DC 
maturation and antigen presentation. For example, the LPS-stimulated 
maturation and activation of DC isolated from IL-37b-tg mice was markedly 
reduced (Luo et al, 2014). This was evidenced by the IL-37 treated DC reduced 
expression of MHC II and costimulatory molecule CD40 and the reduced 
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production of inflammatory cytokines, IL-1β, IL-6, and IL-12 (Luo et al, 2014). 
More importantly, the IL-37b-treated DC failed to effectively activate naive T 
cells (Luo Y, et al, 2014). Thus, control of DC function by IL-37b will affect the 
development of antigen-specific immune activation. Treg, in particular the 
Forkhead box proteins-3 (FOXP3+)Treg, are fundamentally required for the 
control of development of inflammatory and autoimmune disease (Long and 
Buckner, 2011). In order to elitcit a maximum and systemic regulatory effect, IL-
37 can also promote the Treg development but suppress antigen-presenting cell 
(APC) function. It has been reported that T cells also express IL-37 and IL-37 
differently modulates the function of CD4+ T cell subsets. IL-37 treatment 
selectively decreases Th1 and Th17 cell development but increases Treg cell 
polarisation and function (Ji et al, 2017). CD4+ Treg also express IL-37 and IL-37 
promotes the expression of Treg transcript factor fork head/winged helix 
transcription factor p3 (FOXP3) and the suppressive cytokines such as TGF- and 
IL-10 in Treg (Shuai et al, 2015). Furthermore, silencing the IL-37 gene in human 
Treg impairs the suppressive function of Treg (Shuai et al, 2015). 
IL-37 may also control inflammatory response via the induction of tolerogenic 
tDC. The tDC is a subset of DC and plays a regulatory role in immune tolerance. 
Different from other DC, tDC is characterised by its ability of immune 
suppression and the polarisation of Treg (Chang et al, 2017). It has been 
demonstrated that the DC isolated from IL-37 transgenic mice expresses high 
level of IL-10 and reduced its ability in the activation of antigen-specific T cells, 
suggesting that the DC is the tDC. Furthermore, the tDC can polarise Treg and 
suppress the CD8 cytotoxic function in vitro and in contact hypersensitivity in 
mice (Luo et al, 2014). Thus, by inhibiting APC and promoting Treg and tDC 
development and functions, IL-37 could maximise its systemic regulatory effect 
in order to more effectively control inflammatory response. However, the 
potential effect of other IL-37 isoforms in the regulation of APC, Treg and tDC is 
still unknown. 
6.2.1.2 IL-37 can enhance function of some immune cell sets 
Whereas the inhibitory effect of IL-37 in immunity and in disease has been well 
documented, the immune enhancement effect of IL-37 has been largely 
overlooked. By review and analysis of the results from our and other labs, there 
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is good evidence demonstrated that IL-37 can also effectively promote immune 
cell functions.  
We found that IL-37a can promote B cell antibody production and proliferation 
(Chapter 4). The effect is not limited to IL-37a, as IL-37b is also be able to do so. 
Thus, it is likely that enhanced B cell function is a general phenomenon for IL-
37.  
As discussed above, while IL-37 decreases the function and development of 
effector T cell, such as Th1 and Th17 cells, it selectively increases Treg cell 
polarisation and function (Ji et al, 2017). Treg express IL-37 and IL-37 enhances 
the expression of Treg transcript factor FOXP3 and the suppressive cytokines 
TGF- and IL-10 in Treg (Shuai et al, 2015). It will be important to see if other 
IL-37 isoforms have same effect on Treg. 
Macrophages can be further polarised into M1 or M2 subtypes (Martinez and 
Gordon, 2014). The M1 macrophages play an important role in infection and 
inflammation. They are characterised by the expression of iNOS and the 
production of NO and pro-inﬂammatory cytokines, including IL-1β and IL-12 
(Castleberry et al, 2008). The M2 macrophages, on the other hand, are involved 
in immunoregulation and tissue repair by producing IL-10, TGF-, arginase 1 
(ARG1) and inhibit NO production. It has been reported that IL-37 increases the 
development of M2 macrophage in mycobacterium tuberculous infected 
macrophages by enhancing the expression of ARG1, TGF-, IL-10 and reducing 
NO production in the macrophages (Huang et al, 2015). Consistently, IL-37b also 
effectively inhibits the ox-LDL-induced M1 macrophage development; and turned 
the cells into M2 cells (Huang et al, 2016). This demonstrated that IL-37 can 
selectively polarise M2 macrophages and may be involved in tissue repair and 
homeostasis. 
6.2.2 Transcriptomic evidence supports that IL-37 can enhance immune 
response 
The transcriptomic (RNA sequencing) results from other and our own lab also 
demonstrated the enhancement effect of IL-37 in transcriptome in immune cells. 
It has been reported that IL-37b predominantly upregulated the expression of 
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many genes, while it is also able to down regulate gene expression in the LPS-
stimulated spleenocytesfrom IL-37b transgenic (Nold-Petry et al, 2015). Genes 
were highly upregulated and only 448 genes were downregulated in LPS 
stimulated IL-37-tg spleenocytes compared to the wt controls, suggesting that 
IL-37b mainly enhanced gene expression in the LPS-stimulated cells. 
Unfortunately, the nature and related signal pathways of the enhanced genes 
have not been provided in the report. Instead, the authors focused on only the 
139 genes associated with innate immune response and showed that among 
these genes, 46% were increased by IL-37b in the context. By further analysing 
the genes upregulated by IL-37b, they found that while some of the genes 
encoded inhibitors of inflammation, others are closely associated with 
inflammatory response, for example, the Tnfa gene, TRAIP (a TLR adaptor), 
Plcd3 (Nold-Petry et al, 2015), S100a (a TLR4 agonist) and Pycard (Nold-Petry et 
al, 2015). However, the significance of the upregulated inflammatory genes in 
IL-37-mediated effect in the immune context has not been explored. 
Nonetheless, these results demonstrated that IL-37b not only inhibits but also 
enhances gene expression in immune cells. 
We also studied the transcriptome of both IL-37a and IL-37b in the LPS-activated 
spleenocytes from wt, IL-37a or IL-37b transgenic mice (Chapter 5). Our own 
transcriptomic results show that, firstly, consistent with the published result, 
5263 genes were upregulated and 4666 genes down regulated by IL-37b when 
compared to the wt control. More importantly, compared to the wt control, IL-
37a also significantly upregulated 2881 and down regulated 2905 genes in the 
LPS-stimulated cells, indicating that IL-37a also has a broad regulatory effect on 
global gene expression, not only suppressing but also enhancing gene 
expressions. 
The gene ontology study of these common upregulated genes by both IL-37a and 
IL-37b reveals that both the cytokines significantly upregulated genes in at least 
10 pathways (Fig 5-4B, Chapter 5). These enhanced key pathways 
includecytokine-cytokine receptor interaction, JAK-STAT, TLR, NLR, chemokine, 
apoptosis, endocytosis, and the TCR. While the impact of the upregulated genes 
and pathways is largely unknown, given the importance of these pathways in 
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immune activation, these IL-37-upregulated important genes and pathways may 
play a promoting part in IL-37-regulated immunity and disease. 
6.2.3 Conclusion and future directions 
Together, growing evidence strongly suggests that IL-37 can not only inhibit but 
also promote immune cell function. IL-37 does so by upregulating immune 
activating gene expression and promoting immune cell development and 
activation. Thus, we believe that IL-37 should be characterised as an immune 
regulator rather than immune inhibitor. 
Whereas the positive impacts of IL-37 on immune cell function is still less 
understood, it may influence immune response in at least three aspects: 
promoting certain type of immune response, for instance B cell and M2. 
Selectively enhancing the function of immune regulatory cell sets, for example, 
polarising T-reg to enlarge IL-37-mediated immune regulatory effect in immune 
tolerance; and finally, balancing IL-37-mediated inhibitory effect in the same 
cell and the same immune context in order to avoid immune deficiency by 
inducing both immune suppressive and immune active gene expressions. All the 
hypotheses need to be validated experimentally. 
6.3 Role of IL-37 in immunity and disease, friend or foe? 
Accumulating reports suggest that IL-37 plays a critical role in a wide range of 
diseases, including inflammatory, autoimmune, and infectious and tumour 
disorders (Wang et al, 2018). It has been suggested that IL-37 may be a potential 
therapeutic drug for the treatment of inflammatory diseases. However, some of 
the diseases may be exacerbated by IL-37, for instance some infectious diseases. 
Thus, it is important to be fully aware of the dual effects of IL-37 on disease for 
better drug development and clinical application. Here I reviewed the IL-37-
related publications in PubMed and classified the IL-37-associated diseases into 
clinical category -allergic, autoimmune, tumour and infectious diseases. I will 
give a general view of each type of disease categories first, and then focus on 
the representative and best studied IL-37-regulated diseases in this category as 
an example to assess the impact of IL-37 on this type of disease. I hope the 
review and analysis will help to understand the potential beneficial and 
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detrimental effect of IL-37 on the development and pathogenesis of a variety of 
diseases. 
6.3.1 Allergic disorders 
Allergy is an allergen-induced and Th2 cell-mediated hyperactive disorder in 
which IgE, mast cells and eosinophils play a pathogenic role (Galli and Tsai, 
2012). The allergen can be microorganisms, food and chemicals. Allergen can 
cause a variety of allergic disorders in different organs, for instance, asthma in 
lung, allergic rhinitis in nose, food allergy in gut and dermatitis in skin (Holgate 
and Polosa, 2006). There are 40 research and review articles in PubMed by so far 
that are related to the function of IL-37 in allergic disorders, including allergic 
asthma, rhinitis and dermatitis (Luo et al, 2014; Charrad et al, 2016; Kim et al, 
2017; Lv et al, 2018; Zhu et al, 2018). Importantly, all the reports suggest that 
IL-37 plays a protective role against the development of allergy by suppressing 
the development of allergen-induced Th2 response. Allergic asthma perhaps is 
the most important allergic disorder and the best studied IL-37-regulated 
allergic condition, therefore I should like to use asthma as an example to see 
how IL-37 may control allergic response and disease. Asthma is one of the most 
common chronic inflammatory disorders and a major public health concern. It 
affects 300 million people worldwide and has unresolved aetiology. It affects 
more than 5 million people in UK and this number is rising (Holgate et al, 2006; 
Charrad et al, 2016). It is a complex syndrome characterised by airflow 
obstruction, bronchial hyper-responsiveness and airway inflammation. Allergic 
asthma results from multiple pathogenic events involving both genetic and 
environmental factors (Holgate et al, 2006; Charrad et al, 2016). Dysregulation 
of function of Th type 2 (Th2) cells that secrete IL-4, IL-5 and IL-13 is thought to 
play a pivotal role by driving IgE production, recruiting pathogenic cell 
eosinophils and mast cells to the airway and enhancing their pathogenic 
functions (Holgate et al, 2006; Charrad et al, 2016). While the detailed 
mechanisms are still missing, several animal and clinical studies demonstrated 
that IL-37 is able to inhibit the key pathogenic response in asthma by different 
mechanisms. It has been shown that IL-37 expression level in asthma patients is 
low compared to that in healthy controls (McNamee et al, 2011; Zhao et al, 
2014). Furthermore, rIL-37 is able to inhibit inflammatory cytokine production in 
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PBMC and CD4+ T cells from asthma patients (Luo et al, 2014; Charrad et al, 
2016; Kim et al, 2017; Lv et al, 2018; Zhu et al, 2018).  
In an OVA-induced asthma in normal mice, intranasal administration of rIL-37b 
markedly impaired airway inflammation, mucus production and airway 
hyperactivity (McNamee et al, 2011). In contrast, the IL-37b failed to protectin 
asthma mice lacking the IL-37 receptor complex, either IL18Rα or IL-1R8, 
suggesting that the IL-37-mediated effect is receptor dependent (McNamee et 
al, 2011). Using a house dust mite (HDM)-induced humanized asthma model in 
NOD/SCID mice, it has been shown that intra venous administration of IL-37b can 
also suppress the asthma pathogenesis in the airways, including eosinophilia, 
mucus production, leucocyte infiltration, thickened airway wall (Song et al, 
2012). This protective effect mediated by IL-37 in asthma in all the studies is 
attributed to its immune suppressive effect on Th2 cell function and related 
cytokine production (IL-4, IL-6, and IL-13) and mast cell as well as the eosinophil 
functions in these asthmatic contexts (McNamee et al, 2011; Song et al, 2012; 
Zhao et al, 2014; Godsell et al, 2016). Thus, IL-37b has therapeutic potential for 
the treatment of asthma. However, the effect of IL-37 on other allergic 
conditions, for instance food allergy, has not been explored. Furthermore, the 
function and relative contribution of other IL-37 isoforms to allergic diseases is 
still unknown. All of these should be studied in the future (Galli et al, 2012). 
6.3.2 Autoimmune diseases 
Autoimmune diseases are a group of diseases in which dysregulated immune cells 
target self-cells and organs and cause tissue damage and dysfunction (Rose and 
Bona, 1993; Walsh and Rau, 2000). Autoimmune diseases can be organ specific 
and systemic based on one or multiple organs being affected. The common 
autoimmune diseases are rheumatoid arthritis (RA), systemic lupus 
erythematosus (SLE), type I diabetes, inflammatory bowel disease (IBD), and 
psoriasis (Rose and Bona, 1993; Walsh and Rau, 2000). While most autoimmune 
diseases are with unknown aetiology, abnormality of adaptive immune cell 
function plays a common pathogenic role in the pathogenesis of the diseases 
(Rose and Bona, 1993; Singh et al, 2012). T and B-lymphocytes, and particularly 
T-helper1 (Th1) and Th17 cell-dependent pathways are pivotal in the initiation 
and persistence of most, if not all, autoimmune diseases (Singh et al, 2012). Th1 
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cells are polarized by IL-12 and IL-18, which are characterized by selective 
expression of transcription factor T-bet and IFNγ. Th17 cells are characterised 
by dominant expression of IL-17 and IL-22 and the transcription factor RORϒt. 
The active self-antigen specific T and B cells will cause tissue damage by 
subsequent activation of tissue specific innate immune cells including 
macrophage, monocytes and mast cells and the production of proinflammatory 
mediators (Singh et al, 2012).  
Current evidence suggests that IL-37 also plays an anti-inflammatory role in a 
variety of autoimmune disorders, including rheumatoid arthritis (RA), 
inflammatory bowel diseases (IBD), systemic lupus erythematosus (SLE), Graves' 
disease (GD), ankylosing spondylitis (AS), multiple sclerosis (MS) and psoriasis 
(Singh et al, 2012). In all the reported autoimmune diseases, the serum levels of 
IL-37 have been measured and compared with the healthy control. In most of the 
diseases, the IL-37 levels are elevated compared to the healthy controls (Singh 
et al, 2012; Chen et al, 2014). The levels of IL-37 in the patients, in general, 
were positively correlated with the parameters of disease activity (Singh et al, 
2012; Chen et al, 2014). To understand whether the enhanced IL-37 plays a 
pathogenic or protective effect in autoimmune diseases, some of the studies 
further investigated the effect of IL-37 on the inflamed cells ex in vivo. The 
results show that IL-37 can suppress the production of inflammatory cytokines, 
TNF-α, IL1, IL-6 and IL-17 in the PBMCs from AS, GD, and SLE patients (McInnes 
and Schett, 2011; Li et al, 2014; El-Barbary et al, 2018). Since IL-37 is 
inflammatory signals induced, the enhanced IL-37 may represent a feedback 
inhibition of ongoing inflammation in the patients. However, it may suggest that 
this enhanced level of IL-37 may be still not enough to control the vigorous 
inflammatory response in the autoimmune conditions. On the other hand, it is 
still possible that the enhanced IL-37 may contribute to disease development, as 
it is positively correlated with disease parameters. More research is needed to 
answer the question. Nevertheless, I sought next, as an example, to discuss the 
role of IL-37 in RA in more detail. 
Rheumatoid arthritis (RA) is asystemic autoimmune condition. It is the most 
common inflammatory joint disorder, affecting about 3% world population. 
Genetic factors, operating together with environmental triggers including 
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smoking, obesity and unhealthy lifestyle, appear to drive the evolution of 
disease. It is typically characterised by inflammation and hyperplasia of the 
synovium, autoantibody production and the destruction of bone and cartilage 
tissue, which produces considerable pain and disability in severe cases (Singh et 
al, 2012; Nold- Petry et al, 2015). Moreover, RA sufferers are susceptible to a 
range of systemic disorders that affects quality of life, including coronary artery 
disease, stroke and metabolic syndrome arising from the development of insulin 
resistance. 
The T and B-lymphocytes, and particularly Th17 cell-dependent pathways play a 
pivotal role in the initiation and persistence of RA (Singh et al, 2012; Nold- Petry 
et al, 2015). Whereas their mode of initiation in the context of RA is currently 
unknown, Th17 cells may subsequently trigger joint inflammation by activating a 
wide range of downstream innate effector cells including monocytes and 
fibroblasts in the synovium and the release of inflammatory cytokines (Singh et 
al, 2012; Nold- Petry et al, 2015). Several reports show that the levels of IL-37 in 
serum and cultured PBMCs from RA patients were markedly elevated compared 
to healthy controls (Singh et al, 2012; Ye et al, 2015). Furthermore, the levels of 
IL-37 in RA patients were closely associated with the levels of pro-inflammatory 
cytokines TNF-α, IL-6, IL-17a and the disease severity. This is consistent with the 
IL-37 levels in AS, GD, and SLE patients. This is also the case in Juvenile 
Idiopathic Arthritis (El-Barbary et al, 2018). The potential function of IL-37 in 
the pathogenic Th17 development and function in arthritis has also been studied 
(Singh et al, 2012).  
It has shown that rhIL-37 can effectively reduce the production of IL-17 and Th17 
cell numbers in the PBMCs and CD4+ T cells in patients with RA (Singh et al, 
2012). The reduced Th17 and cytokines number was mainly due to IL-37 
inhibiting Th17 cell proliferation, but not Th17 cell differentiation (Singh et al, 
2012). In animal RA model, administration of IL-37 delivered by adenovirus 
system markedly impaired joint inflammation and bone damage. Thus, 
production of IL-37 in RA may be beneficial. In summary, IL-37 plays a repressing 
role in several autoimmune diseases tested, suggesting that IL-37 may do so by 
targeting the key inflammatory pathways including Th17 function and inhibiting 
the NF-κB pathways in these diseases (Singh et al, 2012; Nold-Petry et al, 2015). 
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However, many autoimmune diseases have not been studied and it will be 
important to know whether if IL-37 has general suppressive effect on all 
autoimmune diseases. If this is the case, IL-37 may be more valuable to control a 
wide range of autoimmune disorders. 
 
6.3.3 Malignancies 
Cancer still is one of the most serious diseases and a therapeutic challenge in 
human health (Balkwill and Mantovani, 2001). While the mechanism underlying 
tumour development is still unclear, inflammation plays a critical role in the 
initiation, perpetuation and resolution of cancer (Balkwill and Mantovani, 2001; 
Hagemann et al, 2007). However, current evidence suggests that inflammation is 
a double-edged sword in tumour development, progression and metastasis 
(Balkwill and Mantovani, 2001; Karin, 2017).  The acute inflammation is thought 
to be immune protective to remove the mutant and tumour cells by enhancing 
the function of APC, cytotoxic T cells (CTL) and tumour-specific Th1 cells (Wang 
and Goldenring; 2002; He and Karin, 2010). However, it has been known that 
many cancers are developed from chronic inﬂammation or persistent infections 
(Balkwill and Mantovani, 2001; Hagemann et al, 2007; Karin, 2017). Several key 
inflammatory pathways that promote malignancy have been identified, including 
TLR, nuclear factor κB (NF-κB), RONS, Akt and ARRB 1 pathways that promote 
cell proliferation, survival and mutagenesis (Meira et al, 2008; Tarang et al, 
2012; Taniguchi and Karin; 2014). Cytokines also play an important role in the 
tumour development and progression (Sangaletti et al, 2010; Taniguchi and 
Karin, 2014). Cytokines such as IL-1, IL-6, and TNF-α are highly expressed in 
many cancer cells; and promote tumorigenesis and metastasis by stimulating the 
inflammatory NF-κB and STAT3 pathways (Sangaletti et al, 2010; Taniguchi and 
Karin, 2014). Immunosuppressive cells, in particular the FOXP3+ regulatory T 
cells (Treg), also contribute to tumour immune evasion. These cells can abolish 
anti-tumour immune cell functions by several mechanisms including 
immunosuppressive cytokine secretion, direct cytotoxicity, and activation of 
inhibitory receptors (Sakaguchi, 2005; Zou, 2006). 
Given its ability in the induction of Treg and suppression of immune cell 
functions, it has been speculated originally that IL-37 may promote cancer 
217 
 
development by suppressing anti-tumour immune response. However, the 
current research findings show surprisingly that IL-37 primarily mediates an anti-
tumour response in several cancers, including fibrosarcomas, colorectal (CRC), 
cervical, breast, non-small cell lung cancer (NSCLC) and hepatocellular 
carcinoma (HCC) (Ding et al, 2016; Abulkhir et al, 2017). IL-37 is expressed in all 
the tested cancer cells and plays an anti-tumour role in all the studies (Ding et 
al, 2016; Abulkhir et al, 2017). Here, I should like to focus on three of the best 
and representative studies to reveal the current understanding of the effect of 
IL-37b on tumorigenesis in vitro and in animal in vivo. 
Fibrosarcomas: The potential therapeutic effect of IL-37b on established 
fibrosarcoma (A549 lung carcinoma cells) has been studied in animal model in 
vivo (Gao et al, 2003). A single intratumoral injection of IL-37b-expressing 
adenovirus into the established fibrosarcoma in mice led to a delayed 
development and regression of the tumour, the therapeutic effect was more 
pronounced after multiple injections of IL-37 construct (Gao et al, 2003). While 
the detailed underlying protective mechanism of IL-37b in cancer is still 
unknown, it has been shown in the study that IL-37b failed to treat the 
fibrosarcoma in nude and Severe combined imunne deficiency (SCID) mice 
without T cells and in IL-12, IFNγ, or Fas ligand-deficient mice (Gao et al, 2003). 
This is an interesting finding and suggests that IL-37b may kill the cancer cells by 
inducing a Th1 cell-mediated, Fas-dependent mechanism (Gao et al, 2003). 
However, the finding is against current belief of IL-37b function as an immune 
inhibitor, therefore, more solid evidence is needed to support the hypothesis. 
Hepatocellular carcinoma (HCC): HCC is a common cancer and mainly developed 
in patients with chronic hepatitis after hepatitis virus infection or inflammation. 
The role of IL-37 in HCC has also been investigated (Zhao et al, 2014).  
Using immunohistochemical analysis of HCC clinical samples, the authors found 
that the level of IL-37 in tumour tissues was generally low compared to the 
normal tissues, and negatively correlated with tumour volumes. Importantly, the 
HCC patients with higher levels of IL-37 in HCC tumour tissues have better 
survival rate (Zhao et al, 2014). To understand the potential beneficial effect of 
IL-37 on HCC, the authors also found that IL-37 levels were correlated with NK 
but not the CD3+ T cells in the tumour and the overexpression of IL-37 in the 
218 
 
HCC cells enhanced NK cell chemotaxis. In vivo, the HCC cells were transfected 
with or without IL-37 in lent viral vectors and transplanted into syngeneic mice 
and then the tumour growth was compared. Consistently, the IL-37 enhanced 
tumour NK cells infiltration and reduced tumour growth in the mice (Zhao et al, 
2014). However, the role of NK cells and the systemic immune response in IL-37-
mediated protective effect has not been defined in vivo. 
6.3.3.1  Cervical Cancer: 
Cervical cancer (CC) is the second most common cancer in women and 
associated with human papillomavirus (HPV) infection (Sushma et al, 2014). 
Using mouse cell lines infected (HPV+) or not infected (HPV) with HPV, the role 
of IL-37 in the proliferation and invasion of CC has been investigated in vitro 
(Wang et al, 2015). The authors found that overexpression of IL-37 in the cell 
lines resulted in a significantly reduced tumour cell proliferation and invasion 
(Transwell invasion assay). Since STAT3 can promote inflammation and cancer, 
cell proliferation and IL-37b can suppress STAT3 pathway in macrophages (Yu et 
al, 2009; Nold-Petry et al, 2015). The authors determined the expression and 
function of STAT3 in IL-37-mediated anti-tumour effect. They found that IL-37 
overexpression suppressed STAT3 production and phosphorylation and the 
production of inflammatory cytokines TNF-α and IL-1β. Furthermore, knockdown 
STAT3 using siRNAs abolished IL-37’s ability in the reduction of cell proliferation 
and invasion as well as the expression of TNF-α and IL-1β (Yu et al, 2009). This 
result suggests that IL-37 may affect tumour cells expansion and invasion by 
targeting the key pro-inflammatory pathway STAT3. However, the importance of 
the IL-37/STAT3-induced anti-tumour effect has not been demonstrated in vivo. 
These reports suggest that IL-37 can also suppress tumour growth by different 
mechanisms and may have impact on treatment and prognostic in human 
cancers. However, there are some limitations in these studies; all these studies 
are focused on the direct effect of IL-37 on solid tumours in vitro and vivo. While 
this is potentially important for therapy, the systemic effect of IL-37 on tumour 
metastasis and tumour immunity in vivo has not been explored. Since 
inflammation is a double-edged sword in cancer, it is clinically important to 
understand and discriminate the IL-37’s anti-inflammatory effect on cancer 
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development and cancer therapy. Furthermore, the effect and importance of 
other IL-37 isoforms in cancer have not been studied. 
6.3.4 Infectious diseases 
Notwithstanding the successes of antibiotics and vaccination, pathogenic 
infection is still a big health problem. This is mainly due to the increasing 
antibiotic resistant bacteria and the emerging mutant or new strains of 
pathogens. Some pathogens can also evolutionarily develop the ability to help 
them to survive and colonise in the human environment by silencing host 
protective immune mechanisms, for instance the vIL-10 produced by EBV (Kanai 
et al, 2007).  
Immune system plays an essential part in protection against infection. As 
described in (Chapter 1), during the early infection, innate immune cells, 
including macrophages, DC and neutrophils can be rapidly activated to control 
pathogen spread and colonisation in the host. Later, the adaptive immune cells, 
T and B cells will also be specifically activated, and can eliminate the pathogens 
by cytotoxicity (CD8 T cells), helping other cells (CD4+ T cells) and producing 
antibody (B cells). While a rapid and strong pro-inflammatory response helps in 
pathogen clearance, host tissue destruction secondary to immunopathology can 
be a deleterious side effect. An appropriate anti-pathogenic response is 
therefore necessary for minimising tissue damage while still allowing clearance 
of the invading pathogen. The study of IL-37 in infection has just started and 
available reports suggest that IL-37 plays a regulatory role in bacterial, virus, 
parasitic and fungus infections. However, its role in infection is variable 
depending on the pathogen. 
6.3.5 Viral infection 
It has been shown that IL-37 can influence the infection and pathogenesis of 
HBV, HIV and influenza infection (O'Garra, 2013; Højen and Rasmussen, 2015; 
Zhou et al, 2018). A clinical study involving in 60 HIV-1-infected patients and 20 
healthy controls showed that IL-37 expression is associated with levels of 
inflammatory marker and HIV (Højen and Rasmussen, 2015). IL-37 mRNA levels in 
PBMCs from patients with HIV were significantly higher than the healthy 
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controls. The levels of IL-37 mRNA were positively associated with the level of 
monocyte, but not T, cell markers. In addition, IL-37 expression levels also were 
correlated with the HIV DNA levels. Thus, the result suggests that IL-37 produced 
by monocytes may promote HIV replication or infection (Højen and Rasmussen, 
2015). However, the real effect on HIV replication has not been revealed. 
The expression and function of IL-37 in influenza A virus (IAV) infection was also 
studied (Zhou et al, 2018). The levels of IL-37 mRNA and protein levels in the 
PBMC and serum samples from patients with influenza A virus (IAV) infection 
were enhanced compared to the healthy subjects. To understand the effect of 
IL-37 on IAV replication in epithelia cells, A549 cell line was infected with IAV 
first and then treated with rIL-37. The authors found that the titer of IAV RNA 
was significantly reducedin IL-37 treated cells. The result suggested that IL-37 
may be able to inhibit the replication of IAV RNA in infected cells. However, the 
mechanism underlying the IL-37-reduced virus replication has not been explored. 
6.3.6 Bacterial infection 
The role of IL-37 in mycobacterium tuberculosis (Mtb), Strongyloidesstercoralis 
and pneumococcal pneumonia infection has been reported (Paterson and 
Orihuela, 2010; Liu et al, 2017; Schauer et al, 2017). Tuberculosis (TB) is caused 
by Mycobacterium tuberculosis and affects one quarter of the world's 
population. Th1 cells that produce IFNϒ play a protective effect on TB (O'Garra, 
2013). 
A recent report shows that IL-37 may be protective against mycobacterial 
infection in vitro and in mouse model in vivo (Liu et al, 2017). They found that 
IL-37 single nucleotide polymorphism (SNP) is closely associated with TB 
susceptibility. The levels of IL-37 protein in TB patients were elevated compared 
to levels in healthy controls. Furthermore, Mtb infection enhanced IL-37 but 
reduced proinflammatory cytokines including IL-6 and TNF-α production in 
macrophages.  In vivo, BCG-infected IL-37-tg mice have less mycobacterial 
burden and tissue damage in the lung, compared to the infected wt control 
mice. This suggests that IL-37 can protect against Mtb infection in mice. 
Moreover, the immune mechanism study demonstrated that the protective 
effect of IL-37 was associated with an enhanced levelof Th1 cells and reduced 
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regulatory T cells in the spleen (Liu et al, 2017). Thus, IL-37 may protect by 
promoting anti-bacterial Th1 response and down regulating disease-promoting T-
reg response in Mtb infection. Unfortunately, how IL-37 promotes Th1 and 
inhibits Treg response in Mtb infection is still unclear and this is controversy in 
current ideas of IL-37 function.  
Streptococcus pneumonia (SP) infections can cause several human diseases, 
including pneumonia, bacteraemia, and meningitis by enhancing inflammatory 
pathological response (Paterson and Orihuela, 2010).  
Given the effect of IL-37 as a suppressor of innate and acquired immunity, its 
impact on SP infection has been studied (Schauer et al, 2017). In vitro, the 
overexpression of IL-37 in the macrophages infected with pneumococci 
decreased the levels of proinflammatory cytokines IL-6, TNF-α, and IL-1β, but 
increased the intracellular pneumococcal infection. Consistently, in vivo, 
compared to the wt control mice, infection with S.pneumonia in IL-37b 
transgenic mice also decreased the expression of inflammatory cytokines IL-6, 
TNF-α, and IL-1β, but enhanced the pneumococcal burden, lung tissue damage 
and mortality. Thus, IL-37 is a therapeutic target in SP-induced pneumonia. 
6.3.7 Helminth infection 
The role of IL-37 in parasite infection is still largely unknown. Only two reports 
from same research group so far show that IL-37 can modulate T cell immune 
response and cytokine balance in Strongyloidesstercoralis infection (Anuradha et 
al, 2015; Breloer and Abraham, 2018). 
Strongyloidiasisis a common parasitic diseasethat affects about 100 million 
people worldwide (Anuradha et al, 2015; Anuradha et al, 2017; Breloer and 
Abraham, 2018). The protective immune mechanism in strongyloidiasis in human 
is largely unknown. The Th1 or Th17 response can be protective or pathogenic 
depending on the degree of T cell responses. Th2 cell-mediated immune 
response is thought to play a protective role in the strongyloidiasis by counter-
regulation of Th1/Th17-mediated pro-inflammatory response (Anuradha et al, 
2015; Anuradha et al, 2017; Breloer and Abraham, 2018). It has been shown that 
the patients with strongyloides infection contain significantly higher levels of 
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serum proinflammatory cytokines IFNγ, TNF-α, and IL-1β and significantly lower 
levels of anti-inflammatory cytokines IL-4, IL-10, IL-13, IL-27, IL-37, and TGF-, 
compared to healthy controls (Anuradha et al, 2015). However, after treatment; 
the cytokine profiles were reversed with negative enhanced levels of 
inflammatory cytokines and IL-1β but reduced anti-inflammatory cytokines 
including IL-37(Anuradha et al, 2015). To assess the role of IL-37 in the 
regulation of CD4+ and CD8+ T cell responses in strongyloidiasis, the authors 
measured the changes of parasite specific Th1/Tc1, Th2/Tc2, Th9/Tc9, 
Th17/Tc17, and Th22/Tc22 cell response in the PBMC fromthe patients with 
strongyloidiasis and healthy controls following the anti-IL-37 neutralizing 
antibody treatment in vitro. They found that IL-37 neutralization markedly 
increased the level of parasite-specific Th1/Tc1, Th2/Tc2, Th17/Tc17, Th9, and 
Th22 cells by FACSand related cytokines IFNγ, IL-5, IL-9, IL-17, and IL-22 by 
ELISA in the cultures. Thus, while the reports demonstrate that IL-37 can 
modulate S. Stercoralis-specific T cell response, the precise role of IL-37 in the 
protective immunity against strongyloidiasis is still unclear (Anuradha et al, 
2017). 
6.3.8 Fungal infection 
There are only two reports in PubMed so far that studied the potential role of IL-
37 in candida and paracoccidioidomycosis (Veerdonk et al, 2015). Only the 
candida has been studied in detail. 
Candidiasis is a disease of fungal infection. While the protective immunity 
against candida infection is still not fully understood, the innate immune cells, 
in particular the neutrophils in the mucosal tissue, play an important role in 
anti-candida infection (Anuradha et al, 2017). The influence of IL-37 in 
candidiasis is unknown. Given its effect on the suppression of neutrophil 
migration and function, the authors proposed that IL-37 may promote infection 
by affecting neutrophils function (Veerdonk et al, 2015). They demonstrated the 
hypothesis in a murine model of disseminated candidiasis using IL-37b transgenic 
mice. Compared to the wt control mice, IL-37-tg mice were susceptible to 
candida infection, enhanced fungal growth in the organ and mortality. The mice 
also failed to effectively produce inflammatory cytokines and recruit neutrophils 
to the site of infection. Thus, IL-37 may be pathogenic in candidiasis by 
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interfering with host innate protective inflammatory immune response. 
However, its effect in human candidiasis has not been explored. 
6.4 Conclusion and remark 
In summary, IL-37b exhibits a profound effect on the development and 
perpetuation of a wide range of diseases, including allergic, autoimmune, and 
infectious and tumour diseases. However, the effect of IL-37 on diseases is 
varying, and can be beneficial or detrimental. 
In allergic diseases tested, IL-37b is generally protective and may be potentially 
therapeutic in the treatment of allergy and asthma. This is mainly due to its 
ability to suppress Th2 response and the function of key pathogenic cell sets in 
allergy, including eosinophils, mast and Th2 cells. It will be important to reveal 
the effect of IL-37 on other allergic diseases, for instance food allergy, in the 
future.  
IL-37 signal may also be beneficial in the regulation and treatment of several 
autoimmune diseases by targeting the key inflammatory pathways, including 
Th1, Th17 and NF-κB pathways in these diseases. However, its role in the 
regulation of other autoimmune diseases has not been studied. It will be 
interesting to know if IL-37 is capable to controlling a wide range of autoimmune 
disorders. 
It is intriguing that IL-37 can also directly suppress the growth of tumour, mainly 
the solid tumours. Thus, IL-37 may have impact on the treatment and prognostic 
of human cancers. Future studies should focus on the systemic effect of IL-37 on 
metastatic tumours and tumour immunity in vivo. The implication of IL-37 on 
infectious disorders is less clear, particularly the parasite and fungus infection, 
and likely to be complicated, depending on the pathogen. While this basic and 
clinical research projects have greatly enhanced our knowledge of the potential 
application of IL-37 in clinical diseases, the current results are largely generated 
from animal models. Furthermore, the function and relation of other IL-37 
isoforms to diseases is still unknown. All this a waits future should be studied in 
the future 
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